{"PMC7327150": [["INTRODUCTIONThe defense against pathogens is composed of innate and adaptive immunities.", [["pathogens", "PROBLEM", 32, 41], ["innate and adaptive immunities", "TREATMENT", 57, 87], ["pathogens", "OBSERVATION", 32, 41]]], ["While innate response mounts in a few hours by the recognition of molecular patterns, adaptive immune system takes a few days to initiate Ag-dependent specific response.", [["immune system", "ANATOMY", 95, 108], ["Ag", "CHEMICAL", 138, 140], ["Ag", "CHEMICAL", 138, 140], ["Ag", "GENE_OR_GENE_PRODUCT", 138, 140], ["Ag", "PROTEIN", 138, 140], ["adaptive immune system", "TREATMENT", 86, 108]]], ["The adaptive immune system employs B cells, which produce antibodies, and T cells to mediate cellular immunity.", [["immune system", "ANATOMY", 13, 26], ["B cells", "ANATOMY", 35, 42], ["T cells", "ANATOMY", 74, 81], ["cellular", "ANATOMY", 93, 101], ["B cells", "CELL", 35, 42], ["T cells", "CELL", 74, 81], ["cellular", "CELL", 93, 101], ["B cells", "CELL_TYPE", 35, 42], ["antibodies", "PROTEIN", 58, 68], ["T cells", "CELL_TYPE", 74, 81], ["The adaptive immune system", "TREATMENT", 0, 26], ["B cells", "PROBLEM", 35, 42], ["antibodies", "TEST", 58, 68]]], ["One cardinal feature of the adaptive immune system is \u201cmemory\u201d response to the same Ag.", [["immune system", "ANATOMY", 37, 50]]], ["Once the adaptive immune system has been stimulated with vaccines or pathogens, challenges with the same Ag induce a faster and stronger response than the primary response.", [["Ag", "CHEMICAL", 105, 107], ["Ag", "CHEMICAL", 105, 107], ["Ag", "GENE_OR_GENE_PRODUCT", 105, 107], ["Ag", "PROTEIN", 105, 107], ["the adaptive immune system", "TREATMENT", 5, 31], ["vaccines", "TREATMENT", 57, 65], ["pathogens", "PROBLEM", 69, 78], ["faster", "OBSERVATION_MODIFIER", 117, 123]]], ["These memory responses are mainly mediated by Ab-producing plasma cells and memory T (TM) cells.", [["plasma cells", "ANATOMY", 59, 71], ["memory T (TM) cells", "ANATOMY", 76, 95], ["Ab", "GENE_OR_GENE_PRODUCT", 46, 48], ["plasma cells", "CELL", 59, 71], ["memory T (TM) cells", "CELL", 76, 95], ["Ab-producing plasma cells", "CELL_TYPE", 46, 71], ["memory T (TM) cells", "CELL_TYPE", 76, 95], ["Ab", "TEST", 46, 48]]], ["Through these memory responses, vaccines can protect our body against fatal or serious infectious agents.", [["body", "ANATOMY", 57, 61], ["body", "ORGANISM_SUBDIVISION", 57, 61], ["vaccines", "TREATMENT", 32, 40], ["serious infectious agents", "PROBLEM", 79, 104]]], ["Although vaccination is the most efficient way to prevent infectious disease, few vaccines have been developed to induce functional TM cells for certain infectious diseases, which is probably because of the lack of knowledge about TM cell development and homeostasis.INTRODUCTIONMigratory capacity is another important feature of the adaptive immunity, which enables adaptive immune cells to circulate constantly among tissues.", [["TM cells", "ANATOMY", 132, 140], ["TM cell", "ANATOMY", 231, 238], ["immune cells", "ANATOMY", 376, 388], ["tissues", "ANATOMY", 419, 426], ["infectious disease", "DISEASE", 58, 76], ["infectious diseases", "DISEASE", 153, 172], ["TM cells", "CELL", 132, 140], ["TM cell", "CELL", 231, 238], ["immune cells", "CELL", 376, 388], ["tissues", "TISSUE", 419, 426], ["TM cells", "CELL_TYPE", 132, 140], ["immune cells", "CELL_TYPE", 376, 388], ["vaccination", "TREATMENT", 9, 20], ["infectious disease", "PROBLEM", 58, 76], ["few vaccines", "TREATMENT", 78, 90], ["functional TM cells", "PROBLEM", 121, 140], ["certain infectious diseases", "PROBLEM", 145, 172], ["TM cell development", "TREATMENT", 231, 250], ["INTRODUCTIONMigratory capacity", "PROBLEM", 267, 297], ["adaptive immune cells", "TREATMENT", 367, 388], ["infectious", "OBSERVATION", 58, 68]]], ["Depending on their activation status, these cells generally circulate throughout the body to search for their cognate Ags.", [["cells", "ANATOMY", 44, 49], ["body", "ANATOMY", 85, 89], ["cells", "CELL", 44, 49], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["Ags", "GENE_OR_GENE_PRODUCT", 118, 121], ["Ags", "PROTEIN", 118, 121], ["these cells", "PROBLEM", 38, 49]]], ["For example, na\u00efve T cells are activated with Ags in the secondary lymphoid organs (SLOs) where adaptive immune responses initiate.", [["na\u00efve T cells", "ANATOMY", 13, 26], ["lymphoid organs", "ANATOMY", 67, 82], ["SLOs", "ANATOMY", 84, 88], ["na\u00efve T cells", "CELL", 13, 26], ["Ags", "GENE_OR_GENE_PRODUCT", 46, 49], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 67, 82], ["SLOs", "CANCER", 84, 88], ["na\u00efve T cells", "CELL_TYPE", 13, 26], ["Ags", "PROTEIN", 46, 49], ["na\u00efve T cells", "PROBLEM", 13, 26], ["Ags", "PROBLEM", 46, 49], ["adaptive immune responses", "TREATMENT", 96, 121], ["secondary lymphoid organs", "OBSERVATION", 57, 82]]], ["When T cells are properly activated, they develop into effector T (TE) cells and migrate into infected sites.", [["T cells", "ANATOMY", 5, 12], ["effector T (TE) cells", "ANATOMY", 55, 76], ["sites", "ANATOMY", 103, 108], ["T cells", "CELL", 5, 12], ["effector T (TE) cells", "CELL", 55, 76], ["T cells", "CELL_TYPE", 5, 12], ["effector T (TE) cells", "CELL_TYPE", 55, 76], ["effector T (TE) cells", "TREATMENT", 55, 76]]], ["While effector CD4+ T cells provide \u201chelp\u201d to other immune cells, effector CD8+ T cells, also called CTLs, kill infected or damaged cells.", [["effector CD4+ T cells", "ANATOMY", 6, 27], ["immune cells", "ANATOMY", 52, 64], ["effector CD8+ T cells", "ANATOMY", 66, 87], ["CTLs", "ANATOMY", 101, 105], ["cells", "ANATOMY", 132, 137], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["immune cells", "CELL", 52, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["CTLs", "CELL", 101, 105], ["cells", "CELL", 132, 137], ["effector CD4+ T cells", "CELL_TYPE", 6, 27], ["immune cells", "CELL_TYPE", 52, 64], ["effector CD8+ T cells", "CELL_TYPE", 66, 87], ["CTLs", "CELL_TYPE", 101, 105], ["infected or damaged cells", "CELL_TYPE", 112, 137], ["T cells", "PROBLEM", 20, 27], ["damaged cells", "PROBLEM", 124, 137], ["damaged cells", "OBSERVATION", 124, 137]]], ["Hence, T cell homing is crucial to fight against invading pathogens so that their migration is tightly regulated.", [["T cell", "ANATOMY", 7, 13], ["T cell", "CELL", 7, 13], ["T cell homing", "TREATMENT", 7, 20], ["invading pathogens", "PROBLEM", 49, 67]]], ["It has been well documented that stimulation of chemokine receptors and adhesion molecules on T cell surface allows for an orderly access to a specific microenvironment.", [["T cell surface", "ANATOMY", 94, 108], ["T cell", "CELL", 94, 100], ["chemokine receptors", "PROTEIN", 48, 67], ["adhesion molecules", "PROTEIN", 72, 90], ["chemokine receptors", "TREATMENT", 48, 67], ["adhesion molecules", "PROBLEM", 72, 90], ["T cell surface", "TREATMENT", 94, 108]]], ["Therefore, it is known that various chemokine receptors are sequentially expressed in the course of immune response to pathogens.", [["chemokine receptors", "PROTEIN", 36, 55], ["various chemokine receptors", "TREATMENT", 28, 55], ["pathogens", "PROBLEM", 119, 128]]], ["Recently, the migratory capacities of TM cells have been highlighted because their recall response and survival are affected by their localization.INTRODUCTIONIn this review, we discussed memory CD8+ T cells and their migratory capacities, particularly the C-C chemokine receptor 7 (CCR7)-dependent pathway, for their survival and longevity.", [["TM cells", "ANATOMY", 38, 46], ["memory CD8+ T cells", "ANATOMY", 188, 207], ["TM cells", "CELL", 38, 46], ["CD8", "GENE_OR_GENE_PRODUCT", 195, 198], ["C-C chemokine receptor 7", "GENE_OR_GENE_PRODUCT", 257, 281], ["CCR7", "GENE_OR_GENE_PRODUCT", 283, 287], ["TM cells", "CELL_TYPE", 38, 46], ["memory CD8+ T cells", "CELL_TYPE", 188, 207], ["CCR7", "PROTEIN", 283, 287], ["TM cells", "PROBLEM", 38, 46], ["T cells", "PROBLEM", 200, 207], ["their migratory capacities", "PROBLEM", 212, 238], ["the C-C chemokine receptor", "TREATMENT", 253, 279], ["migratory", "OBSERVATION_MODIFIER", 14, 23], ["capacities", "OBSERVATION_MODIFIER", 24, 34], ["migratory capacities", "OBSERVATION", 218, 238]]], ["We also highlighted recent studies describing the expression of CCR7 and its ligands, CCL19 and CCL21.Development of memory CD8+ T cells ::: MEMORY CD8+ T CELLSNa\u00efve CD8+ T cells constantly circulate throughout the body through SLOs including the lymph nodes (LNs), spleen, and Peyer's patches (PPs) (1234).", [["memory CD8+ T cells", "ANATOMY", 117, 136], ["CD8+ T CELLSNa\u00efve CD8+ T cells", "ANATOMY", 148, 178], ["body", "ANATOMY", 215, 219], ["SLOs", "ANATOMY", 228, 232], ["lymph nodes", "ANATOMY", 247, 258], ["LNs", "ANATOMY", 260, 263], ["spleen", "ANATOMY", 266, 272], ["Peyer's patches", "ANATOMY", 278, 293], ["PPs", "ANATOMY", 295, 298], ["CCR7", "GENE_OR_GENE_PRODUCT", 64, 68], ["CCL19", "GENE_OR_GENE_PRODUCT", 86, 91], ["CCL21", "GENE_OR_GENE_PRODUCT", 96, 101], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["CD8", "GENE_OR_GENE_PRODUCT", 148, 151], ["body", "ORGANISM_SUBDIVISION", 215, 219], ["SLOs", "GENE_OR_GENE_PRODUCT", 228, 232], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 247, 258], ["LNs", "MULTI-TISSUE_STRUCTURE", 260, 263], ["spleen", "ORGAN", 266, 272], ["PPs", "MULTI-TISSUE_STRUCTURE", 295, 298], ["CCR7", "PROTEIN", 64, 68], ["CCL19", "PROTEIN", 86, 91], ["CCL21", "PROTEIN", 96, 101], ["memory CD8+ T cells", "CELL_TYPE", 117, 136], ["CD8", "PROTEIN", 148, 151], ["T CELLSNa\u00efve CD8+ T cells", "CELL_TYPE", 153, 178], ["recent studies", "TEST", 20, 34], ["CCL19", "TEST", 86, 91], ["CCL21", "TEST", 96, 101], ["MEMORY CD8", "TEST", 141, 151], ["CELLSNa\u00efve", "TEST", 155, 165], ["CD8", "TEST", 166, 169], ["T cells", "PROBLEM", 171, 178], ["memory CD8", "OBSERVATION", 117, 127], ["body", "ANATOMY_MODIFIER", 215, 219], ["SLOs", "OBSERVATION", 228, 232], ["lymph nodes", "OBSERVATION", 247, 258], ["spleen", "ANATOMY", 266, 272]]], ["The activation of T cells was first reported in 1970s using a mouse model of lymphocytic choriomeningitis virus (LCMV) infection (56).", [["T cells", "ANATOMY", 18, 25], ["lymphocytic choriomeningitis virus (LCMV) infection", "DISEASE", 77, 128], ["T cells", "CELL", 18, 25], ["mouse", "ORGANISM", 62, 67], ["lymphocytic choriomeningitis virus", "ORGANISM", 77, 111], ["LCMV", "ORGANISM", 113, 117], ["T cells", "CELL_TYPE", 18, 25], ["mouse", "SPECIES", 62, 67], ["lymphocytic choriomeningitis virus", "SPECIES", 77, 111], ["mouse", "SPECIES", 62, 67], ["lymphocytic choriomeningitis virus", "SPECIES", 77, 111], ["LCMV", "SPECIES", 113, 117], ["T cells", "PROBLEM", 18, 25], ["lymphocytic choriomeningitis virus (LCMV) infection", "PROBLEM", 77, 128], ["lymphocytic choriomeningitis virus", "OBSERVATION", 77, 111]]], ["During viral infections, antigen presenting cells (APCs) such as dendritic cells (DCs) obtain viruses and migrate into the SLOs where na\u00efve T cells search for their cognate Ags.", [["antigen presenting cells", "ANATOMY", 25, 49], ["APCs", "ANATOMY", 51, 55], ["dendritic cells", "ANATOMY", 65, 80], ["DCs", "ANATOMY", 82, 85], ["SLOs", "ANATOMY", 123, 127], ["T cells", "ANATOMY", 140, 147], ["viral infections", "DISEASE", 7, 23], ["antigen presenting cells", "CELL", 25, 49], ["APCs", "CELL", 51, 55], ["dendritic cells", "CELL", 65, 80], ["DCs", "CELL", 82, 85], ["SLOs", "CELL", 123, 127], ["na\u00efve T cells", "CELL", 134, 147], ["Ags", "GENE_OR_GENE_PRODUCT", 173, 176], ["antigen presenting cells", "CELL_TYPE", 25, 49], ["APCs", "CELL_TYPE", 51, 55], ["dendritic cells", "CELL_TYPE", 65, 80], ["DCs", "CELL_TYPE", 82, 85], ["SLOs", "CELL_TYPE", 123, 127], ["na\u00efve T cells", "CELL_TYPE", 134, 147], ["Ags", "PROTEIN", 173, 176], ["viral infections", "PROBLEM", 7, 23], ["antigen presenting cells", "PROBLEM", 25, 49], ["APCs", "TEST", 51, 55], ["dendritic cells", "PROBLEM", 65, 80], ["viruses", "PROBLEM", 94, 101], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["infections", "OBSERVATION", 13, 23], ["dendritic cells", "OBSERVATION", 65, 80]]], ["Activated CD8+ T cells by these APCs undergo several pathways to proliferate and gain effector functions important to fight against infectious agents.", [["CD8+ T cells", "ANATOMY", 10, 22], ["APCs", "ANATOMY", 32, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 10, 13], ["APCs", "CELL", 32, 36], ["Activated CD8+ T cells", "CELL_TYPE", 0, 22], ["APCs", "CELL_TYPE", 32, 36], ["Activated CD8+ T cells", "TREATMENT", 0, 22], ["infectious agents", "TREATMENT", 132, 149]]], ["In addition, CD8+ TE cells modulate the expression of their homing receptors to egress from the SLOs and move into the infected area to induce protective immunity (78).", [["CD8+ TE cells", "ANATOMY", 13, 26], ["SLOs", "ANATOMY", 96, 100], ["area", "ANATOMY", 128, 132], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["SLOs", "GENE_OR_GENE_PRODUCT", 96, 100], ["CD8", "PROTEIN", 13, 16], ["TE cells", "CELL_TYPE", 18, 26], ["homing receptors", "PROTEIN", 60, 76], ["CD8+ TE cells", "TREATMENT", 13, 26], ["the SLOs", "PROBLEM", 92, 100], ["infected", "OBSERVATION", 119, 127]]], ["After the pathogens are cleared, majority (up to 90%) of the activated CD8+ T cells dies, while only a fraction (up to 10%) survives and are maintained as TM (9) cells.", [["CD8+ T cells", "ANATOMY", 71, 83], ["TM (9) cells", "ANATOMY", 155, 167], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["TM (9) cells", "CELL", 155, 167], ["activated CD8+ T cells", "CELL_TYPE", 61, 83], ["TM (9) cells", "CELL_LINE", 155, 167], ["the pathogens", "PROBLEM", 6, 19], ["a fraction", "TEST", 101, 111], ["pathogens", "OBSERVATION", 10, 19]]], ["These TM cells survive for an extended period of time and provide rapid and robust secondary response to the same Ag.", [["TM cells", "ANATOMY", 6, 14], ["TM cells", "CELL", 6, 14], ["TM cells", "CELL_TYPE", 6, 14], ["These TM cells", "TREATMENT", 0, 14]]], ["In addition, they undergo self-renewal without Ag exposure and subsets of TM cells undergo a series of steps to re-circulate the whole body searching for re-infections.", [["TM cells", "ANATOMY", 74, 82], ["body", "ANATOMY", 135, 139], ["Ag", "CHEMICAL", 47, 49], ["Ag", "CHEMICAL", 47, 49], ["Ag", "GENE_OR_GENE_PRODUCT", 47, 49], ["TM cells", "CELL", 74, 82], ["body", "ORGANISM_SUBDIVISION", 135, 139], ["Ag", "PROTEIN", 47, 49], ["TM cells", "CELL_TYPE", 74, 82], ["TM cells", "TREATMENT", 74, 82], ["re-infections", "PROBLEM", 154, 167]]], ["These prominent characteristics enable TM cells to fight against secondary infections with the same pathogens efficiently (10).The subsets of memory CD8+ T cells ::: MEMORY CD8+ T CELLSCD8+ TM cells with these cardinal characteristics can be categorized into diverse subsets including effector memory T (TEM) (11), central memory T (TCM), and tissue-resident memory T (TRM) cells (Fig. 1) (12).", [["TM cells", "ANATOMY", 39, 47], ["memory CD8+ T cells", "ANATOMY", 142, 161], ["CD8+ T CELLSCD8+ TM cells", "ANATOMY", 173, 198], ["effector memory T (TEM", "ANATOMY", 285, 307], ["central memory T", "ANATOMY", 315, 331], ["TCM", "ANATOMY", 333, 336], ["tissue-resident memory T (TRM) cells", "ANATOMY", 343, 379], ["infections", "DISEASE", 75, 85], ["TM cells", "CELL", 39, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 149, 152], ["CD8", "GENE_OR_GENE_PRODUCT", 173, 176], ["effector memory T", "CANCER", 285, 302], ["central memory T", "CELL", 315, 331], ["TCM", "CELL", 333, 336], ["tissue-resident memory T (TRM) cells", "CELL", 343, 379], ["TM cells", "CELL_TYPE", 39, 47], ["memory CD8+ T cells", "CELL_TYPE", 142, 161], ["MEMORY CD8+ T CELLSCD8+ TM cells", "CELL_LINE", 166, 198], ["effector memory T (TEM) (11)", "CELL_TYPE", 285, 313], ["central memory T (TCM), and tissue-resident memory T (TRM) cells", "CELL_TYPE", 315, 379], ["TM cells", "TREATMENT", 39, 47], ["secondary infections", "PROBLEM", 65, 85], ["MEMORY CD8", "TEST", 166, 176], ["CELLSCD8", "TEST", 180, 188], ["TM cells", "PROBLEM", 190, 198], ["infections", "OBSERVATION", 75, 85], ["tissue", "ANATOMY", 343, 349]]], ["These subsets were initially identified based on their differential localizations by the expressions of homing receptors, but they also differ from each other in terms of their cytokine production and proliferation capacities.", [["homing receptors", "PROTEIN", 104, 120], ["cytokine", "PROTEIN", 177, 185], ["homing receptors", "TREATMENT", 104, 120], ["proliferation capacities", "PROBLEM", 201, 225], ["cytokine production", "OBSERVATION", 177, 196], ["proliferation capacities", "OBSERVATION", 201, 225]]], ["These abilities are regulated by a series of expression of their receptors, signaling molecules, transcription factors, and other important factors.", [["signaling molecules", "PROTEIN", 76, 95], ["transcription factors", "PROTEIN", 97, 118], ["signaling molecules", "PROBLEM", 76, 95], ["transcription factors", "PROBLEM", 97, 118]]], ["Of note, different subsets of TM cells form depending on the tropism and characteristics of infectious agents and these subsets cooperate to eradicate infections.The subsets of memory CD8+ T cells ::: MEMORY CD8+ T CELLSTCM cells monitor infection in the body by circulating in the SLOs.", [["TM cells", "ANATOMY", 30, 38], ["memory CD8+ T cells", "ANATOMY", 177, 196], ["CD8+ T CELLSTCM cells", "ANATOMY", 208, 229], ["body", "ANATOMY", 255, 259], ["SLOs", "ANATOMY", 282, 286], ["infections", "DISEASE", 151, 161], ["infection", "DISEASE", 238, 247], ["TM cells", "CELL", 30, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 184, 187], ["CD8", "GENE_OR_GENE_PRODUCT", 208, 211], ["body", "ORGANISM_SUBDIVISION", 255, 259], ["TM cells", "CELL_TYPE", 30, 38], ["memory CD8+ T cells", "CELL_TYPE", 177, 196], ["MEMORY CD8+ T CELLSTCM cells", "CELL_LINE", 201, 229], ["TM cells", "TREATMENT", 30, 38], ["the tropism", "PROBLEM", 57, 68], ["infectious agents", "TREATMENT", 92, 109], ["infections", "PROBLEM", 151, 161], ["T CELLSTCM cells", "PROBLEM", 213, 229], ["infection in the body", "PROBLEM", 238, 259], ["infectious", "OBSERVATION", 92, 102], ["body", "ANATOMY_MODIFIER", 255, 259], ["SLOs", "OBSERVATION", 282, 286]]], ["In contrast, TEM and TRM cells do not survey SLOs and are located in peripheral tissues (Fig. 1).", [["TRM cells", "ANATOMY", 21, 30], ["peripheral tissues", "ANATOMY", 69, 87], ["TEM", "CELL", 13, 16], ["TRM cells", "CELL", 21, 30], ["SLOs", "GENE_OR_GENE_PRODUCT", 45, 49], ["peripheral tissues", "TISSUE", 69, 87], ["TEM", "CELL_TYPE", 13, 16], ["TRM cells", "CELL_LINE", 21, 30], ["SLOs", "PROTEIN", 45, 49], ["TRM cells", "TEST", 21, 30], ["TRM cells", "OBSERVATION", 21, 30], ["peripheral tissues", "ANATOMY", 69, 87]]], ["However, TEM cells can return to the SLOs if the Ags exist in the SLOs even after Ag is cleared in the infected target area (13141516).", [["TEM cells", "ANATOMY", 9, 18], ["Ag", "CHEMICAL", 82, 84], ["Ag", "CHEMICAL", 82, 84], ["TEM cells", "CELL", 9, 18], ["SLOs", "GENE_OR_GENE_PRODUCT", 37, 41], ["Ags", "GENE_OR_GENE_PRODUCT", 49, 52], ["SLOs", "CANCER", 66, 70], ["Ag", "GENE_OR_GENE_PRODUCT", 82, 84], ["TEM cells", "CELL_LINE", 9, 18], ["Ags", "PROTEIN", 49, 52], ["Ag", "PROTEIN", 82, 84], ["TEM cells", "PROBLEM", 9, 18], ["the Ags", "TEST", 45, 52], ["infected", "OBSERVATION", 103, 111]]], ["In 2009, Gebhardt et al. (17) reported that TRM cells stay in the non-lymphoid tissues (NLTs) without returning to the SLOs.", [["TRM cells", "ANATOMY", 44, 53], ["non-lymphoid tissues", "ANATOMY", 66, 86], ["NLTs", "ANATOMY", 88, 92], ["SLOs", "ANATOMY", 119, 123], ["TRM cells", "CELL", 44, 53], ["non-lymphoid tissues", "TISSUE", 66, 86], ["NLTs", "CELL", 88, 92], ["TRM cells", "CELL_LINE", 44, 53], ["TRM cells", "PROBLEM", 44, 53], ["non-lymphoid tissues", "ANATOMY", 66, 86]]], ["They prepare to fight against local infections and are found in many different organs including the brain, lung, gut, skin, and other peripheral organs (181920).The subsets of memory CD8+ T cells ::: MEMORY CD8+ T CELLSThe generation of specific subsets of CD8+ TM cells has been attempted using different animal models.", [["organs", "ANATOMY", 79, 85], ["brain", "ANATOMY", 100, 105], ["lung", "ANATOMY", 107, 111], ["gut", "ANATOMY", 113, 116], ["skin", "ANATOMY", 118, 122], ["peripheral organs", "ANATOMY", 134, 151], ["memory CD8+ T cells", "ANATOMY", 176, 195], ["CD8+ TM cells", "ANATOMY", 257, 270], ["infections", "DISEASE", 36, 46], ["organs", "ORGAN", 79, 85], ["brain", "ORGAN", 100, 105], ["lung", "ORGAN", 107, 111], ["gut", "ORGAN", 113, 116], ["skin", "ORGAN", 118, 122], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 134, 151], ["CD8", "GENE_OR_GENE_PRODUCT", 183, 186], ["CD8", "GENE_OR_GENE_PRODUCT", 207, 210], ["CD8", "GENE_OR_GENE_PRODUCT", 257, 260], ["memory CD8+ T cells", "CELL_TYPE", 176, 195], ["CD8", "PROTEIN", 207, 210], ["CD8+ TM cells", "CELL_TYPE", 257, 270], ["local infections", "PROBLEM", 30, 46], ["CD8+ TM cells", "PROBLEM", 257, 270], ["infections", "OBSERVATION", 36, 46], ["brain", "ANATOMY", 100, 105], ["lung", "ANATOMY", 107, 111], ["gut", "ANATOMY", 113, 116], ["skin", "ANATOMY", 118, 122], ["peripheral", "ANATOMY_MODIFIER", 134, 144], ["organs", "ANATOMY", 145, 151], ["CD8+ TM cells", "OBSERVATION", 257, 270]]], ["It is generally assumed that systemic infections or vaccinations can induce TCM and TRM cell formation, while local infections induce TRM cell development (21).", [["TRM cell", "ANATOMY", 84, 92], ["TRM cell", "ANATOMY", 134, 142], ["infections", "DISEASE", 38, 48], ["infections", "DISEASE", 116, 126], ["TCM", "CELL", 76, 79], ["TRM cell", "CELL", 84, 92], ["TRM cell", "CELL", 134, 142], ["systemic infections", "PROBLEM", 29, 48], ["vaccinations", "TREATMENT", 52, 64], ["TCM", "PROBLEM", 76, 79], ["TRM cell formation", "PROBLEM", 84, 102], ["local infections", "PROBLEM", 110, 126], ["systemic", "OBSERVATION_MODIFIER", 29, 37], ["infections", "OBSERVATION", 38, 48], ["TRM cell formation", "OBSERVATION", 84, 102]]], ["Thus, Ag tropism or location determines the fate of TM cells.", [["TM cells", "ANATOMY", 52, 60], ["Ag", "CHEMICAL", 6, 8], ["Ag", "CHEMICAL", 6, 8], ["Ag", "GENE_OR_GENE_PRODUCT", 6, 8], ["TM cells", "CELL", 52, 60], ["TM cells", "CELL_TYPE", 52, 60], ["Ag tropism", "PROBLEM", 6, 16], ["tropism", "OBSERVATION", 9, 16], ["TM cells", "OBSERVATION", 52, 60]]], ["For example, the presence of TRM cells in the liver substantially enhances protection against Plasmodium (23).", [["TRM cells", "ANATOMY", 29, 38], ["liver", "ANATOMY", 46, 51], ["TRM cells", "CELL", 29, 38], ["liver", "ORGAN", 46, 51], ["Plasmodium", "ORGANISM", 94, 104], ["TRM cells", "CELL_LINE", 29, 38], ["TRM cells", "PROBLEM", 29, 38], ["Plasmodium", "TEST", 94, 104], ["TRM cells", "OBSERVATION", 29, 38], ["liver", "ANATOMY", 46, 51]]], ["Altogether, the modulation of TM cell mobility would benefit our body to fight properly against pathogens by placing TM cells in proper positions.The survival and homeostasis of TM cells ::: MEMORY CD8+ T CELLSA remarkable aspect of TM cells is their longevity and homeostasis without further antigenic stimulation.", [["TM cell", "ANATOMY", 30, 37], ["body", "ANATOMY", 65, 69], ["TM cells", "ANATOMY", 117, 125], ["TM cells", "ANATOMY", 178, 186], ["TM cells", "ANATOMY", 233, 241], ["TM cell", "CELL", 30, 37], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["TM cells", "CELL", 117, 125], ["TM cells", "CELL", 178, 186], ["CD8", "GENE_OR_GENE_PRODUCT", 198, 201], ["TM cells", "CELL", 233, 241], ["TM cells", "CELL_TYPE", 117, 125], ["TM cells", "CELL_TYPE", 178, 186], ["CD8", "PROTEIN", 198, 201], ["TM cells", "CELL_TYPE", 233, 241], ["TM cell mobility", "TREATMENT", 30, 46], ["pathogens", "PROBLEM", 96, 105], ["TM cells", "TREATMENT", 117, 125], ["MEMORY CD8", "TEST", 191, 201], ["T CELLSA", "TEST", 203, 211], ["TM cells", "PROBLEM", 233, 241], ["further antigenic stimulation", "TREATMENT", 285, 314], ["without", "UNCERTAINTY", 277, 284], ["antigenic stimulation", "OBSERVATION", 293, 314]]], ["The underlying mechanisms of their homeostasis are based on the exposure to the homeostatic cytokines such as IL-7 and -15 (24-31).", [["IL-7", "GENE_OR_GENE_PRODUCT", 110, 114], ["homeostatic cytokines", "PROTEIN", 80, 101], ["IL", "PROTEIN", 110, 112], ["the homeostatic cytokines", "TEST", 76, 101], ["IL", "TEST", 110, 112]]], ["IL-7 has been well documented as a survival cytokine of na\u00efve, memory precursor (MP) and TM cells.", [["memory precursor (MP)", "ANATOMY", 63, 84], ["TM cells", "ANATOMY", 89, 97], ["IL-7", "GENE_OR_GENE_PRODUCT", 0, 4], ["memory precursor", "CELL", 63, 79], ["MP", "CELL", 81, 83], ["TM cells", "CELL", 89, 97], ["IL-7", "PROTEIN", 0, 4], ["survival cytokine", "PROTEIN", 35, 52], ["na\u00efve, memory precursor (MP) and TM cells", "CELL_TYPE", 56, 97]]], ["This cytokine is provided by stromal cells including fibroblastic reticular cells (FRCs) in the spleen and LNs (323334).", [["stromal cells", "ANATOMY", 29, 42], ["fibroblastic reticular cells", "ANATOMY", 53, 81], ["FRCs", "ANATOMY", 83, 87], ["spleen", "ANATOMY", 96, 102], ["LNs", "ANATOMY", 107, 110], ["stromal cells", "CELL", 29, 42], ["fibroblastic reticular cells", "CELL", 53, 81], ["FRCs", "CELL", 83, 87], ["spleen", "ORGAN", 96, 102], ["LNs", "MULTI-TISSUE_STRUCTURE", 107, 110], ["cytokine", "PROTEIN", 5, 13], ["stromal cells", "CELL_TYPE", 29, 42], ["fibroblastic reticular cells", "CELL_TYPE", 53, 81], ["FRCs", "CELL_TYPE", 83, 87], ["stromal cells", "OBSERVATION", 29, 42], ["fibroblastic", "OBSERVATION_MODIFIER", 53, 65], ["reticular cells", "OBSERVATION", 66, 81], ["spleen", "ANATOMY", 96, 102], ["LNs", "ANATOMY", 107, 110]]], ["In conjunction with IL-7, IL-15 can induce homeostatic proliferation of TM cells.", [["TM cells", "ANATOMY", 72, 80], ["IL-7", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-15", "GENE_OR_GENE_PRODUCT", 26, 31], ["TM cells", "CELL", 72, 80], ["IL-7", "PROTEIN", 20, 24], ["IL-15", "PROTEIN", 26, 31], ["TM cells", "CELL_TYPE", 72, 80], ["IL", "TEST", 20, 22], ["IL", "TREATMENT", 26, 28], ["homeostatic proliferation of TM cells", "PROBLEM", 43, 80], ["homeostatic proliferation", "OBSERVATION", 43, 68], ["TM cells", "OBSERVATION", 72, 80]]], ["IL-15 also helps for the survival of KLRG1hi terminally differentiated TE and TM cells.", [["TE", "ANATOMY", 71, 73], ["TM cells", "ANATOMY", 78, 86], ["IL-15", "GENE_OR_GENE_PRODUCT", 0, 5], ["KLRG1hi terminally", "CELL", 37, 55], ["TE", "CELL", 71, 73], ["TM cells", "CELL", 78, 86], ["IL-15", "PROTEIN", 0, 5], ["KLRG1hi terminally differentiated TE and TM cells", "CELL_LINE", 37, 86], ["IL", "TREATMENT", 0, 2]]], ["Therefore, it is crucial for TM cells to \u201csee\u201d these cytokines in order to develop and maintain homeostasis.The survival and homeostasis of TM cells ::: MEMORY CD8+ T CELLSTM cells develop and maintain in multiple organs including the spleen, LNs, liver, lung, and bone marrow (BM) (35).", [["TM cells", "ANATOMY", 29, 37], ["TM cells", "ANATOMY", 140, 148], ["CD8+ T CELLSTM cells", "ANATOMY", 160, 180], ["organs", "ANATOMY", 214, 220], ["spleen", "ANATOMY", 235, 241], ["LNs", "ANATOMY", 243, 246], ["liver", "ANATOMY", 248, 253], ["lung", "ANATOMY", 255, 259], ["bone marrow", "ANATOMY", 265, 276], ["BM", "ANATOMY", 278, 280], ["TM cells", "CELL", 29, 37], ["TM cells", "CELL", 140, 148], ["CD8", "GENE_OR_GENE_PRODUCT", 160, 163], ["organs", "ORGAN", 214, 220], ["spleen", "ORGAN", 235, 241], ["LNs", "MULTI-TISSUE_STRUCTURE", 243, 246], ["liver", "ORGAN", 248, 253], ["lung", "ORGAN", 255, 259], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 265, 276], ["BM", "TISSUE", 278, 280], ["TM cells", "CELL_TYPE", 29, 37], ["cytokines", "PROTEIN", 53, 62], ["TM cells", "CELL_TYPE", 140, 148], ["MEMORY CD8+ T CELLSTM cells", "CELL_LINE", 153, 180], ["TM cells", "TREATMENT", 29, 37], ["these cytokines", "TEST", 47, 62], ["MEMORY CD8", "TEST", 153, 163], ["T CELLSTM cells", "PROBLEM", 165, 180], ["spleen", "ANATOMY", 235, 241], ["LNs", "ANATOMY", 243, 246], ["liver", "ANATOMY", 248, 253], ["lung", "ANATOMY", 255, 259], ["bone marrow", "ANATOMY", 265, 276]]], ["After systemic infection, TM cells can survive and proliferate in these organs, particularly in the BM (36).", [["TM cells", "ANATOMY", 26, 34], ["organs", "ANATOMY", 72, 78], ["BM", "ANATOMY", 100, 102], ["systemic infection", "DISEASE", 6, 24], ["TM cells", "CELL", 26, 34], ["organs", "ORGAN", 72, 78], ["BM", "TISSUE", 100, 102], ["TM cells", "CELL_TYPE", 26, 34], ["systemic infection", "PROBLEM", 6, 24], ["TM cells", "PROBLEM", 26, 34], ["systemic", "OBSERVATION_MODIFIER", 6, 14], ["infection", "OBSERVATION", 15, 24], ["organs", "ANATOMY", 72, 78], ["BM", "ANATOMY", 100, 102]]], ["However, different TM cell subsets are differentially localized within different organs, suggesting that these cells may be exposed to different survival factors depending on their location (3738).", [["TM cell", "ANATOMY", 19, 26], ["organs", "ANATOMY", 81, 87], ["cells", "ANATOMY", 111, 116], ["TM cell", "CELL", 19, 26], ["organs", "ORGAN", 81, 87], ["cells", "CELL", 111, 116], ["TM cell subsets", "CELL_TYPE", 19, 34], ["different TM cell subsets", "PROBLEM", 9, 34], ["these cells", "PROBLEM", 105, 116], ["different survival factors", "PROBLEM", 135, 161], ["different TM", "OBSERVATION_MODIFIER", 9, 21], ["cell subsets", "OBSERVATION", 22, 34]]], ["Since leukocyte recruitment is tightly regulated, it is interesting to understand the homing of each subset.CCR7 is a homing receptor ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSCCR7 is a lymphocyte-specific G-protein-coupled receptor with 7 transmembrane spanning alpha helices for CCL19 and CCL21 as ligands.", [["leukocyte", "ANATOMY", 6, 15], ["lymphocyte", "ANATOMY", 195, 205], ["transmembrane", "ANATOMY", 249, 262], ["leukocyte", "CELL", 6, 15], ["CCR7", "GENE_OR_GENE_PRODUCT", 108, 112], ["CD8+ T CELLSCCR7", "GENE_OR_GENE_PRODUCT", 173, 189], ["lymphocyte", "CELL", 195, 205], ["G-protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 215, 241], ["alpha helices", "GENE_OR_GENE_PRODUCT", 272, 285], ["CCL19", "GENE_OR_GENE_PRODUCT", 290, 295], ["CCL21", "GENE_OR_GENE_PRODUCT", 300, 305], ["CCR7", "PROTEIN", 108, 112], ["homing receptor", "PROTEIN", 118, 133], ["CD8", "PROTEIN", 173, 176], ["T CELLSCCR7", "PROTEIN", 178, 189], ["G-protein-coupled receptor", "PROTEIN", 215, 241], ["7 transmembrane spanning alpha helices", "PROTEIN", 247, 285], ["CCL19", "PROTEIN", 290, 295], ["CCL21", "PROTEIN", 300, 305], ["leukocyte recruitment", "PROBLEM", 6, 27], ["MEMORY CD8", "TEST", 166, 176], ["CELLSCCR7", "TEST", 180, 189], ["a lymphocyte", "TEST", 193, 205], ["transmembrane spanning alpha helices", "TREATMENT", 249, 285], ["CCL19", "TEST", 290, 295], ["leukocyte recruitment", "OBSERVATION", 6, 27]]], ["It was first named Epstein-Barr virus (EBV)-indicted gene 1, a gene induced by EBV and Burkitt's lymphoma cells in B-lymphocytes.", [["Burkitt's lymphoma cells", "ANATOMY", 87, 111], ["B-lymphocytes", "ANATOMY", 115, 128], ["Burkitt's lymphoma", "DISEASE", 87, 105], ["Epstein-Barr virus", "ORGANISM", 19, 37], ["EBV", "ORGANISM", 39, 42], ["indicted gene 1", "GENE_OR_GENE_PRODUCT", 44, 59], ["EBV", "ORGANISM", 79, 82], ["Burkitt's lymphoma cells", "CELL", 87, 111], ["B-lymphocytes", "CELL", 115, 128], ["indicted gene 1", "DNA", 44, 59], ["EBV and Burkitt's lymphoma cells", "CELL_LINE", 79, 111], ["B-lymphocytes", "CELL_TYPE", 115, 128], ["Epstein-Barr virus", "SPECIES", 19, 37], ["EBV", "SPECIES", 39, 42], ["EBV", "SPECIES", 79, 82], ["Barr virus", "PROBLEM", 27, 37], ["EBV", "PROBLEM", 79, 82], ["Burkitt's lymphoma cells", "PROBLEM", 87, 111], ["Barr virus", "OBSERVATION", 27, 37], ["EBV", "ANATOMY", 79, 82], ["lymphoma cells", "OBSERVATION", 97, 111], ["lymphocytes", "ANATOMY", 117, 128]]], ["In the same study, it was shown that it plays an important role in response to virus infection and is detected only in B- and T-lymphocytes (3940).CCR7 is a homing receptor ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSIn the late 1990s, a study using CCR7-deficient mice showed that CCR7 plays an important role in controlling T cell movement to SLOs, particularly LNs and PPs.", [["B-", "ANATOMY", 119, 121], ["T-lymphocytes", "ANATOMY", 126, 139], ["T cell", "ANATOMY", 333, 339], ["SLOs", "ANATOMY", 352, 356], ["LNs", "ANATOMY", 371, 374], ["infection", "DISEASE", 85, 94], ["B-", "CELL", 119, 121], ["T-lymphocytes", "CELL", 126, 139], ["3940", "CELL", 141, 145], ["CCR7", "GENE_OR_GENE_PRODUCT", 147, 151], ["CCR7", "GENE_OR_GENE_PRODUCT", 257, 261], ["mice", "ORGANISM", 272, 276], ["CCR7", "GENE_OR_GENE_PRODUCT", 289, 293], ["T cell", "CELL", 333, 339], ["SLOs", "GENE_OR_GENE_PRODUCT", 352, 356], ["LNs", "MULTI-TISSUE_STRUCTURE", 371, 374], ["PPs", "MULTI-TISSUE_STRUCTURE", 379, 382], ["B- and T-lymphocytes", "CELL_TYPE", 119, 139], ["CCR7", "PROTEIN", 147, 151], ["homing receptor", "PROTEIN", 157, 172], ["CD8", "PROTEIN", 212, 215], ["CCR7", "PROTEIN", 257, 261], ["CCR7", "PROTEIN", 289, 293], ["LNs", "CELL_TYPE", 371, 374], ["PPs", "CELL_TYPE", 379, 382], ["mice", "SPECIES", 272, 276], ["mice", "SPECIES", 272, 276], ["the same study", "TEST", 3, 17], ["virus infection", "PROBLEM", 79, 94], ["a study", "TEST", 243, 250], ["PPs", "PROBLEM", 379, 382], ["lymphocytes", "ANATOMY", 128, 139]]], ["In addition, the formation of T cell zone was abolished due to abnormal T cell migration.", [["T cell zone", "ANATOMY", 30, 41], ["T cell", "ANATOMY", 72, 78], ["T cell", "CELL", 30, 36], ["T cell", "CELL", 72, 78], ["T cell zone", "PROBLEM", 30, 41], ["abnormal T cell migration", "PROBLEM", 63, 88], ["T cell zone", "OBSERVATION", 30, 41], ["abnormal", "OBSERVATION_MODIFIER", 63, 71], ["T cell migration", "OBSERVATION", 72, 88]]], ["After immunization, the migration of mature skin DCs into the LNs resulted in delayed immune response to injected Ags (4142).", [["skin DCs", "ANATOMY", 44, 52], ["LNs", "ANATOMY", 62, 65], ["skin DCs", "CELL", 44, 52], ["LNs", "MULTI-TISSUE_STRUCTURE", 62, 65], ["mature skin DCs", "CELL_TYPE", 37, 52], ["LNs", "CELL_TYPE", 62, 65], ["Ags", "PROTEIN", 114, 117], ["immunization", "TREATMENT", 6, 18], ["the migration of mature skin DCs", "TREATMENT", 20, 52], ["delayed immune response", "PROBLEM", 78, 101], ["skin", "ANATOMY", 44, 48], ["LNs", "ANATOMY", 62, 65]]], ["Based on this observation, CCR7 has been established as one of the crucial receivers responsible for lymphocyte homing (41).CD8+ T cells and CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSAmong the CD8+ T cells, na\u00efve and TCM cells generally express high levels of CCR7 (3124344), hence they can migrate to the T cell zone of the LNs and spleen.", [["lymphocyte", "ANATOMY", 101, 111], ["CD8+ T cells", "ANATOMY", 124, 136], ["CD8+ T cells", "ANATOMY", 207, 219], ["na\u00efve", "ANATOMY", 221, 226], ["TCM cells", "ANATOMY", 231, 240], ["T cell zone", "ANATOMY", 320, 331], ["LNs", "ANATOMY", 339, 342], ["spleen", "ANATOMY", 347, 353], ["CCR7", "GENE_OR_GENE_PRODUCT", 27, 31], ["lymphocyte", "CELL", 101, 111], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["CCR7", "GENE_OR_GENE_PRODUCT", 141, 145], ["CD8", "GENE_OR_GENE_PRODUCT", 207, 210], ["TCM cells", "CELL", 231, 240], ["CCR7", "GENE_OR_GENE_PRODUCT", 274, 278], ["T cell", "CELL", 320, 326], ["LNs", "MULTI-TISSUE_STRUCTURE", 339, 342], ["spleen", "ORGAN", 347, 353], ["CCR7", "PROTEIN", 27, 31], ["CD8", "PROTEIN", 124, 127], ["T cells", "CELL_TYPE", 129, 136], ["CCR7", "PROTEIN", 141, 145], ["CD8", "PROTEIN", 185, 188], ["CD8+ T cells", "CELL_TYPE", 207, 219], ["na\u00efve and TCM cells", "CELL_TYPE", 221, 240], ["CCR7", "PROTEIN", 274, 278], ["this observation", "TEST", 9, 25], ["lymphocyte homing", "TEST", 101, 118], ["CCR7", "TEST", 141, 145], ["MEMORY CD8", "TEST", 178, 188], ["T", "TEST", 190, 191], ["CELLSAmong", "TEST", 192, 202], ["the CD8", "TEST", 203, 210], ["T cells", "TEST", 212, 219], ["na\u00efve", "TEST", 221, 226], ["TCM cells", "TEST", 231, 240], ["CCR7", "TEST", 274, 278], ["T cells", "OBSERVATION", 129, 136], ["TCM cells", "OBSERVATION", 231, 240], ["high", "OBSERVATION_MODIFIER", 259, 263], ["LNs", "ANATOMY", 339, 342], ["spleen", "ANATOMY", 347, 353]]], ["These T cells can be activated in the T cell zone by the APCs and developed into TE cells.", [["T cells", "ANATOMY", 6, 13], ["T cell zone", "ANATOMY", 38, 49], ["APCs", "ANATOMY", 57, 61], ["TE cells", "ANATOMY", 81, 89], ["T cells", "CELL", 6, 13], ["T cell", "CELL", 38, 44], ["APCs", "CELL", 57, 61], ["TE cells", "CELL", 81, 89], ["T cells", "CELL_TYPE", 6, 13], ["APCs", "CELL_TYPE", 57, 61], ["TE cells", "CELL_TYPE", 81, 89], ["These T cells", "PROBLEM", 0, 13]]], ["During this process, TE cells can move from the T cell zone to the red pulp and the infected area by the downregulation of CCR7 expression (45).", [["TE cells", "ANATOMY", 21, 29], ["T cell zone", "ANATOMY", 48, 59], ["red pulp", "ANATOMY", 67, 75], ["area", "ANATOMY", 93, 97], ["TE cells", "CELL", 21, 29], ["T cell", "CELL", 48, 54], ["red pulp", "TISSUE", 67, 75], ["CCR7", "GENE_OR_GENE_PRODUCT", 123, 127], ["TE cells", "CELL_TYPE", 21, 29], ["CCR7", "PROTEIN", 123, 127], ["TE cells", "PROBLEM", 21, 29], ["the infected area", "PROBLEM", 80, 97], ["red pulp", "ANATOMY", 67, 75], ["infected", "OBSERVATION_MODIFIER", 84, 92], ["area", "OBSERVATION_MODIFIER", 93, 97], ["downregulation", "OBSERVATION_MODIFIER", 105, 119], ["CCR7 expression", "OBSERVATION", 123, 138]]], ["Through this regulation of CCR7 expression, CD8+ T cells can find their cognate Ag in the SLOs to be activated and migrated into infected locus.", [["CD8+ T cells", "ANATOMY", 44, 56], ["SLOs", "ANATOMY", 90, 94], ["Ag", "CHEMICAL", 80, 82], ["CCR7", "GENE_OR_GENE_PRODUCT", 27, 31], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["Ag", "GENE_OR_GENE_PRODUCT", 80, 82], ["SLOs", "GENE_OR_GENE_PRODUCT", 90, 94], ["CCR7", "PROTEIN", 27, 31], ["CD8", "PROTEIN", 44, 47], ["T cells", "CELL_TYPE", 49, 56], ["Ag", "PROTEIN", 80, 82], ["CCR7 expression", "TREATMENT", 27, 42], ["infected locus", "OBSERVATION", 129, 143]]], ["After infections are cleared, TM cells form and circulate to different parts of the body based on the levels of CCR7 expression (454647).CD8+ T cells and CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSDuring TE\u2013TM cell transition, CCR7 expression influences the fate of these cells.", [["TM cells", "ANATOMY", 30, 38], ["body", "ANATOMY", 84, 88], ["CD8+ T cells", "ANATOMY", 137, 149], ["CD8+ T CELLSDuring TE\u2013TM cell", "ANATOMY", 198, 227], ["cells", "ANATOMY", 285, 290], ["infections", "DISEASE", 6, 16], ["TM cells", "CELL", 30, 38], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["CCR7", "GENE_OR_GENE_PRODUCT", 112, 116], ["CD8", "GENE_OR_GENE_PRODUCT", 137, 140], ["CCR7", "GENE_OR_GENE_PRODUCT", 154, 158], ["CCR7", "GENE_OR_GENE_PRODUCT", 240, 244], ["cells", "CELL", 285, 290], ["TM cells", "CELL_TYPE", 30, 38], ["CCR7", "PROTEIN", 112, 116], ["CD8", "PROTEIN", 137, 140], ["T cells", "CELL_TYPE", 142, 149], ["CCR7", "PROTEIN", 154, 158], ["CD8", "PROTEIN", 198, 201], ["CCR7", "PROTEIN", 240, 244], ["infections", "PROBLEM", 6, 16], ["TM cells", "TEST", 30, 38], ["CCR7", "TEST", 154, 158], ["MEMORY CD8", "TEST", 191, 201], ["CELLSDuring", "TEST", 205, 216], ["TE", "TEST", 217, 219], ["TM cell transition", "TEST", 220, 238], ["CCR7 expression", "TEST", 240, 255], ["infections", "OBSERVATION", 6, 16], ["body", "ANATOMY_MODIFIER", 84, 88], ["CCR7 expression", "OBSERVATION", 112, 127], ["T cells", "OBSERVATION", 142, 149]]], ["It was reported that the mRNA levels of CCR7 were more pronounced in memory precursor T cells (MPECs) than in short-lived effector cells (SLECs) (48).", [["memory precursor T cells", "ANATOMY", 69, 93], ["MPECs", "ANATOMY", 95, 100], ["short-lived effector cells", "ANATOMY", 110, 136], ["SLECs", "ANATOMY", 138, 143], ["CCR7", "GENE_OR_GENE_PRODUCT", 40, 44], ["memory precursor T cells", "CELL", 69, 93], ["MPECs", "CELL", 95, 100], ["short-lived effector cells", "CELL", 110, 136], ["SLECs", "CELL", 138, 143], ["CCR7", "PROTEIN", 40, 44], ["memory precursor T cells", "CELL_TYPE", 69, 93], ["MPECs", "CELL_TYPE", 95, 100], ["short-lived effector cells", "CELL_TYPE", 110, 136], ["SLECs", "CELL_TYPE", 138, 143], ["the mRNA levels", "TEST", 21, 36], ["CCR7", "TEST", 40, 44], ["MPECs", "TEST", 95, 100], ["CCR7", "ANATOMY", 40, 44]]], ["In addition, the TCM and TEM cells were found in different locations of the SLOs depending on CCR7 concentration.CD8+ T cells and CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSCCR7 expression was inhibited in TRM cells, the recently identified TM cell subset, making it possible for TRM cells to act as the first line of defense within peripheral tissues (49).", [["TCM", "ANATOMY", 17, 20], ["TEM cells", "ANATOMY", 25, 34], ["SLOs", "ANATOMY", 76, 80], ["CD8+ T cells", "ANATOMY", 113, 125], ["TRM cells", "ANATOMY", 219, 228], ["TM cell", "ANATOMY", 254, 261], ["TRM cells", "ANATOMY", 293, 302], ["peripheral tissues", "ANATOMY", 346, 364], ["TCM", "CELL", 17, 20], ["TEM cells", "CELL", 25, 34], ["SLOs", "GENE_OR_GENE_PRODUCT", 76, 80], ["CCR7", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD8", "GENE_OR_GENE_PRODUCT", 113, 116], ["CCR7", "GENE_OR_GENE_PRODUCT", 130, 134], ["CD8+ T CELLSCCR7", "GENE_OR_GENE_PRODUCT", 174, 190], ["TRM cells", "CELL", 219, 228], ["TM cell", "CELL", 254, 261], ["TRM cells", "CELL", 293, 302], ["peripheral tissues", "TISSUE", 346, 364], ["TCM", "CELL_TYPE", 17, 20], ["TEM cells", "CELL_LINE", 25, 34], ["CCR7", "PROTEIN", 94, 98], ["CD8", "PROTEIN", 113, 116], ["T cells", "CELL_TYPE", 118, 125], ["CCR7", "PROTEIN", 130, 134], ["CD8", "PROTEIN", 174, 177], ["CELLSCCR7", "PROTEIN", 181, 190], ["TRM cells", "CELL_LINE", 219, 228], ["TM cell subset", "CELL_LINE", 254, 268], ["TRM cells", "CELL_LINE", 293, 302], ["the SLOs", "PROBLEM", 72, 80], ["CCR7 concentration", "TREATMENT", 94, 112], ["CCR7", "TEST", 130, 134], ["MEMORY CD8", "TEST", 167, 177], ["TRM cells", "PROBLEM", 219, 228], ["TM cell subset", "PROBLEM", 254, 268], ["TRM cells", "PROBLEM", 293, 302], ["SLOs", "OBSERVATION", 76, 80], ["T cells", "OBSERVATION", 118, 125], ["TRM cells", "OBSERVATION", 219, 228], ["TM cell subset", "OBSERVATION", 254, 268], ["defense", "OBSERVATION", 331, 338], ["peripheral tissues", "ANATOMY", 346, 364]]], ["Altogether, the regulation of CCR7 expression controls the recruitment and release of CD8+ T cells from SLOs, determining the CD8+ T cell response outcome.Transcriptional regulation of CCR7 and microRNAs (miRNAs) ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSThe expression of CCR7 on CD8+ T cells is regulated by several transcription factors.", [["CD8+ T cells", "ANATOMY", 86, 98], ["SLOs", "ANATOMY", 104, 108], ["CD8+ T cell", "ANATOMY", 126, 137], ["CD8+ T cells", "ANATOMY", 290, 302], ["CCR7", "GENE_OR_GENE_PRODUCT", 30, 34], ["CD8", "GENE_OR_GENE_PRODUCT", 86, 89], ["SLOs", "GENE_OR_GENE_PRODUCT", 104, 108], ["CD8", "GENE_OR_GENE_PRODUCT", 126, 129], ["CCR7", "GENE_OR_GENE_PRODUCT", 185, 189], ["CCR7", "GENE_OR_GENE_PRODUCT", 282, 286], ["CD8", "GENE_OR_GENE_PRODUCT", 290, 293], ["CCR7", "PROTEIN", 30, 34], ["CD8+ T cells", "CELL_TYPE", 86, 98], ["CD8", "PROTEIN", 126, 129], ["CCR7", "PROTEIN", 185, 189], ["microRNAs", "DNA", 194, 203], ["miRNAs", "DNA", 205, 211], ["CD8", "PROTEIN", 252, 255], ["CCR7", "PROTEIN", 282, 286], ["CD8+ T cells", "CELL_TYPE", 290, 302], ["transcription factors", "PROTEIN", 327, 348], ["SLOs", "TEST", 104, 108], ["MEMORY CD8", "TEST", 245, 255], ["CCR7", "TEST", 282, 286], ["CD8", "TEST", 290, 293], ["T cells", "PROBLEM", 295, 302], ["T cell response outcome", "OBSERVATION", 131, 154], ["CCR7", "ANATOMY", 185, 189], ["CCR7", "ANATOMY", 282, 286]]], ["In the CCR7 promoter region, there are 3 binding sites specific for protein 1 (Sp1) and one Ets-1-binding site (50), which suggests that the increased expression of CCR7 is mediated at least partially by transcription factors such as Sp1 and Ets-1 (Fig. 2) (3550).", [["CCR7", "GENE_OR_GENE_PRODUCT", 7, 11], ["protein 1", "GENE_OR_GENE_PRODUCT", 68, 77], ["Sp1", "GENE_OR_GENE_PRODUCT", 79, 82], ["Ets-1", "GENE_OR_GENE_PRODUCT", 92, 97], ["CCR7", "GENE_OR_GENE_PRODUCT", 165, 169], ["Sp1", "GENE_OR_GENE_PRODUCT", 234, 237], ["Ets-1", "GENE_OR_GENE_PRODUCT", 242, 247], ["CCR7 promoter region", "DNA", 7, 27], ["binding sites", "DNA", 41, 54], ["protein 1", "PROTEIN", 68, 77], ["Sp1", "PROTEIN", 79, 82], ["Ets-1-binding site", "DNA", 92, 110], ["CCR7", "PROTEIN", 165, 169], ["transcription factors", "PROTEIN", 204, 225], ["Sp1", "PROTEIN", 234, 237], ["Ets-1", "PROTEIN", 242, 247], ["3 binding sites", "PROBLEM", 39, 54], ["protein", "TEST", 68, 75], ["Sp1", "TEST", 79, 82], ["one Ets", "TEST", 88, 95], ["the increased expression of CCR7", "PROBLEM", 137, 169], ["Sp1 and Ets", "TEST", 234, 245], ["CCR7", "ANATOMY", 7, 11], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["CCR7", "ANATOMY", 165, 169]]], ["AP1 and NF-\u03baB were also reported to upregulate CCR7 expression via binding to the CCR7 promoter locus in various cancer cell lines (515253).", [["cancer cell lines", "ANATOMY", 113, 130], ["515253", "ANATOMY", 132, 138], ["cancer", "DISEASE", 113, 119], ["AP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 8, 13], ["CCR7", "GENE_OR_GENE_PRODUCT", 47, 51], ["CCR7", "GENE_OR_GENE_PRODUCT", 82, 86], ["cancer cell lines", "CELL", 113, 130], ["515253", "CELL", 132, 138], ["AP1", "PROTEIN", 0, 3], ["NF-\u03baB", "PROTEIN", 8, 13], ["CCR7", "PROTEIN", 47, 51], ["CCR7 promoter locus", "DNA", 82, 101], ["cancer cell lines", "CELL_LINE", 113, 130], ["515253", "CELL_LINE", 132, 138], ["AP1", "TEST", 0, 3], ["various", "OBSERVATION_MODIFIER", 105, 112], ["cancer cell lines", "OBSERVATION", 113, 130]]], ["In addition, Kr\u00fcppel-like factor 2 (KLF2) and T cell factor 1 (TCF1) are significantly upregulated in na\u00efve and TCM cells and regulate the expression of several molecules including CCR7, CD62L (L-selectin; encoded by Sell), and sphingosine-1-phosphate receptor 1 in order to modulate the migration into the SLOs (54).", [["TCM cells", "ANATOMY", 112, 121], ["SLOs", "ANATOMY", 307, 311], ["sphingosine-1-phosphate", "CHEMICAL", 228, 251], ["sphingosine-1-phosphate", "CHEMICAL", 228, 251], ["Kr\u00fcppel-like factor 2", "GENE_OR_GENE_PRODUCT", 13, 34], ["KLF2", "GENE_OR_GENE_PRODUCT", 36, 40], ["T cell factor 1", "GENE_OR_GENE_PRODUCT", 46, 61], ["TCF1", "GENE_OR_GENE_PRODUCT", 63, 67], ["na\u00efve", "CELL", 102, 107], ["TCM cells", "CELL", 112, 121], ["CCR7", "GENE_OR_GENE_PRODUCT", 181, 185], ["CD62L", "GENE_OR_GENE_PRODUCT", 187, 192], ["L-selectin", "GENE_OR_GENE_PRODUCT", 194, 204], ["Sell", "GENE_OR_GENE_PRODUCT", 217, 221], ["sphingosine-1-phosphate receptor 1", "GENE_OR_GENE_PRODUCT", 228, 262], ["Kr\u00fcppel-like factor 2", "PROTEIN", 13, 34], ["KLF2", "PROTEIN", 36, 40], ["T cell factor 1", "PROTEIN", 46, 61], ["TCF1", "PROTEIN", 63, 67], ["na\u00efve and TCM cells", "CELL_TYPE", 102, 121], ["CCR7", "PROTEIN", 181, 185], ["CD62L", "PROTEIN", 187, 192], ["L-selectin", "PROTEIN", 194, 204], ["Sell", "PROTEIN", 217, 221], ["sphingosine-1-phosphate receptor 1", "PROTEIN", 228, 262], ["Kr\u00fcppel", "TEST", 13, 20], ["KLF2", "TEST", 36, 40], ["T cell factor", "TEST", 46, 59], ["TCF1", "TEST", 63, 67], ["TCM cells", "TEST", 112, 121], ["CCR7", "TEST", 181, 185], ["CD62L", "TEST", 187, 192], ["sphingosine-1-phosphate receptor", "TREATMENT", 228, 260], ["TCM cells", "OBSERVATION", 112, 121], ["CCR7", "ANATOMY", 181, 185], ["migration", "OBSERVATION", 288, 297]]], ["In contrast, CD8+ TEM and TRM cells suppress KLF2 and TCF1, while simultaneously expressing Blimp-1 and suppressing the transcription of CCR7 independently (555657).Transcriptional regulation of CCR7 and microRNAs (miRNAs) ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSIt was also reported that Forkhead O 1 (FOXO1), another transcription factor, regulates CCR7 transcription during TE\u2013TM cell transition, and not during na\u00efve\u2013CD8+ TE cell transition.", [["CD8+ TEM", "ANATOMY", 13, 21], ["TRM cells", "ANATOMY", 26, 35], ["TE\u2013TM cell", "ANATOMY", 388, 398], ["na\u00efve\u2013CD8+ TE cell", "ANATOMY", 426, 444], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["TRM cells", "CELL", 26, 35], ["KLF2", "GENE_OR_GENE_PRODUCT", 45, 49], ["TCF1", "GENE_OR_GENE_PRODUCT", 54, 58], ["Blimp-1", "GENE_OR_GENE_PRODUCT", 92, 99], ["CCR7", "GENE_OR_GENE_PRODUCT", 137, 141], ["CCR7", "GENE_OR_GENE_PRODUCT", 195, 199], ["Forkhead O 1", "GENE_OR_GENE_PRODUCT", 300, 312], ["FOXO1", "GENE_OR_GENE_PRODUCT", 314, 319], ["CCR7", "GENE_OR_GENE_PRODUCT", 362, 366], ["TM cell", "CELL", 391, 398], ["CD8", "GENE_OR_GENE_PRODUCT", 432, 435], ["CD8", "PROTEIN", 13, 16], ["TEM", "CELL_TYPE", 18, 21], ["TRM cells", "CELL_TYPE", 26, 35], ["KLF2", "PROTEIN", 45, 49], ["TCF1", "PROTEIN", 54, 58], ["Blimp-1", "PROTEIN", 92, 99], ["CCR7", "PROTEIN", 137, 141], ["CCR7", "PROTEIN", 195, 199], ["microRNAs", "DNA", 204, 213], ["miRNAs", "DNA", 215, 221], ["CD8", "PROTEIN", 262, 265], ["T CELLSIt", "PROTEIN", 267, 276], ["Forkhead O 1", "PROTEIN", 300, 312], ["FOXO1", "PROTEIN", 314, 319], ["transcription factor", "PROTEIN", 330, 350], ["CCR7", "PROTEIN", 362, 366], ["CD8", "PROTEIN", 432, 435], ["CD8", "TEST", 13, 16], ["TRM cells", "TEST", 26, 35], ["KLF2", "TEST", 45, 49], ["TCF1", "TEST", 54, 58], ["CCR7", "ANATOMY", 195, 199], ["cell transition", "OBSERVATION", 440, 455]]], ["A study using FOXO1 knockout (KO) mice demonstrated that FOXO1 promoted enrichment of MP cells, thus wild-type TE cells highly proliferated upon secondary infections in CD8+ T cells compared to FOXO1-deficient TE cells (58).", [["MP cells", "ANATOMY", 86, 94], ["wild-type TE cells", "ANATOMY", 101, 119], ["CD8+ T cells", "ANATOMY", 169, 181], ["FOXO1-deficient TE cells", "ANATOMY", 194, 218], ["infections", "DISEASE", 155, 165], ["FOXO1", "GENE_OR_GENE_PRODUCT", 14, 19], ["FOXO1", "GENE_OR_GENE_PRODUCT", 57, 62], ["MP cells", "CELL", 86, 94], ["TE cells", "CELL", 111, 119], ["CD8", "GENE_OR_GENE_PRODUCT", 169, 172], ["FOXO1", "GENE_OR_GENE_PRODUCT", 194, 199], ["FOXO1", "PROTEIN", 14, 19], ["FOXO1", "PROTEIN", 57, 62], ["MP cells", "CELL_TYPE", 86, 94], ["wild-type TE cells", "CELL_TYPE", 101, 119], ["CD8+ T cells", "CELL_TYPE", 169, 181], ["FOXO1", "PROTEIN", 194, 199], ["TE cells", "CELL_TYPE", 210, 218], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38], ["A study", "TEST", 0, 7], ["FOXO1", "PROBLEM", 57, 62], ["MP cells", "PROBLEM", 86, 94], ["wild-type TE cells", "PROBLEM", 101, 119], ["secondary infections", "PROBLEM", 145, 165], ["CD8+ T cells", "PROBLEM", 169, 181], ["FOXO1", "TEST", 194, 199], ["MP cells", "OBSERVATION", 86, 94], ["secondary", "OBSERVATION_MODIFIER", 145, 154], ["infections", "OBSERVATION", 155, 165]]], ["In a related study, it was observed that FOXO1 expression is significantly higher in MPECs than in SLECs, and it increase the levels of IL-7Ra and TCF7 expression to help create and maintain TCM cells which were derived from MPECs (59).Transcriptional regulation of CCR7 and microRNAs (miRNAs) ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSCCR7 expression is also controlled by miRNAs.", [["MPECs", "ANATOMY", 85, 90], ["SLECs", "ANATOMY", 99, 104], ["TCM cells", "ANATOMY", 191, 200], ["MPECs", "ANATOMY", 225, 230], ["FOXO1", "GENE_OR_GENE_PRODUCT", 41, 46], ["MPECs", "PATHOLOGICAL_FORMATION", 85, 90], ["SLECs", "CELL", 99, 104], ["IL-7Ra", "GENE_OR_GENE_PRODUCT", 136, 142], ["TCF7", "GENE_OR_GENE_PRODUCT", 147, 151], ["TCM cells", "CELL", 191, 200], ["MPECs", "CELL", 225, 230], ["CCR7", "GENE_OR_GENE_PRODUCT", 266, 270], ["CD8+ T CELLSCCR7", "GENE_OR_GENE_PRODUCT", 333, 349], ["FOXO1", "PROTEIN", 41, 46], ["MPECs", "CELL_TYPE", 85, 90], ["SLECs", "CELL_TYPE", 99, 104], ["TCF7", "PROTEIN", 147, 151], ["TCM cells", "CELL_TYPE", 191, 200], ["CCR7", "PROTEIN", 266, 270], ["microRNAs", "DNA", 275, 284], ["miRNAs", "DNA", 286, 292], ["CD8", "PROTEIN", 333, 336], ["CELLSCCR7", "PROTEIN", 340, 349], ["a related study", "TEST", 3, 18], ["FOXO1 expression", "PROBLEM", 41, 57], ["IL-7Ra", "TREATMENT", 136, 142], ["TCM cells", "PROBLEM", 191, 200], ["MPECs", "TEST", 225, 230], ["significantly", "OBSERVATION_MODIFIER", 61, 74], ["higher", "OBSERVATION_MODIFIER", 75, 81], ["TCM cells", "OBSERVATION", 191, 200], ["CCR7", "ANATOMY", 266, 270]]], ["MiRNAs consisting of small RNA fragments under 23 nucleotides generally bind to 3' UTRs of complementary target sequences on target mRNAs to decay or stabilize the mRNA (60).", [["small RNA fragments", "DNA", 21, 40], ["3' UTRs", "DNA", 80, 87], ["complementary target sequences", "DNA", 91, 121], ["target mRNAs", "RNA", 125, 137], ["mRNA", "RNA", 164, 168], ["small RNA fragments", "PROBLEM", 21, 40], ["small", "OBSERVATION_MODIFIER", 21, 26], ["RNA fragments", "OBSERVATION", 27, 40]]], ["Using big data analysis, several T-cell-associated genes including CCR7 were discovered to be targeted by miR-21, an anti-apoptotic factor (616263).", [["T-cell", "ANATOMY", 33, 39], ["T-cell", "CELL", 33, 39], ["CCR7", "GENE_OR_GENE_PRODUCT", 67, 71], ["miR-21", "GENE_OR_GENE_PRODUCT", 106, 112], ["T-cell-associated genes", "DNA", 33, 56], ["CCR7", "PROTEIN", 67, 71], ["miR-21", "DNA", 106, 112], ["anti-apoptotic factor", "PROTEIN", 117, 138], ["big data analysis", "TEST", 6, 23], ["CCR7", "TEST", 67, 71], ["an anti-apoptotic factor", "TEST", 114, 138]]], ["MiR-21, a miRNA inhibiting post-transcription levels of CCR7, led to a significant reduction of CCR7 protein expression when na\u00efve and CD4+ TM cells are activated.", [["CD4+ TM cells", "ANATOMY", 135, 148], ["MiR-21", "GENE_OR_GENE_PRODUCT", 0, 6], ["CCR7", "GENE_OR_GENE_PRODUCT", 56, 60], ["CCR7", "GENE_OR_GENE_PRODUCT", 96, 100], ["CD4", "GENE_OR_GENE_PRODUCT", 135, 138], ["MiR-21", "PROTEIN", 0, 6], ["CCR7", "PROTEIN", 56, 60], ["CCR7", "PROTEIN", 96, 100], ["na\u00efve and CD4+ TM cells", "CELL_TYPE", 125, 148], ["MiR", "TEST", 0, 3], ["CCR7", "TEST", 56, 60], ["a significant reduction of CCR7 protein expression", "PROBLEM", 69, 119], ["na\u00efve", "TEST", 125, 130], ["CD4", "TEST", 135, 138], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["reduction", "OBSERVATION_MODIFIER", 83, 92], ["CCR7 protein expression", "OBSERVATION", 96, 119]]], ["Indeed, it is activated in inverse correlation to the amount of CCR7 protein (Fig. 2) (64).", [["CCR7", "GENE_OR_GENE_PRODUCT", 64, 68], ["CCR7 protein", "PROTEIN", 64, 76]]], ["Further, it was reported that the expression of CCR7 was adjusted by miRNAs in several cancers, such as let-7\u03b1 (in breast cancer cells and patients) (65), miR-320d (in oral squamous cell carcinoma) (66), miR-532-3p (in tongue squamous cell carcinoma) (67) and head and neck squamous cell carcinoma (68), and miR-199a (in human mantle cell lymphoma) (69).Epigenetic and post-translational modification (PTM) of CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSAlthough there is little report of epigenetic regulators for CCR7, it has been documented based on CCR7 gene methylation using big data analysis.", [["cancers", "ANATOMY", 87, 94], ["breast cancer cells", "ANATOMY", 115, 134], ["oral squamous cell carcinoma", "ANATOMY", 168, 196], ["miR-532-3p", "ANATOMY", 204, 214], ["tongue squamous cell carcinoma", "ANATOMY", 219, 249], ["head and neck squamous cell carcinoma", "ANATOMY", 260, 297], ["mantle cell lymphoma", "ANATOMY", 327, 347], ["cancers", "DISEASE", 87, 94], ["breast cancer", "DISEASE", 115, 128], ["oral squamous cell carcinoma", "DISEASE", 168, 196], ["miR-532-3p", "CHEMICAL", 204, 214], ["tongue squamous cell carcinoma", "DISEASE", 219, 249], ["head and neck squamous cell carcinoma", "DISEASE", 260, 297], ["mantle cell lymphoma", "DISEASE", 327, 347], ["CCR7", "GENE_OR_GENE_PRODUCT", 48, 52], ["cancers", "CANCER", 87, 94], ["let-7\u03b1", "GENE_OR_GENE_PRODUCT", 104, 110], ["breast cancer cells", "CELL", 115, 134], ["patients", "ORGANISM", 139, 147], ["miR-320d", "GENE_OR_GENE_PRODUCT", 155, 163], ["oral squamous cell carcinoma", "CANCER", 168, 196], ["miR-532-3p", "GENE_OR_GENE_PRODUCT", 204, 214], ["tongue squamous cell carcinoma", "CANCER", 219, 249], ["head and neck squamous cell carcinoma", "CANCER", 260, 297], ["miR-199a", "GENE_OR_GENE_PRODUCT", 308, 316], ["human", "ORGANISM", 321, 326], ["mantle cell lymphoma", "CANCER", 327, 347], ["CCR7", "GENE_OR_GENE_PRODUCT", 410, 414], ["CCR7", "GENE_OR_GENE_PRODUCT", 527, 531], ["CCR7", "GENE_OR_GENE_PRODUCT", 565, 569], ["CCR7", "PROTEIN", 48, 52], ["let-7\u03b1", "PROTEIN", 104, 110], ["breast cancer cells", "CELL_TYPE", 115, 134], ["miR-320d", "DNA", 155, 163], ["miR-532-3p", "DNA", 204, 214], ["miR-199a", "DNA", 308, 316], ["CCR7", "PROTEIN", 410, 414], ["CD8", "PROTEIN", 454, 457], ["epigenetic regulators", "PROTEIN", 501, 522], ["CCR7", "PROTEIN", 527, 531], ["CCR7 gene", "DNA", 565, 574], ["patients", "SPECIES", 139, 147], ["human", "SPECIES", 321, 326], ["human", "SPECIES", 321, 326], ["several cancers", "PROBLEM", 79, 94], ["miR", "TEST", 155, 158], ["oral squamous cell carcinoma", "PROBLEM", 168, 196], ["miR", "TEST", 204, 207], ["tongue squamous cell carcinoma", "PROBLEM", 219, 249], ["head and neck squamous cell carcinoma", "PROBLEM", 260, 297], ["miR", "TEST", 308, 311], ["human mantle cell lymphoma", "PROBLEM", 321, 347], ["big data analysis", "TEST", 593, 610], ["CCR7", "ANATOMY", 48, 52], ["several", "OBSERVATION_MODIFIER", 79, 86], ["cancers", "OBSERVATION", 87, 94], ["breast", "ANATOMY", 115, 121], ["cancer", "OBSERVATION", 122, 128], ["squamous cell carcinoma", "OBSERVATION", 173, 196], ["tongue", "ANATOMY", 219, 225], ["squamous cell carcinoma", "OBSERVATION", 226, 249], ["head", "ANATOMY", 260, 264], ["neck", "ANATOMY", 269, 273], ["squamous cell carcinoma", "OBSERVATION", 274, 297], ["mantle cell lymphoma", "OBSERVATION", 327, 347], ["post-translational modification", "OBSERVATION", 369, 400], ["CCR7", "ANATOMY", 410, 414]]], ["CCR7 methylation in human CD8+ TM cells increased in the order of CD8+ TM cell differentiation state: na\u00efve<TSCM (stem cell memory)<TCM<TEM, when this locus was analyzed using whole-genome bisulfite sequencing, a next-generation sequencing method (Fig. 2) (4).", [["CD8+ TM cells", "ANATOMY", 26, 39], ["CD8+ TM cell", "ANATOMY", 66, 78], ["TSCM", "ANATOMY", 108, 112], ["stem cell", "ANATOMY", 114, 123], ["bisulfite", "CHEMICAL", 189, 198], ["bisulfite", "CHEMICAL", 189, 198], ["CCR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 20, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD8", "GENE_OR_GENE_PRODUCT", 66, 69], ["stem cell", "CELL", 114, 123], ["locus", "CELLULAR_COMPONENT", 151, 156], ["CCR7", "PROTEIN", 0, 4], ["human CD8+ TM cells", "CELL_TYPE", 20, 39], ["CD8", "PROTEIN", 66, 69], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["CCR7 methylation", "TEST", 0, 16], ["human CD8", "TEST", 20, 29], ["TM cells", "TEST", 31, 39], ["CD8", "TEST", 66, 69], ["na\u00efve", "TEST", 102, 107], ["TSCM", "TEST", 108, 112], ["whole-genome bisulfite sequencing", "TREATMENT", 176, 209], ["a next-generation sequencing method", "TREATMENT", 211, 246], ["stem cell", "OBSERVATION", 114, 123]]], ["As the DNA methylation state is known as silent chromatin (called as heterochromatin), the expression of the gene was inhibited (70).", [["chromatin", "ANATOMY", 48, 57], ["heterochromatin", "ANATOMY", 69, 84], ["DNA", "CELLULAR_COMPONENT", 7, 10], ["chromatin", "CELLULAR_COMPONENT", 48, 57], ["heterochromatin", "CELLULAR_COMPONENT", 69, 84], ["chromatin", "DNA", 48, 57], ["heterochromatin", "DNA", 69, 84], ["the DNA methylation state", "PROBLEM", 3, 28]]], ["Another report showed that monocyte-derived DCs in the mouse lung homing into SLOs are significantly lower in number than conventional DCs.", [["monocyte", "ANATOMY", 27, 35], ["DCs", "ANATOMY", 44, 47], ["lung", "ANATOMY", 61, 65], ["SLOs", "ANATOMY", 78, 82], ["DCs", "ANATOMY", 135, 138], ["monocyte", "CELL", 27, 35], ["DCs", "CELL", 44, 47], ["mouse", "ORGANISM", 55, 60], ["lung", "ORGAN", 61, 65], ["SLOs", "GENE_OR_GENE_PRODUCT", 78, 82], ["DCs", "CELL", 135, 138], ["DCs", "CELL_TYPE", 44, 47], ["SLOs", "CELL_TYPE", 78, 82], ["DCs", "CELL_TYPE", 135, 138], ["mouse", "SPECIES", 55, 60], ["mouse", "SPECIES", 55, 60], ["monocyte", "TEST", 27, 35], ["monocyte", "OBSERVATION", 27, 35], ["lung", "ANATOMY", 61, 65], ["significantly", "OBSERVATION_MODIFIER", 87, 100], ["lower", "OBSERVATION_MODIFIER", 101, 106]]], ["In correlation with this observation, monocyte-derived DCs was highly methylated in H3K27 (H3K27me3), which forms heterochromatin, thus blocking their homing into the SLOs (71).Epigenetic and post-translational modification (PTM) of CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSCCR7 can also be regulated by PTM (Fig. 2).", [["monocyte", "ANATOMY", 38, 46], ["DCs", "ANATOMY", 55, 58], ["heterochromatin", "ANATOMY", 114, 129], ["monocyte", "CELL", 38, 46], ["DCs", "CELL", 55, 58], ["H3K27", "GENE_OR_GENE_PRODUCT", 84, 89], ["H3K27me3", "GENE_OR_GENE_PRODUCT", 91, 99], ["heterochromatin", "CELLULAR_COMPONENT", 114, 129], ["CCR7", "GENE_OR_GENE_PRODUCT", 233, 237], ["CD8+ T CELLSCCR7", "GENE_OR_GENE_PRODUCT", 277, 293], ["DCs", "CELL_TYPE", 55, 58], ["H3K27", "DNA", 84, 89], ["H3K27me3", "DNA", 91, 99], ["CCR7", "PROTEIN", 233, 237], ["CD8", "PROTEIN", 277, 280], ["T CELLSCCR7", "PROTEIN", 282, 293], ["PTM", "PROTEIN", 319, 322], ["this observation", "TEST", 20, 36], ["heterochromatin", "PROBLEM", 114, 129], ["Epigenetic and post-translational modification", "TREATMENT", 177, 223], ["CCR7", "ANATOMY", 233, 237]]], ["Glycosylation in the N-terminus of CCR7 protein in TE cells not only blocks, but also decreases receptor sensitivity, resulting in chemokine-induced downstream signaling modulation.", [["TE cells", "ANATOMY", 51, 59], ["CCR7", "GENE_OR_GENE_PRODUCT", 35, 39], ["TE cells", "CELL", 51, 59], ["CCR7 protein", "PROTEIN", 35, 47], ["TE cells", "CELL_LINE", 51, 59], ["chemokine", "PROTEIN", 131, 140], ["Glycosylation", "TREATMENT", 0, 13], ["CCR7 protein in TE cells", "TREATMENT", 35, 59], ["receptor sensitivity", "PROBLEM", 96, 116], ["chemokine-induced downstream signaling modulation", "TREATMENT", 131, 180], ["signaling modulation", "OBSERVATION", 160, 180]]], ["It was also reported that de-glycosylation with enzymes produced by DCs changed the folding of CCR7 protein to increase the activity of this receptor (9).", [["DCs", "ANATOMY", 68, 71], ["DCs", "CELL", 68, 71], ["CCR7", "GENE_OR_GENE_PRODUCT", 95, 99], ["enzymes", "PROTEIN", 48, 55], ["DCs", "CELL_TYPE", 68, 71], ["CCR7 protein", "PROTEIN", 95, 107], ["enzymes", "TEST", 48, 55], ["CCR7 protein", "TREATMENT", 95, 107], ["this receptor", "TREATMENT", 136, 149]]], ["Conversely, the induction of sulfation in tyrosine residue of the CCR7 protein N-terminus can increase the affinity between CCR7 and its ligands (72).Epigenetic and post-translational modification (PTM) of CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSAltogether the expression of CCR7 can be altered by many different factors in several steps, possibly indicating that the regulation of this receptor is critical for the immune response to pathogen.", [["tyrosine", "CHEMICAL", 42, 50], ["tyrosine", "CHEMICAL", 42, 50], ["N", "CHEMICAL", 79, 80], ["tyrosine", "AMINO_ACID", 42, 50], ["CCR7", "GENE_OR_GENE_PRODUCT", 66, 70], ["CCR7", "GENE_OR_GENE_PRODUCT", 124, 128], ["CCR7", "GENE_OR_GENE_PRODUCT", 206, 210], ["CCR7", "GENE_OR_GENE_PRODUCT", 291, 295], ["CCR7 protein N-terminus", "PROTEIN", 66, 89], ["CCR7", "PROTEIN", 124, 128], ["CCR7", "PROTEIN", 206, 210], ["CD8", "PROTEIN", 250, 253], ["CCR7", "PROTEIN", 291, 295], ["sulfation in tyrosine residue", "TREATMENT", 29, 58], ["this receptor", "TREATMENT", 398, 411], ["pathogen", "PROBLEM", 451, 459], ["post-translational modification", "OBSERVATION", 165, 196], ["CCR7", "ANATOMY", 206, 210], ["CCR7", "ANATOMY", 291, 295], ["possibly indicating", "UNCERTAINTY", 355, 374]]], ["In addition, it has been suggested that this receptor can be modulated using multiple methods in order to enhance adaptive immunity.CCL19 and CCL21, ligands of CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSCCR7hi CD8+ na\u00efve and TM cells have chemotaxis features toward CCL19 and CCL21 in a concentration-dependent manner (73747576).", [["CD8+ T CELLSCCR7hi CD8+ na\u00efve", "ANATOMY", 204, 233], ["TM cells", "ANATOMY", 238, 246], ["CCL19", "GENE_OR_GENE_PRODUCT", 132, 137], ["CCL21", "GENE_OR_GENE_PRODUCT", 142, 147], ["CCR7", "GENE_OR_GENE_PRODUCT", 160, 164], ["CD8", "GENE_OR_GENE_PRODUCT", 223, 226], ["CCL19", "GENE_OR_GENE_PRODUCT", 279, 284], ["CCL21", "GENE_OR_GENE_PRODUCT", 289, 294], ["CCL19", "PROTEIN", 132, 137], ["CCL21", "PROTEIN", 142, 147], ["CCR7", "PROTEIN", 160, 164], ["CD8", "PROTEIN", 204, 207], ["T CELLSCCR7hi CD8+ na\u00efve and TM cells", "CELL_TYPE", 209, 246], ["CCL19", "PROTEIN", 279, 284], ["CCL21", "PROTEIN", 289, 294], ["multiple methods", "TREATMENT", 77, 93], ["CCL19", "TEST", 132, 137], ["CCL21", "TEST", 142, 147], ["CCR7", "TEST", 160, 164], ["CCR7\u2014CHEMOKINE RECEPTOR", "TEST", 169, 192], ["MEMORY", "TEST", 197, 203], ["CD8", "TEST", 204, 207], ["T", "TEST", 209, 210], ["CELLSCCR7hi", "TEST", 211, 222], ["CD8", "TEST", 223, 226], ["na\u00efve", "TEST", 228, 233], ["TM cells", "TEST", 238, 246], ["chemotaxis features", "TEST", 252, 271], ["CCL19", "TEST", 279, 284], ["CCL21", "TEST", 289, 294], ["CCR7", "ANATOMY", 160, 164]]], ["These chemokines were reported to be produced by high endothelial venules (63) in the T cell zone of SLOs (7778).", [["high endothelial venules", "ANATOMY", 49, 73], ["T cell zone", "ANATOMY", 86, 97], ["SLOs", "ANATOMY", 101, 105], ["endothelial venules", "TISSUE", 54, 73], ["T cell", "CELL", 86, 92], ["chemokines", "PROTEIN", 6, 16], ["endothelial venules", "CELL_TYPE", 54, 73], ["These chemokines", "TEST", 0, 16], ["high", "OBSERVATION_MODIFIER", 49, 53], ["endothelial venules", "OBSERVATION", 54, 73]]], ["When na\u00efve T cells enter the SLOs, they are located in the T and B cell zones.", [["T cells", "ANATOMY", 11, 18], ["SLOs", "ANATOMY", 29, 33], ["T", "ANATOMY", 59, 60], ["B cell zones", "ANATOMY", 65, 77], ["na\u00efve T cells", "CELL", 5, 18], ["SLOs", "GENE_OR_GENE_PRODUCT", 29, 33], ["T", "CELL", 59, 60], ["B cell zones", "CELL", 65, 77], ["na\u00efve T cells", "CELL_TYPE", 5, 18], ["cell", "ANATOMY", 67, 71], ["zones", "ANATOMY_MODIFIER", 72, 77]]], ["Particularly, na\u00efve CD8+ T cells with CCR7 expression are enriched by FRCs in the T cell zones within the spleen and LNs, where CCL19 and CCL21 are highly enriched (3379).", [["CD8+ T cells", "ANATOMY", 20, 32], ["FRCs", "ANATOMY", 70, 74], ["T cell zones", "ANATOMY", 82, 94], ["spleen", "ANATOMY", 106, 112], ["LNs", "ANATOMY", 117, 120], ["CD8", "GENE_OR_GENE_PRODUCT", 20, 23], ["CCR7", "GENE_OR_GENE_PRODUCT", 38, 42], ["FRCs", "GENE_OR_GENE_PRODUCT", 70, 74], ["T cell zones", "CELL", 82, 94], ["spleen", "ORGAN", 106, 112], ["LNs", "MULTI-TISSUE_STRUCTURE", 117, 120], ["CCL19", "GENE_OR_GENE_PRODUCT", 128, 133], ["CCL21", "GENE_OR_GENE_PRODUCT", 138, 143], ["na\u00efve CD8+ T cells", "CELL_TYPE", 14, 32], ["CCR7", "PROTEIN", 38, 42], ["FRCs", "PROTEIN", 70, 74], ["CCL19", "PROTEIN", 128, 133], ["CCL21", "PROTEIN", 138, 143], ["CCR7 expression", "TEST", 38, 53], ["CCL19", "TEST", 128, 133], ["CCL21", "TEST", 138, 143], ["CCR7 expression", "OBSERVATION", 38, 53], ["FRCs", "OBSERVATION_MODIFIER", 70, 74], ["T cell", "OBSERVATION", 82, 88], ["zones", "ANATOMY_MODIFIER", 89, 94], ["spleen", "ANATOMY", 106, 112], ["LNs", "ANATOMY", 117, 120], ["CCL19", "ANATOMY_MODIFIER", 128, 133], ["CCL21", "ANATOMY", 138, 143]]], ["Correlated with the role of these chemokines, the rate of movement of na\u00efve T cells in the SLOs decreases in plt/plt mouse (paucity of LN; naturally weak CCL19 and CCL21 mutant mice) regardless of T cells lacking CCR7 (8081).", [["na\u00efve T cells", "ANATOMY", 70, 83], ["SLOs", "ANATOMY", 91, 95], ["LN", "ANATOMY", 135, 137], ["T cells", "ANATOMY", 197, 204], ["na\u00efve T cells", "CELL", 70, 83], ["SLOs", "GENE_OR_GENE_PRODUCT", 91, 95], ["plt", "GENE_OR_GENE_PRODUCT", 109, 112], ["mouse", "ORGANISM", 117, 122], ["LN", "CANCER", 135, 137], ["CCL19", "GENE_OR_GENE_PRODUCT", 154, 159], ["CCL21", "GENE_OR_GENE_PRODUCT", 164, 169], ["T cells", "CELL", 197, 204], ["CCR7", "GENE_OR_GENE_PRODUCT", 213, 217], ["chemokines", "PROTEIN", 34, 44], ["na\u00efve T cells", "CELL_TYPE", 70, 83], ["CCL19", "PROTEIN", 154, 159], ["CCL21", "PROTEIN", 164, 169], ["T cells", "CELL_TYPE", 197, 204], ["CCR7", "PROTEIN", 213, 217], ["mouse", "SPECIES", 117, 122], ["mice", "SPECIES", 177, 181], ["mouse", "SPECIES", 117, 122], ["these chemokines", "TEST", 28, 44], ["na\u00efve T cells", "PROBLEM", 70, 83], ["the SLOs", "TEST", 87, 95], ["plt", "TEST", 109, 112], ["plt mouse", "TEST", 113, 122], ["LN", "TEST", 135, 137], ["CCL19", "TEST", 154, 159], ["decreases", "OBSERVATION_MODIFIER", 96, 105], ["LN", "ANATOMY", 135, 137]]], ["In the CCL21-deficient-special niche, CCR7-positive na\u00efve and TM cells circulate themselves within the interstitial lymphoid organs after being ejected from SLOs.CCL19 and CCL21, ligands of CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSThe quality and quantity of these microenvironmental niches were dynamically changed by several factors during the state of immune responses.", [["niche", "ANATOMY", 31, 36], ["TM cells", "ANATOMY", 62, 70], ["interstitial lymphoid organs", "ANATOMY", 103, 131], ["CCL21", "GENE_OR_GENE_PRODUCT", 7, 12], ["CCR7", "GENE_OR_GENE_PRODUCT", 38, 42], ["TM cells", "CELL", 62, 70], ["interstitial lymphoid organs", "TISSUE", 103, 131], ["CCL19", "GENE_OR_GENE_PRODUCT", 162, 167], ["CCL21", "GENE_OR_GENE_PRODUCT", 172, 177], ["CCR7", "GENE_OR_GENE_PRODUCT", 190, 194], ["CCL21", "PROTEIN", 7, 12], ["CCR7", "PROTEIN", 38, 42], ["positive na\u00efve and TM cells", "CELL_TYPE", 43, 70], ["CCL19", "PROTEIN", 162, 167], ["CCL21", "PROTEIN", 172, 177], ["CCR7", "PROTEIN", 190, 194], ["CD8", "PROTEIN", 234, 237], ["CCR7", "TEST", 38, 42], ["TM cells circulate themselves", "PROBLEM", 62, 91], ["CCL19", "TEST", 162, 167], ["CCL21", "TEST", 172, 177], ["these microenvironmental niches", "PROBLEM", 274, 305], ["CCL21", "ANATOMY", 7, 12], ["interstitial", "ANATOMY_MODIFIER", 103, 115], ["lymphoid organs", "OBSERVATION", 116, 131], ["SLOs", "OBSERVATION", 157, 161], ["CCR7", "ANATOMY", 190, 194], ["microenvironmental niches", "OBSERVATION", 280, 305]]], ["Among these factors, IFN-\u03b3, an antiviral-related cytokine, can transiently but substantially downregulate the expressions of CCL19 and CCL21 in the spleen and LNs.", [["spleen", "ANATOMY", 148, 154], ["LNs", "ANATOMY", 159, 162], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 21, 26], ["CCL19", "GENE_OR_GENE_PRODUCT", 125, 130], ["CCL21", "GENE_OR_GENE_PRODUCT", 135, 140], ["spleen", "ORGAN", 148, 154], ["LNs", "MULTI-TISSUE_STRUCTURE", 159, 162], ["IFN-\u03b3", "PROTEIN", 21, 26], ["cytokine", "PROTEIN", 49, 57], ["CCL19", "PROTEIN", 125, 130], ["CCL21", "PROTEIN", 135, 140], ["IFN", "TEST", 21, 24], ["CCL19", "TEST", 125, 130], ["spleen", "ANATOMY", 148, 154], ["LNs", "ANATOMY", 159, 162]]], ["During viral infections, IFN-\u03b3 is released by effector immune cells including CD8+ TE cells, which then reduces the concentration of CCL19 and CCL21 in the T cell zone of the SLOs.", [["immune cells", "ANATOMY", 55, 67], ["CD8+ TE cells", "ANATOMY", 78, 91], ["T cell zone", "ANATOMY", 156, 167], ["SLOs", "ANATOMY", 175, 179], ["viral infections", "DISEASE", 7, 23], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 25, 30], ["effector immune cells", "CELL", 46, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["CCL19", "GENE_OR_GENE_PRODUCT", 133, 138], ["CCL21", "GENE_OR_GENE_PRODUCT", 143, 148], ["T cell", "CELL", 156, 162], ["SLOs", "PATHOLOGICAL_FORMATION", 175, 179], ["IFN-\u03b3", "PROTEIN", 25, 30], ["effector immune cells", "CELL_TYPE", 46, 67], ["CD8+ TE cells", "CELL_TYPE", 78, 91], ["CCL19", "PROTEIN", 133, 138], ["CCL21", "PROTEIN", 143, 148], ["viral infections", "PROBLEM", 7, 23], ["IFN", "PROBLEM", 25, 28], ["CD8+ TE cells", "PROBLEM", 78, 91], ["CCL19", "TEST", 133, 138], ["CCL21", "TEST", 143, 148], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["infections", "OBSERVATION", 13, 23], ["effector immune cells", "OBSERVATION", 46, 67], ["T cell", "OBSERVATION", 156, 162], ["SLOs", "OBSERVATION", 175, 179]]], ["In turn, TE cells escape SLOs possibly due to the low levels of CCL19 and CCL21 (82).CCL19 and CCL21, ligands of CCR7 ::: CCR7\u2014CHEMOKINE RECEPTOR FOR MEMORY CD8+ T CELLSCCL21 was also reported to participate in cancer metastasis.", [["TE cells", "ANATOMY", 9, 17], ["SLOs", "ANATOMY", 25, 29], ["cancer", "ANATOMY", 211, 217], ["cancer", "DISEASE", 211, 217], ["TE cells", "CELL", 9, 17], ["SLOs", "GENE_OR_GENE_PRODUCT", 25, 29], ["CCL19", "GENE_OR_GENE_PRODUCT", 64, 69], ["CCL21", "GENE_OR_GENE_PRODUCT", 74, 79], ["CCL19", "GENE_OR_GENE_PRODUCT", 85, 90], ["CCL21", "GENE_OR_GENE_PRODUCT", 95, 100], ["CCR7", "GENE_OR_GENE_PRODUCT", 113, 117], ["CD8+ T CELLSCCL21", "GENE_OR_GENE_PRODUCT", 157, 174], ["cancer", "CANCER", 211, 217], ["TE cells", "CELL_TYPE", 9, 17], ["CCL19", "PROTEIN", 64, 69], ["CCL21", "PROTEIN", 74, 79], ["CCL19", "PROTEIN", 85, 90], ["CCL21", "PROTEIN", 95, 100], ["CCR7", "PROTEIN", 113, 117], ["CD8", "PROTEIN", 157, 160], ["T CELLSCCL21", "PROTEIN", 162, 174], ["TE cells escape SLOs", "TEST", 9, 29], ["the low levels of CCL19", "PROBLEM", 46, 69], ["CCL21", "TEST", 74, 79], ["CCL19", "TEST", 85, 90], ["CCL21", "TEST", 95, 100], ["CELLSCCL21", "TEST", 164, 174], ["cancer metastasis", "PROBLEM", 211, 228], ["CCR7", "ANATOMY", 113, 117], ["cancer", "OBSERVATION", 211, 217], ["metastasis", "OBSERVATION", 218, 228]]], ["Certain types of cancer cells express CCR7, so that they have the ability to migrate towards the SLOs, particularly LNs (83).", [["cancer cells", "ANATOMY", 17, 29], ["SLOs", "ANATOMY", 97, 101], ["LNs", "ANATOMY", 116, 119], ["cancer", "DISEASE", 17, 23], ["cancer cells", "CELL", 17, 29], ["CCR7", "GENE_OR_GENE_PRODUCT", 38, 42], ["SLOs", "CANCER", 97, 101], ["LNs", "MULTI-TISSUE_STRUCTURE", 116, 119], ["cancer cells", "CELL_TYPE", 17, 29], ["CCR7", "PROTEIN", 38, 42], ["cancer cells", "PROBLEM", 17, 29], ["cancer cells", "OBSERVATION", 17, 29]]], ["This migration facilitates cancer metastasis by pushing cancer cells into lymphatic vessels through LNs.", [["cancer", "ANATOMY", 27, 33], ["cancer cells", "ANATOMY", 56, 68], ["lymphatic vessels", "ANATOMY", 74, 91], ["LNs", "ANATOMY", 100, 103], ["cancer", "DISEASE", 27, 33], ["cancer", "DISEASE", 56, 62], ["cancer", "CANCER", 27, 33], ["cancer cells", "CELL", 56, 68], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 74, 91], ["LNs", "MULTI-TISSUE_STRUCTURE", 100, 103], ["cancer cells", "CELL_TYPE", 56, 68], ["LNs", "CELL_TYPE", 100, 103], ["This migration", "PROBLEM", 0, 14], ["cancer metastasis", "PROBLEM", 27, 44], ["pushing cancer cells", "PROBLEM", 48, 68], ["cancer", "OBSERVATION", 27, 33], ["lymphatic vessels", "ANATOMY", 74, 91]]], ["Indeed, the patients with CCR7-positive tumors have significantly poorer prognosis than the patients with CCR7-negative tumors (848586).", [["CCR7-positive tumors", "ANATOMY", 26, 46], ["tumors", "ANATOMY", 120, 126], ["tumors", "DISEASE", 40, 46], ["tumors", "DISEASE", 120, 126], ["patients", "ORGANISM", 12, 20], ["CCR7", "GENE_OR_GENE_PRODUCT", 26, 30], ["tumors", "CANCER", 40, 46], ["patients", "ORGANISM", 92, 100], ["CCR7", "GENE_OR_GENE_PRODUCT", 106, 110], ["tumors", "CANCER", 120, 126], ["CCR7", "PROTEIN", 26, 30], ["CCR7", "PROTEIN", 106, 110], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 92, 100], ["CCR7", "TEST", 26, 30], ["positive tumors", "PROBLEM", 31, 46], ["CCR7", "TEST", 106, 110], ["tumors", "OBSERVATION", 40, 46], ["tumors", "OBSERVATION", 120, 126]]], ["These studies showed that the regulation of these chemokines is also important for the movement and localization of T and cancer cells.Niche for the survival of TM cells ::: CCR7 PROVIDES IMPORTANT HOMING SIGNALS FOR MEMORY CD8+ T CELLSSurvival cytokines are required for the longevity of TM cells; however, it is incompletely defined how these cells \u201csee\u201d these cytokines.", [["T", "ANATOMY", 116, 117], ["cancer cells", "ANATOMY", 122, 134], ["TM cells", "ANATOMY", 161, 169], ["TM cells", "ANATOMY", 289, 297], ["cells", "ANATOMY", 345, 350], ["cancer", "DISEASE", 122, 128], ["T", "CELL", 116, 117], ["cancer cells", "CELL", 122, 134], ["TM cells", "CELL", 161, 169], ["CCR7", "GENE_OR_GENE_PRODUCT", 174, 178], ["TM cells", "CELL", 289, 297], ["cells", "CELL", 345, 350], ["chemokines", "PROTEIN", 50, 60], ["T and cancer cells", "CELL_TYPE", 116, 134], ["TM cells", "CELL_TYPE", 161, 169], ["CCR7", "PROTEIN", 174, 178], ["CD8", "PROTEIN", 224, 227], ["T CELLSSurvival cytokines", "PROTEIN", 229, 254], ["TM cells", "CELL_TYPE", 289, 297], ["cytokines", "PROTEIN", 363, 372], ["These studies", "TEST", 0, 13], ["T and cancer cells", "PROBLEM", 116, 134], ["MEMORY CD8", "TEST", 217, 227], ["T CELLSSurvival cytokines", "TEST", 229, 254], ["the longevity of TM cells", "TREATMENT", 272, 297], ["cancer cells", "OBSERVATION", 122, 134]]], ["One hypothesis is systemic exposure, where one organ provides these cytokines and TM cells recognize them anywhere in the body.", [["organ", "ANATOMY", 47, 52], ["TM cells", "ANATOMY", 82, 90], ["body", "ANATOMY", 122, 126], ["organ", "ORGAN", 47, 52], ["TM cells", "CELL", 82, 90], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["cytokines", "PROTEIN", 68, 77], ["TM cells", "CELL_TYPE", 82, 90], ["systemic exposure", "PROBLEM", 18, 35], ["these cytokines", "TEST", 62, 77], ["TM cells", "TREATMENT", 82, 90], ["systemic exposure", "OBSERVATION", 18, 35], ["body", "ANATOMY", 122, 126]]], ["Another possibility is that these cytokines are present only in specialized microenvironments called niches and TM cells need to home these anatomical locations to receive the required signals.", [["niches", "ANATOMY", 101, 107], ["TM cells", "ANATOMY", 112, 120], ["niches", "CELL", 101, 107], ["TM cells", "CELL", 112, 120], ["cytokines", "PROTEIN", 34, 43], ["TM cells", "CELL_TYPE", 112, 120], ["niches and TM cells", "TREATMENT", 101, 120], ["cytokines", "OBSERVATION", 34, 43]]], ["Although systemic exposure cannot be ruled out, evidence have been accumulated to explain the niche hypothesis.", [["systemic exposure", "PROBLEM", 9, 26], ["the niche hypothesis", "PROBLEM", 90, 110], ["systemic", "OBSERVATION", 9, 17], ["cannot be ruled", "UNCERTAINTY", 27, 42], ["niche hypothesis", "OBSERVATION", 94, 110]]], ["First, BM is the preferred site for the homeostatic proliferation, suggesting that survival cytokines are provided locally.", [["BM", "ANATOMY", 7, 9], ["BM", "CELL", 7, 9], ["cytokines", "PROTEIN", 92, 101], ["the homeostatic proliferation", "PROBLEM", 36, 65], ["survival cytokines", "TREATMENT", 83, 101], ["BM", "OBSERVATION", 7, 9], ["homeostatic proliferation", "OBSERVATION", 40, 65]]], ["Second, differential localization of TE cell subsets within the organ may indicate that they receive different signals depending on their location (3738).", [["TE cell", "ANATOMY", 37, 44], ["organ", "ANATOMY", 64, 69], ["TE cell", "CELL", 37, 44], ["organ", "ORGAN", 64, 69], ["TE cell subsets", "CELL_TYPE", 37, 52], ["TE cell subsets", "PROBLEM", 37, 52], ["TE cell subsets", "OBSERVATION", 37, 52], ["organ", "ANATOMY", 64, 69]]], ["Third, IL-7 has been suggested to be bound to the extracellular matrix near the IL-7 producers (87).", [["extracellular matrix", "ANATOMY", 50, 70], ["IL-7", "GENE_OR_GENE_PRODUCT", 7, 11], ["extracellular matrix", "CELLULAR_COMPONENT", 50, 70], ["IL-7", "GENE_OR_GENE_PRODUCT", 80, 84], ["IL-7", "PROTEIN", 7, 11], ["IL", "PROTEIN", 80, 82]]], ["Finally, IL-15 has been shown to be trans-presented so that cell-to-cell contacts with IL-15 presenting cells are required for optimal simulation (88).", [["cell", "ANATOMY", 60, 64], ["cell", "ANATOMY", 68, 72], ["cells", "ANATOMY", 104, 109], ["IL-15", "GENE_OR_GENE_PRODUCT", 9, 14], ["cell", "CELL", 60, 64], ["cell", "CELL", 68, 72], ["IL-15", "GENE_OR_GENE_PRODUCT", 87, 92], ["cells", "CELL", 104, 109], ["IL-15", "PROTEIN", 9, 14], ["IL", "PROTEIN", 87, 89]]], ["Altogether, it is strongly suggested that TM cells migrate to specialized microenvironments within the organ in order to survive.Niche for the survival of TM cells ::: CCR7 PROVIDES IMPORTANT HOMING SIGNALS FOR MEMORY CD8+ T CELLSAmong the cytokines that are critical for TM cells, it is known that CCL19 and CCL21 maintain a collaborative relationship with IL-7 and IL-15 (Fig. 3) (89).", [["TM cells", "ANATOMY", 42, 50], ["organ", "ANATOMY", 103, 108], ["TM cells", "ANATOMY", 155, 163], ["TM cells", "ANATOMY", 272, 280], ["TM cells", "CELL", 42, 50], ["organ", "ORGAN", 103, 108], ["TM cells", "CELL", 155, 163], ["CCR7", "GENE_OR_GENE_PRODUCT", 168, 172], ["TM cells", "CELL", 272, 280], ["CCL19", "GENE_OR_GENE_PRODUCT", 299, 304], ["CCL21", "GENE_OR_GENE_PRODUCT", 309, 314], ["IL-7", "GENE_OR_GENE_PRODUCT", 358, 362], ["IL-15", "GENE_OR_GENE_PRODUCT", 367, 372], ["TM cells", "CELL_TYPE", 42, 50], ["TM cells", "CELL_TYPE", 155, 163], ["CCR7", "PROTEIN", 168, 172], ["CD8", "PROTEIN", 218, 221], ["T CELLSAmong", "PROTEIN", 223, 235], ["cytokines", "PROTEIN", 240, 249], ["TM cells", "CELL_TYPE", 272, 280], ["CCL19", "PROTEIN", 299, 304], ["CCL21", "PROTEIN", 309, 314], ["IL-7", "PROTEIN", 358, 362], ["IL", "PROTEIN", 367, 369], ["TM cells", "PROBLEM", 42, 50], ["the cytokines", "TEST", 236, 249], ["TM cells", "PROBLEM", 272, 280], ["CCL19", "TEST", 299, 304], ["IL", "TEST", 358, 360], ["IL", "TEST", 367, 369], ["organ", "ANATOMY", 103, 108]]], ["A rich CCL19 within the LNs works in conjunction with IL-7 to improve the survival of the T cells, but no exact mechanism has been identified (33).", [["LNs", "ANATOMY", 24, 27], ["T cells", "ANATOMY", 90, 97], ["CCL19", "GENE_OR_GENE_PRODUCT", 7, 12], ["LNs", "MULTI-TISSUE_STRUCTURE", 24, 27], ["IL-7", "GENE_OR_GENE_PRODUCT", 54, 58], ["T cells", "CELL", 90, 97], ["CCL19", "PROTEIN", 7, 12], ["LNs", "CELL_TYPE", 24, 27], ["IL-7", "PROTEIN", 54, 58], ["T cells", "CELL_TYPE", 90, 97], ["A rich CCL19", "TEST", 0, 12], ["IL", "TREATMENT", 54, 56], ["LNs", "ANATOMY", 24, 27]]], ["Whereas, the adjustment of CD8+ TM cells by IL-15 was found within the NLTs, such as the BM and lung, where distinct from SLOs with large amount of CCL19 and CCL21 (3690).", [["CD8+ TM cells", "ANATOMY", 27, 40], ["NLTs", "ANATOMY", 71, 75], ["BM", "ANATOMY", 89, 91], ["lung", "ANATOMY", 96, 100], ["SLOs", "ANATOMY", 122, 126], ["CD8", "GENE_OR_GENE_PRODUCT", 27, 30], ["IL-15", "GENE_OR_GENE_PRODUCT", 44, 49], ["NLTs", "CANCER", 71, 75], ["BM", "TISSUE", 89, 91], ["lung", "ORGAN", 96, 100], ["SLOs", "CANCER", 122, 126], ["CCL19", "GENE_OR_GENE_PRODUCT", 148, 153], ["CCL21", "GENE_OR_GENE_PRODUCT", 158, 163], ["CD8", "PROTEIN", 27, 30], ["TM cells", "CELL_TYPE", 32, 40], ["IL-15", "PROTEIN", 44, 49], ["CCL19", "PROTEIN", 148, 153], ["CCL21", "PROTEIN", 158, 163], ["IL", "TEST", 44, 46], ["SLOs", "TEST", 122, 126], ["CCL21", "TEST", 158, 163], ["BM", "ANATOMY", 89, 91], ["lung", "ANATOMY", 96, 100], ["large", "OBSERVATION_MODIFIER", 132, 137], ["amount", "OBSERVATION_MODIFIER", 138, 144]]], ["This implies that the importance of the physical microenvironment is formed by CCL19 and CCL21, as well as sufficient CCR7 expression within the T cells.CCR7 expression alters the fate decision of CD8+ T cells ::: CCR7 PROVIDES IMPORTANT HOMING SIGNALS FOR MEMORY CD8+ T CELLSTo understand the roles of CCR7, Junt et al. (91) first reported normal T cell response to viral infection in plt/plt mice with spontaneous mutations in CCL19 and CCL21 locus.", [["T cells", "ANATOMY", 145, 152], ["CD8+ T cells", "ANATOMY", 197, 209], ["T cell", "ANATOMY", 348, 354], ["viral infection", "DISEASE", 367, 382], ["CCL19", "GENE_OR_GENE_PRODUCT", 79, 84], ["CCL21", "GENE_OR_GENE_PRODUCT", 89, 94], ["CCR7", "GENE_OR_GENE_PRODUCT", 118, 122], ["T cells", "CELL", 145, 152], ["CCR7", "GENE_OR_GENE_PRODUCT", 153, 157], ["CD8", "GENE_OR_GENE_PRODUCT", 197, 200], ["CCR7", "GENE_OR_GENE_PRODUCT", 214, 218], ["CCR7", "GENE_OR_GENE_PRODUCT", 303, 307], ["T cell", "CELL", 348, 354], ["plt/plt mice", "ORGANISM", 386, 398], ["CCL19", "GENE_OR_GENE_PRODUCT", 429, 434], ["CCL21", "GENE_OR_GENE_PRODUCT", 439, 444], ["CCL19", "PROTEIN", 79, 84], ["CCL21", "PROTEIN", 89, 94], ["CCR7", "PROTEIN", 118, 122], ["T cells", "CELL_TYPE", 145, 152], ["CCR7", "PROTEIN", 153, 157], ["CD8+ T cells", "CELL_TYPE", 197, 209], ["CCR7", "PROTEIN", 214, 218], ["CD8", "PROTEIN", 264, 267], ["CCR7", "PROTEIN", 303, 307], ["CCL19 and CCL21 locus", "DNA", 429, 450], ["mice", "SPECIES", 394, 398], ["mice", "SPECIES", 394, 398], ["CCL21", "TEST", 89, 94], ["viral infection", "PROBLEM", 367, 382], ["plt", "TEST", 386, 389], ["plt mice", "TEST", 390, 398], ["spontaneous mutations in CCL19", "PROBLEM", 404, 434], ["CCR7 expression", "OBSERVATION", 118, 133], ["CCR7", "ANATOMY", 303, 307], ["viral infection", "OBSERVATION", 367, 382]]], ["Thus, the viral clearance and secondary response to the same pathogen were comparable to those in littermate controls.", [["the viral clearance", "TEST", 6, 25], ["the same pathogen", "PROBLEM", 52, 69]]], ["However, they also observed that the formation of TM cells were significantly reduced, when CCR7-deficient mice were infected with the same virus (92).", [["TM cells", "ANATOMY", 50, 58], ["TM cells", "CELL", 50, 58], ["CCR7", "GENE_OR_GENE_PRODUCT", 92, 96], ["mice", "ORGANISM", 107, 111], ["TM cells", "CELL_TYPE", 50, 58], ["CCR7", "PROTEIN", 92, 96], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["TM cells", "PROBLEM", 50, 58], ["CCR7", "TEST", 92, 96]]], ["It was also observed that viral clearance in CCR7 KO mice was slower than that in wild-type mice, if completely cleared.", [["CCR7", "GENE_OR_GENE_PRODUCT", 45, 49], ["mice", "ORGANISM", 92, 96], ["CCR7", "PROTEIN", 45, 49], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 92, 96], ["viral clearance", "TEST", 26, 41]]], ["Probably due to the reduced number of TM cells, CCR7-deficient mice contained reduced number of IFN-\u03b3+ CD8+ T cells in response to secondary infections.", [["TM cells", "ANATOMY", 38, 46], ["IFN-\u03b3+ CD8+ T cells", "ANATOMY", 96, 115], ["infections", "DISEASE", 141, 151], ["TM cells", "CELL", 38, 46], ["CCR7", "GENE_OR_GENE_PRODUCT", 48, 52], ["mice", "ORGANISM", 63, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 103, 106], ["TM cells", "CELL_TYPE", 38, 46], ["CCR7", "PROTEIN", 48, 52], ["IFN", "PROTEIN", 96, 99], ["CD8", "PROTEIN", 103, 106], ["T cells", "CELL_TYPE", 108, 115], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["the reduced number of TM cells", "PROBLEM", 16, 46], ["CCR7", "TEST", 48, 52], ["IFN", "TEST", 96, 99], ["T cells", "PROBLEM", 108, 115], ["secondary infections", "PROBLEM", 131, 151], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["number", "OBSERVATION_MODIFIER", 28, 34], ["TM cells", "OBSERVATION", 38, 46], ["reduced", "OBSERVATION_MODIFIER", 78, 85], ["secondary", "OBSERVATION_MODIFIER", 131, 140], ["infections", "OBSERVATION", 141, 151]]], ["Since 2 different results were reported, it was suggested that plt/plt mice express CCL21b, a leucine isoform of CCL21, in lymphatic vessels.", [["lymphatic vessels", "ANATOMY", 123, 140], ["leucine", "CHEMICAL", 94, 101], ["plt", "GENE_OR_GENE_PRODUCT", 63, 66], ["plt mice", "ORGANISM", 67, 75], ["CCL21b", "GENE_OR_GENE_PRODUCT", 84, 90], ["CCL21", "GENE_OR_GENE_PRODUCT", 113, 118], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 123, 140], ["CCL21b", "PROTEIN", 84, 90], ["leucine isoform", "PROTEIN", 94, 109], ["CCL21", "PROTEIN", 113, 118], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["plt", "TEST", 63, 66], ["plt mice", "TEST", 67, 75], ["CCL21b", "TEST", 84, 90], ["a leucine isoform", "TEST", 92, 109], ["lymphatic vessels", "ANATOMY", 123, 140]]], ["In addition, CCL21b was also found in peripheral tissue; thus, the recruitment of CCR7hi cells into the peripheral tissues was compensated (7893).", [["peripheral tissue", "ANATOMY", 38, 55], ["CCR7hi cells", "ANATOMY", 82, 94], ["peripheral tissues", "ANATOMY", 104, 122], ["CCL21b", "GENE_OR_GENE_PRODUCT", 13, 19], ["peripheral tissue", "TISSUE", 38, 55], ["CCR7hi cells", "CELL", 82, 94], ["peripheral tissues", "TISSUE", 104, 122], ["CCL21b", "PROTEIN", 13, 19], ["CCR7hi cells", "CELL_LINE", 82, 94], ["CCL21b", "TEST", 13, 19], ["peripheral tissue", "ANATOMY", 38, 55], ["peripheral tissues", "ANATOMY", 104, 122]]], ["In agreement with this report, mice with ubiquitous overexpression of CCL21 showed abnormal viral clearance (94).", [["abnormal viral clearance", "DISEASE", 83, 107], ["mice", "ORGANISM", 31, 35], ["CCL21", "GENE_OR_GENE_PRODUCT", 70, 75], ["CCL21", "PROTEIN", 70, 75], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["CCL21", "TEST", 70, 75], ["abnormal viral clearance", "PROBLEM", 83, 107], ["viral clearance", "OBSERVATION", 92, 107]]], ["These altered immune responses are not restricted to viral infections, because CCR7 KO mice mounted reduced inflammation in response to Toxoplasma gondii infection, an intracellular protozoan parasite (95).CCR7 expression alters the fate decision of CD8+ T cells ::: CCR7 PROVIDES IMPORTANT HOMING SIGNALS FOR MEMORY CD8+ T CELLSIn order to exclude the possibility of delayed viral clearance and emphasize the role of CCR7 in the fate decision of CD8+ TM cells, P14 transgenic mice, which recognize the DbGP33\u201341 epitope of LCMV, were employed (90).", [["intracellular", "ANATOMY", 168, 181], ["CD8+ T cells", "ANATOMY", 250, 262], ["CD8+ TM cells", "ANATOMY", 447, 460], ["viral infections", "DISEASE", 53, 69], ["inflammation", "DISEASE", 108, 120], ["Toxoplasma gondii infection", "DISEASE", 136, 163], ["CCR7", "GENE_OR_GENE_PRODUCT", 79, 83], ["mice", "ORGANISM", 87, 91], ["Toxoplasma gondii", "ORGANISM", 136, 153], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["CCR7", "GENE_OR_GENE_PRODUCT", 206, 210], ["CD8", "GENE_OR_GENE_PRODUCT", 250, 253], ["CCR7", "GENE_OR_GENE_PRODUCT", 267, 271], ["CCR7", "GENE_OR_GENE_PRODUCT", 418, 422], ["CD8", "GENE_OR_GENE_PRODUCT", 447, 450], ["P14 transgenic mice", "ORGANISM", 462, 481], ["DbGP33", "GENE_OR_GENE_PRODUCT", 503, 509], ["LCMV", "ORGANISM", 524, 528], ["CCR7", "PROTEIN", 79, 83], ["CCR7", "PROTEIN", 206, 210], ["CD8+ T cells", "CELL_TYPE", 250, 262], ["CCR7", "PROTEIN", 267, 271], ["CD8", "PROTEIN", 317, 320], ["CCR7", "PROTEIN", 418, 422], ["CD8", "PROTEIN", 447, 450], ["TM cells", "CELL_TYPE", 452, 460], ["DbGP33", "PROTEIN", 503, 509], ["mice", "SPECIES", 87, 91], ["Toxoplasma gondii", "SPECIES", 136, 153], ["mice", "SPECIES", 477, 481], ["mice", "SPECIES", 87, 91], ["Toxoplasma gondii", "SPECIES", 136, 153], ["mice", "SPECIES", 477, 481], ["These altered immune responses", "PROBLEM", 0, 30], ["viral infections", "PROBLEM", 53, 69], ["CCR7", "TEST", 79, 83], ["reduced inflammation", "PROBLEM", 100, 120], ["Toxoplasma gondii infection", "PROBLEM", 136, 163], ["an intracellular protozoan parasite", "TEST", 165, 200], ["delayed viral clearance", "PROBLEM", 368, 391], ["TM cells", "PROBLEM", 452, 460], ["epitope of LCMV", "TREATMENT", 513, 528], ["reduced", "OBSERVATION_MODIFIER", 100, 107], ["inflammation", "OBSERVATION", 108, 120], ["Toxoplasma gondii infection", "OBSERVATION", 136, 163], ["protozoan", "OBSERVATION_MODIFIER", 182, 191], ["parasite", "OBSERVATION_MODIFIER", 192, 200]]], ["By transferring small number of CCR7 wild-type or KO P14 CD8+ T cells into wild-type C57/Bl6 mice, these mice were able to clear the viral infection regardless of the genotypes of P14 cells.", [["T cells", "ANATOMY", 62, 69], ["P14 cells", "ANATOMY", 180, 189], ["viral infection", "DISEASE", 133, 148], ["CCR7", "GENE_OR_GENE_PRODUCT", 32, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 57, 60], ["T cells", "CELL", 62, 69], ["wild-type C57/Bl6 mice", "ORGANISM", 75, 97], ["mice", "ORGANISM", 105, 109], ["P14 cells", "CELL", 180, 189], ["CCR7", "PROTEIN", 32, 36], ["KO P14 CD8", "PROTEIN", 50, 60], ["T cells", "CELL_TYPE", 62, 69], ["P14 cells", "CELL_TYPE", 180, 189], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 105, 109], ["T cells", "TEST", 62, 69], ["the viral infection", "PROBLEM", 129, 148], ["the genotypes of P14 cells", "PROBLEM", 163, 189], ["small", "OBSERVATION_MODIFIER", 16, 21], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["infection", "OBSERVATION", 139, 148], ["P14 cells", "OBSERVATION", 180, 189]]], ["Using this model, increased number of CCR7 KO TM cells was observed with normal recall abilities.", [["CCR7 KO TM cells", "ANATOMY", 38, 54], ["CCR7", "GENE_OR_GENE_PRODUCT", 38, 42], ["CCR7", "PROTEIN", 38, 42], ["TM cells", "CELL_TYPE", 46, 54], ["this model", "TREATMENT", 6, 16], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["number", "OBSERVATION_MODIFIER", 28, 34]]], ["Enhanced survival of CCR7 KO TM cells by IL-15 signaling were found in the lung and BM, because the removal of IL-15, but not IL-7, maintained the comparable number of CCR7-deficient and -sufficient TM cells.", [["CCR7 KO TM cells", "ANATOMY", 21, 37], ["lung", "ANATOMY", 75, 79], ["BM", "ANATOMY", 84, 86], ["TM cells", "ANATOMY", 199, 207], ["CCR7", "GENE_OR_GENE_PRODUCT", 21, 25], ["IL-15", "GENE_OR_GENE_PRODUCT", 41, 46], ["lung", "ORGAN", 75, 79], ["BM", "CELL", 84, 86], ["IL-15", "GENE_OR_GENE_PRODUCT", 111, 116], ["IL-7", "GENE_OR_GENE_PRODUCT", 126, 130], ["CCR7", "GENE_OR_GENE_PRODUCT", 168, 172], ["TM cells", "CELL", 199, 207], ["CCR7 KO TM cells", "CELL_LINE", 21, 37], ["IL", "PROTEIN", 41, 43], ["IL-15", "PROTEIN", 111, 116], ["IL-7", "PROTEIN", 126, 130], ["CCR7", "PROTEIN", 168, 172], ["TM cells", "CELL_TYPE", 199, 207], ["IL", "TEST", 41, 43], ["the removal of IL", "TREATMENT", 96, 113], ["IL", "TEST", 126, 128], ["lung", "ANATOMY", 75, 79], ["BM", "ANATOMY", 84, 86]]], ["In addition, these CCR7-deficient TM cells showed increased ratio of homeostatic turnover compared to CCR7-sufficient cells.", [["TM cells", "ANATOMY", 34, 42], ["cells", "ANATOMY", 118, 123], ["CCR7", "GENE_OR_GENE_PRODUCT", 19, 23], ["TM cells", "CELL", 34, 42], ["CCR7", "GENE_OR_GENE_PRODUCT", 102, 106], ["cells", "CELL", 118, 123], ["CCR7", "PROTEIN", 19, 23], ["TM cells", "CELL_TYPE", 34, 42], ["CCR7", "PROTEIN", 102, 106], ["these CCR7", "TEST", 13, 23], ["deficient TM cells", "PROBLEM", 24, 42], ["increased ratio of homeostatic turnover", "PROBLEM", 50, 89], ["CCR7", "TEST", 102, 106], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["homeostatic turnover", "OBSERVATION", 69, 89]]], ["These results suggest that CCR7 signaling directs the migration toward IL-7-niches, while CCR7lo TM cells migrate toward IL-15 niches for their survival.", [["IL-7-niches", "ANATOMY", 71, 82], ["CCR7lo TM cells", "ANATOMY", 90, 105], ["CCR7", "GENE_OR_GENE_PRODUCT", 27, 31], ["IL-7", "GENE_OR_GENE_PRODUCT", 71, 75], ["CCR7lo TM cells", "CELL", 90, 105], ["IL-15", "GENE_OR_GENE_PRODUCT", 121, 126], ["CCR7", "PROTEIN", 27, 31], ["CCR7lo TM cells", "CELL_LINE", 90, 105], ["IL", "PROTEIN", 121, 123], ["CCR7 signaling", "PROBLEM", 27, 41], ["IL", "TEST", 71, 73], ["CCR7lo TM cells", "TREATMENT", 90, 105], ["migration", "OBSERVATION_MODIFIER", 54, 63]]], ["In addition, inhibition of CCR7 signaling may increase the number of TM cells in the lung, where it has been suggested to be difficult for TM cells to survive (Fig. 3).CCR7 expression alters the fate decision of CD8+ T cells ::: CCR7 PROVIDES IMPORTANT HOMING SIGNALS FOR MEMORY CD8+ T CELLSWhen CCR7 was overexpressed in all T cells, the numbers of TM cells in the spleen and LNs of CCR7-tg mice were increased compared to that in wild-type mice, while CCR7-tg TM cell number reduced in the liver and lung.", [["TM cells", "ANATOMY", 69, 77], ["lung", "ANATOMY", 85, 89], ["TM cells", "ANATOMY", 139, 147], ["CD8+ T cells", "ANATOMY", 212, 224], ["T cells", "ANATOMY", 326, 333], ["TM cells", "ANATOMY", 350, 358], ["spleen", "ANATOMY", 366, 372], ["LNs", "ANATOMY", 377, 380], ["CCR7-tg TM cell", "ANATOMY", 454, 469], ["liver", "ANATOMY", 492, 497], ["lung", "ANATOMY", 502, 506], ["CCR7", "GENE_OR_GENE_PRODUCT", 27, 31], ["TM cells", "CELL", 69, 77], ["lung", "ORGAN", 85, 89], ["TM cells", "CELL", 139, 147], ["CCR7", "GENE_OR_GENE_PRODUCT", 168, 172], ["CD8", "GENE_OR_GENE_PRODUCT", 212, 215], ["CCR7", "GENE_OR_GENE_PRODUCT", 229, 233], ["CCR7", "GENE_OR_GENE_PRODUCT", 296, 300], ["T cells", "CELL", 326, 333], ["TM cells", "CELL", 350, 358], ["spleen", "ORGAN", 366, 372], ["LNs", "MULTI-TISSUE_STRUCTURE", 377, 380], ["CCR7", "GENE_OR_GENE_PRODUCT", 384, 388], ["mice", "ORGANISM", 392, 396], ["mice", "ORGANISM", 442, 446], ["CCR7", "GENE_OR_GENE_PRODUCT", 454, 458], ["liver", "ORGAN", 492, 497], ["lung", "ORGAN", 502, 506], ["CCR7", "PROTEIN", 27, 31], ["TM cells", "CELL_TYPE", 69, 77], ["TM cells", "CELL_TYPE", 139, 147], ["CCR7", "PROTEIN", 168, 172], ["CD8+ T cells", "CELL_TYPE", 212, 224], ["CCR7", "PROTEIN", 229, 233], ["CD8", "PROTEIN", 279, 282], ["CCR7", "PROTEIN", 296, 300], ["T cells", "CELL_TYPE", 326, 333], ["TM cells", "CELL_TYPE", 350, 358], ["CCR7", "PROTEIN", 384, 388], ["CCR7", "PROTEIN", 454, 458], ["mice", "SPECIES", 392, 396], ["mice", "SPECIES", 442, 446], ["mice", "SPECIES", 392, 396], ["mice", "SPECIES", 442, 446], ["CCR7 signaling", "PROBLEM", 27, 41], ["TM cells", "PROBLEM", 139, 147], ["MEMORY CD8", "TEST", 272, 282], ["CCR7", "TEST", 296, 300], ["TM cells", "TEST", 350, 358], ["CCR7", "TEST", 384, 388], ["CCR7", "TEST", 454, 458], ["number", "OBSERVATION_MODIFIER", 59, 65], ["TM cells", "OBSERVATION", 69, 77], ["lung", "ANATOMY", 85, 89], ["spleen", "ANATOMY", 366, 372], ["LNs", "ANATOMY", 377, 380], ["CCR7", "ANATOMY", 384, 388], ["increased", "OBSERVATION_MODIFIER", 402, 411], ["liver", "ANATOMY", 492, 497], ["lung", "ANATOMY", 502, 506]]], ["These mice showed difficulty in clearance of skin infection, suggesting that CCR7 forces the migration of TM cells into the SLOs.", [["skin", "ANATOMY", 45, 49], ["TM cells", "ANATOMY", 106, 114], ["SLOs", "ANATOMY", 124, 128], ["skin infection", "DISEASE", 45, 59], ["mice", "ORGANISM", 6, 10], ["skin", "ORGAN", 45, 49], ["CCR7", "GENE_OR_GENE_PRODUCT", 77, 81], ["TM cells", "CELL", 106, 114], ["SLOs", "PATHOLOGICAL_FORMATION", 124, 128], ["CCR7", "PROTEIN", 77, 81], ["TM cells", "CELL_TYPE", 106, 114], ["SLOs", "CELL_TYPE", 124, 128], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["skin infection", "PROBLEM", 45, 59], ["TM cells", "TREATMENT", 106, 114], ["skin", "ANATOMY", 45, 49], ["infection", "OBSERVATION", 50, 59], ["SLOs", "ANATOMY", 124, 128]]], ["It would be interesting to see if increased survival of CCR7-tg TM cells in the SLOs is IL-7-dependent.", [["CCR7-tg TM cells", "ANATOMY", 56, 72], ["SLOs", "ANATOMY", 80, 84], ["CCR7", "GENE_OR_GENE_PRODUCT", 56, 60], ["SLOs", "CANCER", 80, 84], ["IL-7", "GENE_OR_GENE_PRODUCT", 88, 92], ["CCR7", "PROTEIN", 56, 60], ["tg TM cells", "CELL_TYPE", 61, 72], ["CCR7", "TEST", 56, 60], ["the SLOs", "TEST", 76, 84], ["IL", "TEST", 88, 90]]], ["Taken together, the CCR7 expression of CD8+ TM cells determines the fates of CCR7hi and CCR7lo CD8+ T cells by properly guiding them into survival niches.CONCLUSION AND FUTURE PERSPECTIVESThe importance of TM cell subsets has been well documented, and the roles of each subset shed light on individual infectious disease in the last decade.", [["CD8+ TM cells", "ANATOMY", 39, 52], ["CCR7hi", "ANATOMY", 77, 83], ["CCR7lo CD8+", "ANATOMY", 88, 99], ["T cells", "ANATOMY", 100, 107], ["TM cell", "ANATOMY", 206, 213], ["infectious disease", "DISEASE", 302, 320], ["CCR7", "GENE_OR_GENE_PRODUCT", 20, 24], ["CD8", "GENE_OR_GENE_PRODUCT", 39, 42], ["CCR7hi", "GENE_OR_GENE_PRODUCT", 77, 83], ["CCR7lo CD8", "GENE_OR_GENE_PRODUCT", 88, 98], ["T cells", "CELL", 100, 107], ["TM cell", "CELL", 206, 213], ["CCR7", "PROTEIN", 20, 24], ["CD8", "PROTEIN", 39, 42], ["TM cells", "CELL_TYPE", 44, 52], ["CCR7hi", "PROTEIN", 77, 83], ["CCR7lo CD8", "PROTEIN", 88, 98], ["T cells", "CELL_TYPE", 100, 107], ["TM cell subsets", "CELL_TYPE", 206, 221], ["CD8", "TEST", 39, 42], ["TM cells", "PROBLEM", 44, 52], ["CCR7hi", "TEST", 77, 83], ["TM cell subsets", "TREATMENT", 206, 221], ["individual infectious disease", "PROBLEM", 291, 320], ["infectious", "OBSERVATION", 302, 312]]], ["Accumulating data suggest that specialized niches are present for the survival of TM cells and the migration of MEPCs and TM cells into these niches is crucial for their maintenance.", [["TM cells", "ANATOMY", 82, 90], ["MEPCs", "ANATOMY", 112, 117], ["TM cells", "ANATOMY", 122, 130], ["TM cells", "CELL", 82, 90], ["MEPCs", "CELL", 112, 117], ["TM cells", "CELL", 122, 130], ["TM cells", "CELL_TYPE", 82, 90], ["MEPCs", "CELL_TYPE", 112, 117], ["TM cells", "CELL_TYPE", 122, 130], ["TM cells", "TREATMENT", 82, 90], ["the migration of MEPCs and TM cells", "TREATMENT", 95, 130]]], ["CCR7 may determine the niche suitable for their survival, depending on the subtypes or functions of CD8+ TM cells.", [["CD8+ TM cells", "ANATOMY", 100, 113], ["CCR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD8", "GENE_OR_GENE_PRODUCT", 100, 103], ["CCR7", "PROTEIN", 0, 4], ["CD8", "PROTEIN", 100, 103], ["TM cells", "CELL_TYPE", 105, 113], ["CD8+ TM cells", "PROBLEM", 100, 113]]], ["Therefore, it can be inferred that CCR7 plays a crucial role in the activation of na\u00efve T cells as well as the development and maintenance of CD8+ TM cell subsets according to these studies.CONCLUSION AND FUTURE PERSPECTIVESCurrently, the therapies using T cells, such as chimeric Ag receptor T cells, have shown remarkably effective progresses into clinical phases (969798).", [["na\u00efve T cells", "ANATOMY", 82, 95], ["CD8+ TM cell", "ANATOMY", 142, 154], ["T cells", "ANATOMY", 255, 262], ["Ag receptor T cells", "ANATOMY", 281, 300], ["Ag", "CHEMICAL", 281, 283], ["CCR7", "GENE_OR_GENE_PRODUCT", 35, 39], ["na\u00efve T cells", "CELL", 82, 95], ["CD8", "GENE_OR_GENE_PRODUCT", 142, 145], ["T cells", "CELL", 255, 262], ["CCR7", "PROTEIN", 35, 39], ["na\u00efve T cells", "CELL_TYPE", 82, 95], ["CD8+ TM cell subsets", "CELL_TYPE", 142, 162], ["T cells", "CELL_TYPE", 255, 262], ["chimeric Ag receptor T cells", "CELL_TYPE", 272, 300], ["na\u00efve T cells", "TREATMENT", 82, 95], ["CD8+ TM cell subsets", "TREATMENT", 142, 162], ["these studies", "TEST", 176, 189], ["the therapies", "TREATMENT", 235, 248], ["T cells", "TREATMENT", 255, 262], ["chimeric Ag receptor T cells", "TREATMENT", 272, 300]]], ["Despite these successes, the cancer types where these therapies can be applied are limited till date.", [["cancer", "ANATOMY", 29, 35], ["cancer", "DISEASE", 29, 35], ["cancer", "CANCER", 29, 35], ["the cancer types", "PROBLEM", 25, 41], ["these therapies", "TREATMENT", 48, 63], ["cancer", "OBSERVATION", 29, 35]]], ["One of the reasons for this limitation is the type of T cells used in these therapies.", [["T cells", "ANATOMY", 54, 61], ["T cells", "CELL", 54, 61], ["T cells", "CELL_TYPE", 54, 61], ["T cells", "TREATMENT", 54, 61], ["these therapies", "TREATMENT", 70, 85]]], ["Most therapies use na\u00efve or in vitro activated T cells, which can quickly be inactivated in tumor microenvironments.", [["T cells", "ANATOMY", 47, 54], ["tumor", "ANATOMY", 92, 97], ["tumor", "DISEASE", 92, 97], ["T cells", "CELL", 47, 54], ["tumor", "CANCER", 92, 97], ["na\u00efve or in vitro activated T cells", "CELL_TYPE", 19, 54], ["na\u00efve", "TREATMENT", 19, 24], ["vitro activated T cells", "TREATMENT", 31, 54]]], ["Thus, TM cells have been suggested to be utilized for these applications, particularly since they are seldom exhausted even in various types of immune diseases including cancer, allergic disease, autoimmune disease, and inflammatory bowel disease.CONCLUSION AND FUTURE PERSPECTIVESIn addition to this suggestion, controlling the migration of TM cells by CCR7 modulation may determine the destiny of CD8+ TM cells by changing their location as discussed in this review.", [["TM cells", "ANATOMY", 6, 14], ["cancer", "ANATOMY", 170, 176], ["bowel", "ANATOMY", 233, 238], ["TM cells", "ANATOMY", 342, 350], ["CD8+ TM cells", "ANATOMY", 399, 412], ["immune diseases", "DISEASE", 144, 159], ["cancer", "DISEASE", 170, 176], ["allergic disease", "DISEASE", 178, 194], ["autoimmune disease", "DISEASE", 196, 214], ["inflammatory bowel disease", "DISEASE", 220, 246], ["TM cells", "CELL", 6, 14], ["cancer", "CANCER", 170, 176], ["bowel", "ORGAN", 233, 238], ["TM cells", "CELL", 342, 350], ["CCR7", "GENE_OR_GENE_PRODUCT", 354, 358], ["CD8", "GENE_OR_GENE_PRODUCT", 399, 402], ["TM cells", "CELL_TYPE", 6, 14], ["TM cells", "CELL_TYPE", 342, 350], ["CCR7", "PROTEIN", 354, 358], ["CD8+ TM cells", "CELL_TYPE", 399, 412], ["TM cells", "TREATMENT", 6, 14], ["immune diseases", "PROBLEM", 144, 159], ["cancer", "PROBLEM", 170, 176], ["allergic disease", "PROBLEM", 178, 194], ["autoimmune disease", "PROBLEM", 196, 214], ["inflammatory bowel disease", "PROBLEM", 220, 246], ["the migration of TM cells", "TREATMENT", 325, 350], ["CCR7 modulation", "TREATMENT", 354, 369], ["CD8+ TM cells", "TREATMENT", 399, 412], ["immune diseases", "OBSERVATION", 144, 159], ["cancer", "OBSERVATION", 170, 176], ["allergic disease", "OBSERVATION", 178, 194], ["autoimmune disease", "OBSERVATION", 196, 214], ["inflammatory", "OBSERVATION_MODIFIER", 220, 232], ["bowel", "ANATOMY", 233, 238], ["disease", "OBSERVATION", 239, 246]]], ["Depending on the diseases or cancers, the localization of TM cells is crucial to promote optimal immune response.", [["cancers", "ANATOMY", 29, 36], ["TM cells", "ANATOMY", 58, 66], ["cancers", "DISEASE", 29, 36], ["cancers", "CANCER", 29, 36], ["TM cells", "CELL", 58, 66], ["TM cells", "CELL_TYPE", 58, 66], ["the diseases", "PROBLEM", 13, 25], ["cancers", "PROBLEM", 29, 36], ["TM cells", "TREATMENT", 58, 66], ["diseases", "OBSERVATION", 17, 25], ["cancers", "OBSERVATION", 29, 36]]], ["Taken together, TM cells may be present and respond effectively at the target sites regardless of whether these sites are present in the SLOs or peripheral organs by inducing or inhibiting the CCR7 signaling in TM cells.CONCLUSION AND FUTURE PERSPECTIVESIn the past few decades, new respiratory diseases have been caused by virus infections such as influenza virus, severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus 2 repeatedly.", [["TM cells", "ANATOMY", 16, 24], ["SLOs", "ANATOMY", 137, 141], ["peripheral organs", "ANATOMY", 145, 162], ["TM cells", "ANATOMY", 211, 219], ["respiratory", "ANATOMY", 283, 294], ["respiratory diseases", "DISEASE", 283, 303], ["infections", "DISEASE", 330, 340], ["influenza virus", "DISEASE", 349, 364], ["acute respiratory syndrome coronavirus", "DISEASE", 373, 411], ["SARS-CoV)", "DISEASE", 413, 422], ["middle east respiratory syndrome coronavirus", "DISEASE", 424, 468], ["acute respiratory syndrome coronavirus", "DISEASE", 481, 519], ["TM cells", "CELL", 16, 24], ["SLOs", "GENE_OR_GENE_PRODUCT", 137, 141], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 145, 162], ["CCR7", "GENE_OR_GENE_PRODUCT", 193, 197], ["TM cells", "CELL", 211, 219], ["influenza virus", "ORGANISM", 349, 364], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 366, 411], ["SARS-CoV", "ORGANISM", 413, 421], ["TM cells", "CELL_LINE", 16, 24], ["CCR7", "PROTEIN", 193, 197], ["TM cells", "CELL_TYPE", 211, 219], ["influenza virus", "SPECIES", 349, 364], ["influenza virus", "SPECIES", 349, 364], ["severe acute respiratory syndrome coronavirus", "SPECIES", 366, 411], ["SARS-CoV", "SPECIES", 413, 421], ["middle east respiratory syndrome coronavirus", "SPECIES", 424, 468], ["severe acute respiratory syndrome coronavirus", "SPECIES", 474, 519], ["these sites", "PROBLEM", 106, 117], ["new respiratory diseases", "PROBLEM", 279, 303], ["virus infections", "PROBLEM", 324, 340], ["influenza virus", "PROBLEM", 349, 364], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 366, 411], ["middle east respiratory syndrome coronavirus", "PROBLEM", 424, 468], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 474, 519], ["peripheral", "ANATOMY_MODIFIER", 145, 155], ["organs", "ANATOMY", 156, 162], ["new", "OBSERVATION_MODIFIER", 279, 282], ["respiratory diseases", "OBSERVATION", 283, 303], ["virus", "OBSERVATION", 324, 329], ["influenza virus", "OBSERVATION", 349, 364], ["severe", "OBSERVATION_MODIFIER", 366, 372], ["acute", "OBSERVATION_MODIFIER", 373, 378], ["respiratory syndrome coronavirus", "OBSERVATION", 379, 411], ["middle", "ANATOMY_MODIFIER", 424, 430], ["respiratory syndrome coronavirus", "OBSERVATION", 436, 468], ["severe", "OBSERVATION_MODIFIER", 474, 480], ["acute", "OBSERVATION_MODIFIER", 481, 486], ["respiratory syndrome coronavirus", "OBSERVATION", 487, 519]]], ["All of these pathogenic viruses were derived from coronaviruses that commonly infect humans, but new mutations have made it difficult for our immune system to get rid of these viral infections.", [["viral infections", "DISEASE", 176, 192], ["coronaviruses", "ORGANISM", 50, 63], ["humans", "ORGANISM", 85, 91], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["these pathogenic viruses", "PROBLEM", 7, 31], ["coronaviruses", "PROBLEM", 50, 63], ["new mutations", "PROBLEM", 97, 110], ["our immune system", "TREATMENT", 138, 155], ["these viral infections", "PROBLEM", 170, 192], ["pathogenic", "OBSERVATION_MODIFIER", 13, 23], ["viruses", "OBSERVATION", 24, 31], ["viral", "OBSERVATION_MODIFIER", 176, 181], ["infections", "OBSERVATION", 182, 192]]], ["However, the survival of memory CD8+ T cell responding to SARS-CoV in peripheral blood of the patients possibly suggest the importance of TM cells for the recovery from these diseases (99100).", [["memory CD8+ T cell", "ANATOMY", 25, 43], ["peripheral blood", "ANATOMY", 70, 86], ["TM cells", "ANATOMY", 138, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 32, 35], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["peripheral blood", "MULTI-TISSUE_STRUCTURE", 70, 86], ["patients", "ORGANISM", 94, 102], ["TM cells", "CELL", 138, 146], ["memory CD8+ T cell", "CELL_TYPE", 25, 43], ["TM cells", "CELL_TYPE", 138, 146], ["patients", "SPECIES", 94, 102], ["SARS-CoV", "SPECIES", 58, 66], ["memory CD8", "TEST", 25, 35], ["T cell", "PROBLEM", 37, 43], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["TM cells", "TREATMENT", 138, 146], ["these diseases", "PROBLEM", 169, 183], ["peripheral", "ANATOMY_MODIFIER", 70, 80], ["blood", "ANATOMY", 81, 86]]], ["Particularly, the Ab response to SARS-CoV was short-lived, indicating the biased immune responses toward T cell immunity.", [["T cell", "ANATOMY", 105, 111], ["SARS", "DISEASE", 33, 37], ["Ab", "GENE_OR_GENE_PRODUCT", 18, 20], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["T cell", "CELL", 105, 111], ["SARS-CoV", "SPECIES", 33, 41]]], ["However, it is still not clear whether virus-specific TM cells are also present in the lungs of these survived patients.", [["TM cells", "ANATOMY", 54, 62], ["lungs", "ANATOMY", 87, 92], ["TM cells", "CELL", 54, 62], ["lungs", "ORGAN", 87, 92], ["patients", "ORGANISM", 111, 119], ["TM cells", "CELL_TYPE", 54, 62], ["patients", "SPECIES", 111, 119], ["virus-specific TM cells", "PROBLEM", 39, 62], ["virus", "OBSERVATION", 39, 44], ["TM cells", "OBSERVATION", 54, 62], ["lungs", "ANATOMY", 87, 92]]], ["Since the lungs were proposed to provide unfavorable microenvironments for TM cell homeostasis, it would be particularly challenging to develop proper vaccines or therapies.", [["lungs", "ANATOMY", 10, 15], ["TM cell", "ANATOMY", 75, 82], ["lungs", "ORGAN", 10, 15], ["TM cell", "CELL", 75, 82], ["TM cell homeostasis", "TREATMENT", 75, 94], ["proper vaccines", "TREATMENT", 144, 159], ["therapies", "TREATMENT", 163, 172], ["lungs", "ANATOMY", 10, 15]]], ["However, Jung et al. (90) showed that CCR7-deficient TM cells can heavily populate the lung, possibly indicating that the regulation of CCR7 signaling may give us a chance to prevent these diseases.", [["TM cells", "ANATOMY", 53, 61], ["lung", "ANATOMY", 87, 91], ["CCR7", "GENE_OR_GENE_PRODUCT", 38, 42], ["TM cells", "CELL", 53, 61], ["lung", "ORGAN", 87, 91], ["CCR7", "GENE_OR_GENE_PRODUCT", 136, 140], ["CCR7", "PROTEIN", 38, 42], ["TM cells", "CELL_TYPE", 53, 61], ["CCR7", "PROTEIN", 136, 140], ["Jung et al.", "TEST", 9, 20], ["CCR7", "TEST", 38, 42], ["deficient TM cells", "PROBLEM", 43, 61], ["CCR7 signaling", "PROBLEM", 136, 150], ["these diseases", "PROBLEM", 183, 197], ["lung", "ANATOMY", 87, 91], ["possibly indicating", "UNCERTAINTY", 93, 112], ["diseases", "OBSERVATION", 189, 197]]], ["These approaches may illuminate the future of our novel vaccines or therapies.", [["our novel vaccines", "TREATMENT", 46, 64], ["therapies", "TREATMENT", 68, 77]]]], "PMC7514226": [["IntroductionThe COVID-19 pandemic due to SARS-Cov-2 has rapidly spread all over the world since last December.", [["SARS-Cov-2", "CHEMICAL", 41, 51], ["The COVID", "TEST", 12, 21], ["SARS", "PROBLEM", 41, 45], ["rapidly", "OBSERVATION_MODIFIER", 56, 63], ["spread", "OBSERVATION_MODIFIER", 64, 70]]], ["Although its prevalence in the community is uncertain due to the asymptomatic cases, all age groups seems to be similarly affected (1).", [["the asymptomatic cases", "PROBLEM", 61, 83]]], ["However, older people are at higher risk of suffering negative outcomes, which can lead to an elevated rate of mortality, being five times higher than the global average for those older than 80 years old (2).", [["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21], ["an elevated rate of mortality", "PROBLEM", 91, 120], ["elevated", "OBSERVATION", 94, 102]]], ["Over 95% of fatalities due to COVID-19 in Europe and around 80% in China have included people older than 60 years-old (3, 4).", [["fatalities", "DISEASE", 12, 22], ["COVID", "DISEASE", 30, 35], ["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["COVID", "TEST", 30, 35]]], ["In the US, 80% of deaths were among adults 65 and over (5).", [["deaths", "DISEASE", 18, 24], ["deaths", "PROBLEM", 18, 24]]], ["Hence, health strategies to avoid spread of coronavirus (such as quarantine and social distancing) are important (6, 7).IntroductionThe World Health Organization (WHO) describes a close relationship between physical and mental functions with the level of self-governance and social participation in the community[8].", [["coronavirus", "DISEASE", 44, 55], ["coronavirus", "ORGANISM", 44, 55], ["coronavirus", "PROBLEM", 44, 55]]], ["Various studies have reported protective effects of social participation for the health of the elderly, being considered as a stimulus to increase the level of physical activity and cognitive functions (9, 13, 14).", [["Various studies", "TEST", 0, 15]]], ["The social participation has been associated with a better quality of life, more muscle mass, balance, cognition and lower comorbidities and disability in older people (9, 13, 15\u221320).", [["muscle mass", "ANATOMY", 81, 92], ["disability", "DISEASE", 141, 151], ["muscle", "ORGAN", 81, 87], ["people", "ORGANISM", 161, 167], ["people", "SPECIES", 161, 167], ["more muscle mass", "PROBLEM", 76, 92], ["lower comorbidities", "PROBLEM", 117, 136], ["muscle", "ANATOMY", 81, 87], ["mass", "OBSERVATION", 88, 92]]], ["Participating in social meetings and activities are stimuli that increase the level of physical activity as well as the interaction with other older adults stimulating sensory systems, self-esteem, affectivity, emotional and psychological support (9, 13, 21).", [["psychological support", "TREATMENT", 225, 246]]], ["As a preventive measure during the COVID-19 pandemic, community organizations have closed.", [["the COVID", "TEST", 31, 40]]], ["Old people are constrained from visits with family members, therefore the social participation have been restricted (7).", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10]]], ["Thus, the decreasing of social interaction produced by social distancing could have a negative impact on mental and physical health in older people (22\u221324), since it has limited the social participation in community organizations and in family activities (23, 25).IntroductionWHO defines the \u2018intrinsic capacity\u2019 as the \u2018composite of all the physical, functional, and mental capacities of an individual\u2019 (26\u221328), changing the focus from a negative aging (disability) towards a positive one (optimal aging), being related to the onset of autonomy decline, falls and death (27).", [["disability", "DISEASE", 455, 465], ["falls", "DISEASE", 555, 560], ["death", "DISEASE", 565, 570], ["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["autonomy decline", "PROBLEM", 537, 553], ["falls", "PROBLEM", 555, 560], ["death", "PROBLEM", 565, 570], ["decreasing", "OBSERVATION_MODIFIER", 10, 20], ["autonomy", "OBSERVATION", 537, 545]]], ["Physical activity has a positive impact on the health and quality of life, reducing the risk of functional and cognitive impairment, falls and risk of fractures, depression, disability, risk of geriatrics syndromes, hospitalization rates and, consecutively, mortality in older people (29).IntroductionNot only the physical activity is affected during quarantine, but also mental health.", [["functional and cognitive impairment", "DISEASE", 96, 131], ["falls", "DISEASE", 133, 138], ["fractures", "DISEASE", 151, 160], ["depression", "DISEASE", 162, 172], ["disability", "DISEASE", 174, 184], ["people", "ORGANISM", 277, 283], ["people", "SPECIES", 277, 283], ["functional and cognitive impairment", "PROBLEM", 96, 131], ["falls", "PROBLEM", 133, 138], ["fractures", "PROBLEM", 151, 160], ["depression", "PROBLEM", 162, 172], ["disability", "PROBLEM", 174, 184], ["geriatrics syndromes", "PROBLEM", 194, 214], ["fractures", "OBSERVATION", 151, 160]]], ["Several studies have described mental health consequences in previous quarantines, such as higher risk of depression (30), emotional disturbance (31), stress (32), low mood (33), irritability (33), or insomnia (33), being also associated with higher rates of suicide in elderly population (34).", [["depression", "DISEASE", 106, 116], ["emotional disturbance", "DISEASE", 123, 144], ["low mood", "DISEASE", 164, 172], ["irritability", "DISEASE", 179, 191], ["insomnia", "DISEASE", 201, 209], ["Several studies", "TEST", 0, 15], ["depression", "PROBLEM", 106, 116], ["emotional disturbance", "PROBLEM", 123, 144], ["low mood", "PROBLEM", 164, 172], ["irritability", "PROBLEM", 179, 191], ["insomnia", "PROBLEM", 201, 209]]], ["However, the effects of COVID-19 quarantine on the health of older adults have not yet been broadly studied.", [["COVID-19 quarantine", "CHEMICAL", 24, 43], ["COVID-19", "CHEMICAL", 24, 32], ["adults", "ORGANISM", 67, 73], ["COVID", "TEST", 24, 29]]], ["Hence, the aim of this review is to analyse the potential effects of social isolation caused by COVID-19 pandemic on mental and physical health in older adults.", [["social isolation", "TREATMENT", 69, 85]]], ["Additionally, we have analysed the recommendations and proposed activities to avoid mental and functional decline to carry out at home.MethodsIn this narrative review, the literature search was performed by three authors (WSL, IRS and RT).", [["mental and functional decline", "PROBLEM", 84, 113]]], ["Pubmed, Scielo and Google Scholar databases were consulted using the following terms (\u2018COVID-19\u2019, \u2018coronavirus\u2019, \u2018aging\u2019, \u2018older people\u2019, \u2018elderly\u2019, \u2018social isolation\u2019 and \u2018quarantine\u2019).", [["coronavirus", "SPECIES", 99, 110]]], ["The content of the review was divided into two main areas: 1) effect of the reduction of social participation produced by quarantine for COVID-19 on mental and physical health in elderly people, and 2) recommendations for mental and physical health of older people during the COVID-19 quarantine.Search results ::: ResultsA detailed summary of the literature search is provided in Figure 1.", [["COVID-19", "CHEMICAL", 137, 145], ["people", "ORGANISM", 187, 193], ["people", "ORGANISM", 258, 264], ["people", "SPECIES", 187, 193], ["people", "SPECIES", 258, 264], ["COVID", "TEST", 137, 142], ["the COVID", "TREATMENT", 272, 281]]], ["Six hundred and ninety unique records were identified through database and handsearching, resulting in ten articles involving 20.069 participants included in the final review (women 58%) from Asia, Europe, and America.", [["women", "ORGANISM", 176, 181], ["participants", "SPECIES", 133, 145], ["women", "SPECIES", 176, 181]]], ["All of them are descriptive studies.", [["descriptive studies", "TEST", 16, 35]]], ["A summary of the characteristics of the included studies is presented in table 1.", [["the included studies", "TEST", 36, 56]]]], "PMC7168365": [], "PMC6723519": [], "PMC7300367": [["Virus name: hCoV/Mexico/CDMX/InDRE_01/2020", [["Virus", "ORGANISM", 0, 5], ["CDMX", "PROTEIN", 24, 28], ["Virus name: hCoV/Mexico/CDMX/InDRE_01/2020", "SPECIES", 0, 42]]]], "4ac5f0b8f250b6d6547faecf90f1b0eb6669e1b7": [["' INTRODUCTIONOn December 31, 2019, the World Health Organization (WHO) was informed of a high incidence of pneumonia cases in the city of Wuhan, Hubei Province of China.", [["pneumonia", "DISEASE", 108, 117], ["pneumonia", "PROBLEM", 108, 117], ["pneumonia", "OBSERVATION", 108, 117]]], ["On January 7, 2020, Chinese authorities confirmed the pneumonia outbreak was caused by a new type of virus, which belongs to a family known as Coronaviruses (1) .", [["pneumonia", "DISEASE", 54, 63], ["the pneumonia outbreak", "PROBLEM", 50, 72], ["a new type of virus", "PROBLEM", 87, 106], ["pneumonia", "OBSERVATION", 54, 63], ["virus", "OBSERVATION", 101, 106]]], ["Some of the viruses in the Coronaviruses family already exist in Brazil, and are capable of causing a common cold; however, the coronavirus family also encompasses viruses like SARS and MERS that caused epidemics with a large number of deaths in 2004 and 2012, respectively.", [["SARS", "DISEASE", 177, 181], ["deaths", "DISEASE", 236, 242], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 27, 40], ["coronavirus", "ORGANISM", 128, 139], ["the viruses", "PROBLEM", 8, 19], ["a common cold", "PROBLEM", 100, 113], ["viruses", "PROBLEM", 164, 171], ["SARS", "PROBLEM", 177, 181], ["epidemics", "PROBLEM", 203, 212], ["viruses", "OBSERVATION", 12, 19], ["Coronaviruses", "OBSERVATION", 27, 40], ["viruses", "OBSERVATION", 164, 171], ["large", "OBSERVATION_MODIFIER", 220, 225], ["number", "OBSERVATION_MODIFIER", 226, 232]]], ["The new virus is believed to have been transmitted from another species of animal, bats are currently suspected, to humans (2) .", [["bats", "ORGANISM", 83, 87], ["humans", "ORGANISM", 116, 122], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 116, 122], ["The new virus", "PROBLEM", 0, 13], ["new", "OBSERVATION_MODIFIER", 4, 7], ["virus", "OBSERVATION", 8, 13]]], ["On February 26, 2020, the first case of this disease was reported in Brazil, a 61-year-old man who had recently been abroad.", [["man", "ORGANISM", 91, 94], ["man", "SPECIES", 91, 94], ["this disease", "PROBLEM", 40, 52], ["disease", "OBSERVATION", 45, 52]]], ["Since then, the number of cases grew rapidly, and in early May, the virus death toll in Brazil was over 10,000, with over 600 deaths reported per day (3) .'", [["death", "DISEASE", 74, 79], ["deaths", "DISEASE", 126, 132], ["the virus death", "PROBLEM", 64, 79]]], ["INTRODUCTIONThe coronavirus disease 2019 (COVID-19) is the disease caused by the newly identified virus, of the Coronaviruses family -severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["acute respiratory syndrome coronavirus", "DISEASE", 141, 179], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 134, 181], ["SARS-CoV-2", "ORGANISM", 183, 193], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["severe acute respiratory syndrome coronavirus", "SPECIES", 134, 179], ["SARS-CoV-2", "SPECIES", 183, 193], ["coronavirus disease", "PROBLEM", 16, 35], ["COVID", "TEST", 42, 47], ["the disease", "PROBLEM", 55, 66], ["the newly identified virus", "PROBLEM", 77, 103], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 134, 179], ["CoV", "TEST", 188, 191], ["coronavirus disease", "OBSERVATION", 16, 35], ["disease", "OBSERVATION", 59, 66], ["virus", "OBSERVATION", 98, 103], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["respiratory syndrome", "OBSERVATION", 147, 167]]], ["COVID-19 has evolved rapidly, and based on the increase in the number of cases and fast global spread, the WHO classified the outbreak as a pandemic on March 11, 2020 .", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["fast global spread", "PROBLEM", 83, 101], ["rapidly", "OBSERVATION_MODIFIER", 21, 28], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["This being the case, all health organizations had to drastically rearrange their activities to face the challenges posed by this new disease.", [["this new disease", "PROBLEM", 124, 140]]], ["These changes are even more challenging when they involve patients with chronic diseases, including cancer.", [["cancer", "ANATOMY", 100, 106], ["chronic diseases", "DISEASE", 72, 88], ["cancer", "DISEASE", 100, 106], ["patients", "ORGANISM", 58, 66], ["cancer", "CANCER", 100, 106], ["patients", "SPECIES", 58, 66], ["chronic diseases", "PROBLEM", 72, 88], ["cancer", "PROBLEM", 100, 106], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["diseases", "OBSERVATION", 80, 88], ["cancer", "OBSERVATION", 100, 106]]], ["In particular, in the case of patients with suspected or diagnosed lung cancer, there are peculiarities that must be addressed within the context of the current pandemic.'", [["lung cancer", "ANATOMY", 67, 78], ["lung cancer", "DISEASE", 67, 78], ["patients", "ORGANISM", 30, 38], ["lung cancer", "CANCER", 67, 78], ["patients", "SPECIES", 30, 38], ["diagnosed lung cancer", "PROBLEM", 57, 78], ["lung", "ANATOMY", 67, 71], ["cancer", "OBSERVATION", 72, 78]]], ["INTRODUCTIONClinical findings and imaging in the early stages of COVID-19 pneumonia may resemble common findings in patients with lung cancer, like treatment complications (caused by immunotherapy, chemotherapy, radiotherapy, and/or targeted therapies) and other infectious complications (4) .", [["lung cancer", "ANATOMY", 130, 141], ["COVID", "DISEASE", 65, 70], ["pneumonia", "DISEASE", 74, 83], ["lung cancer", "DISEASE", 130, 141], ["patients", "ORGANISM", 116, 124], ["lung cancer", "CANCER", 130, 141], ["patients", "SPECIES", 116, 124], ["imaging", "TEST", 34, 41], ["COVID", "TEST", 65, 70], ["pneumonia", "PROBLEM", 74, 83], ["lung cancer", "PROBLEM", 130, 141], ["treatment complications", "PROBLEM", 148, 171], ["immunotherapy", "TREATMENT", 183, 196], ["chemotherapy", "TREATMENT", 198, 210], ["radiotherapy", "TREATMENT", 212, 224], ["targeted therapies", "TREATMENT", 233, 251], ["other infectious complications", "PROBLEM", 257, 287], ["pneumonia", "OBSERVATION", 74, 83], ["lung", "ANATOMY", 130, 134], ["cancer", "OBSERVATION", 135, 141], ["infectious", "OBSERVATION_MODIFIER", 263, 273]]], ["Furthermore, patients with suspected or diagnosed lung cancer often undergo invasive thoracic procedures, which increases their risk of complications in case of a SARS-CoV-2 infection.", [["lung cancer", "ANATOMY", 50, 61], ["thoracic", "ANATOMY", 85, 93], ["lung cancer", "DISEASE", 50, 61], ["SARS-CoV-2 infection", "DISEASE", 163, 183], ["patients", "ORGANISM", 13, 21], ["lung cancer", "CANCER", 50, 61], ["thoracic", "ORGAN", 85, 93], ["CoV-2", "ORGANISM", 168, 173], ["patients", "SPECIES", 13, 21], ["diagnosed lung cancer", "PROBLEM", 40, 61], ["invasive thoracic procedures", "TREATMENT", 76, 104], ["complications", "PROBLEM", 136, 149], ["a SARS", "PROBLEM", 161, 167], ["CoV-2 infection", "PROBLEM", 168, 183], ["lung", "ANATOMY", 50, 54], ["cancer", "OBSERVATION", 55, 61], ["invasive", "OBSERVATION_MODIFIER", 76, 84], ["thoracic", "ANATOMY", 85, 93], ["procedures", "OBSERVATION", 94, 104], ["infection", "OBSERVATION", 174, 183]]], ["It is important to mention that most are patients with advanced lung cancer for whom decisions regarding non-invasive, psychological and familiar support, and comfort care measures have a critical role.'", [["lung cancer", "ANATOMY", 64, 75], ["lung cancer", "DISEASE", 64, 75], ["patients", "ORGANISM", 41, 49], ["lung cancer", "CANCER", 64, 75], ["patients", "SPECIES", 41, 49], ["advanced lung cancer", "PROBLEM", 55, 75], ["familiar support", "TREATMENT", 137, 153], ["comfort care measures", "TREATMENT", 159, 180], ["lung", "ANATOMY", 64, 68], ["cancer", "OBSERVATION", 69, 75]]], ["INTRODUCTIONFor these reasons, the Brazilian Thoracic Oncology Group (GBOT) have outlined guidelines that are both consensusbased, representing major cancer treatment medical societies, and localized, taking into account local needs for managing these patients.", [["cancer", "ANATOMY", 150, 156], ["cancer", "DISEASE", 150, 156], ["cancer", "CANCER", 150, 156], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260], ["Thoracic", "ANATOMY", 45, 53], ["major", "OBSERVATION_MODIFIER", 144, 149], ["cancer", "OBSERVATION", 150, 156]]], ["LUNG CANCER AS A RISK FACTOR FOR COVID-19Although any individual can be infected by COVID-19, certain populations are more likely to develop complications and severe forms of the disease.", [["LUNG CANCER", "PROBLEM", 0, 11], ["COVID", "TEST", 33, 38], ["COVID", "TEST", 84, 89], ["complications", "PROBLEM", 141, 154], ["the disease", "PROBLEM", 175, 186], ["CANCER", "OBSERVATION", 5, 11], ["infected", "OBSERVATION", 72, 80], ["more likely", "UNCERTAINTY", 118, 129], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["disease", "OBSERVATION", 179, 186]]], ["Based on previous studies, patients over 65 years of age, living in nursing homes, and suffering from comorbidities, including chronic lung diseases, moderate to severe asthma, heart diseases, immunosuppression conditions, severe obesity (a BMI of 40 or higher), diabetes mellitus, chronic kidney disease on dialysis, and liver disease (5) are more likely to develop severe disease.", [["lung", "ANATOMY", 135, 139], ["heart", "ANATOMY", 177, 182], ["kidney", "ANATOMY", 290, 296], ["liver", "ANATOMY", 322, 327], ["chronic lung diseases", "DISEASE", 127, 148], ["asthma", "DISEASE", 169, 175], ["heart diseases", "DISEASE", 177, 191], ["obesity", "DISEASE", 230, 237], ["diabetes mellitus", "DISEASE", 263, 280], ["chronic kidney disease", "DISEASE", 282, 304], ["liver disease", "DISEASE", 322, 335], ["patients", "ORGANISM", 27, 35], ["lung", "ORGAN", 135, 139], ["heart", "ORGAN", 177, 182], ["kidney", "ORGAN", 290, 296], ["liver", "ORGAN", 322, 327], ["patients", "SPECIES", 27, 35], ["previous studies", "TEST", 9, 25], ["comorbidities", "PROBLEM", 102, 115], ["chronic lung diseases", "PROBLEM", 127, 148], ["moderate to severe asthma", "PROBLEM", 150, 175], ["heart diseases", "PROBLEM", 177, 191], ["immunosuppression conditions", "PROBLEM", 193, 221], ["severe obesity", "PROBLEM", 223, 237], ["a BMI", "TEST", 239, 244], ["diabetes mellitus", "PROBLEM", 263, 280], ["chronic kidney disease", "PROBLEM", 282, 304], ["dialysis", "TREATMENT", 308, 316], ["liver disease", "PROBLEM", 322, 335], ["severe disease", "PROBLEM", 367, 381], ["chronic", "OBSERVATION_MODIFIER", 127, 134], ["lung", "ANATOMY", 135, 139], ["diseases", "OBSERVATION", 140, 148], ["moderate", "OBSERVATION_MODIFIER", 150, 158], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["asthma", "OBSERVATION", 169, 175], ["heart", "ANATOMY", 177, 182], ["diseases", "OBSERVATION", 183, 191], ["immunosuppression", "OBSERVATION", 193, 210], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["obesity", "OBSERVATION", 230, 237], ["diabetes mellitus", "OBSERVATION", 263, 280], ["chronic", "OBSERVATION_MODIFIER", 282, 289], ["kidney", "ANATOMY", 290, 296], ["disease", "OBSERVATION", 297, 304], ["liver", "ANATOMY", 322, 327], ["disease", "OBSERVATION", 328, 335], ["more likely to", "UNCERTAINTY", 344, 358], ["severe", "OBSERVATION_MODIFIER", 367, 373], ["disease", "OBSERVATION", 374, 381]]], ["Consequently, there are greater chances of lung cancer patients falling into a high-risk group.", [["lung cancer", "ANATOMY", 43, 54], ["lung cancer", "DISEASE", 43, 54], ["lung cancer", "CANCER", 43, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["lung cancer", "PROBLEM", 43, 54], ["greater", "OBSERVATION_MODIFIER", 24, 31], ["lung", "ANATOMY", 43, 47], ["cancer", "OBSERVATION", 48, 54]]], ["Although all types of neoplasia appear to be associated with high prevalence, morbidity, and mortality from COVID-19, lung cancer represents a specific situation involving cumulative risk factors for COVID-19 complications, including advanced age, significant cardiovascular and respiratory comorbidities, lung damage caused by smoking, impairment of immune function following cancer treatment (or cancer itself), or the frequent use of corticosteroids.'", [["neoplasia", "ANATOMY", 22, 31], ["lung cancer", "ANATOMY", 118, 129], ["cardiovascular", "ANATOMY", 260, 274], ["respiratory", "ANATOMY", 279, 290], ["lung", "ANATOMY", 306, 310], ["cancer", "ANATOMY", 377, 383], ["cancer", "ANATOMY", 398, 404], ["neoplasia", "DISEASE", 22, 31], ["lung cancer", "DISEASE", 118, 129], ["cardiovascular and respiratory comorbidities", "DISEASE", 260, 304], ["lung damage", "DISEASE", 306, 317], ["impairment of immune function", "DISEASE", 337, 366], ["cancer", "DISEASE", 377, 383], ["cancer", "DISEASE", 398, 404], ["corticosteroids", "CHEMICAL", 437, 452], ["neoplasia", "CANCER", 22, 31], ["lung cancer", "CANCER", 118, 129], ["lung", "ORGAN", 306, 310], ["cancer", "CANCER", 377, 383], ["cancer", "CANCER", 398, 404], ["corticosteroids", "SIMPLE_CHEMICAL", 437, 452], ["neoplasia", "PROBLEM", 22, 31], ["morbidity", "PROBLEM", 78, 87], ["COVID", "TEST", 108, 113], ["lung cancer", "PROBLEM", 118, 129], ["COVID-19 complications", "PROBLEM", 200, 222], ["advanced age", "PROBLEM", 234, 246], ["significant cardiovascular and respiratory comorbidities", "PROBLEM", 248, 304], ["lung damage", "PROBLEM", 306, 317], ["immune function", "PROBLEM", 351, 366], ["cancer treatment", "TREATMENT", 377, 393], ["cancer itself", "PROBLEM", 398, 411], ["corticosteroids", "TREATMENT", 437, 452], ["neoplasia", "OBSERVATION", 22, 31], ["lung", "ANATOMY", 118, 122], ["cancer", "OBSERVATION", 123, 129], ["significant", "OBSERVATION_MODIFIER", 248, 259], ["cardiovascular", "ANATOMY", 260, 274], ["respiratory comorbidities", "OBSERVATION", 279, 304], ["lung", "ANATOMY", 306, 310], ["damage", "OBSERVATION", 311, 317]]], ["LUNG CANCER AS A RISK FACTOR FOR COVID-19Numerous studies on COVID-19 in cancer patients have confirmed this scenario.", [["cancer", "ANATOMY", 73, 79], ["COVID-19", "CHEMICAL", 61, 69], ["cancer", "DISEASE", 73, 79], ["COVID-19", "SIMPLE_CHEMICAL", 61, 69], ["cancer", "CANCER", 73, 79], ["patients", "ORGANISM", 80, 88], ["COVID-19", "DNA", 61, 69], ["patients", "SPECIES", 80, 88], ["LUNG CANCER", "PROBLEM", 0, 11], ["COVID", "TEST", 33, 38], ["COVID", "TEST", 61, 66], ["CANCER", "OBSERVATION", 5, 11], ["cancer", "OBSERVATION", 73, 79]]], ["Among 1,524 cancer patients admitted to the Department of Radiation and Medical Oncology at Zhongnan Hospital of Wuhan University in Wuhan, China, 0.79% had COVID-19 versus 0.37% of the general population of Wuhan over the same study period (OR, 2.31; 95% CI, 1.89-3.02).", [["cancer", "ANATOMY", 12, 18], ["cancer", "DISEASE", 12, 18], ["cancer", "CANCER", 12, 18], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["COVID", "TEST", 157, 162], ["CI", "TEST", 256, 258], ["cancer", "OBSERVATION", 12, 18]]], ["In the same study, patients with non-small cell lung cancer (NSCLC) seemed to have a higher incidence of COVID-19, especially those over 60 years of age (4.3% versus 1.8% in those aged under 60 years with NSCLC) (6) .", [["non-small cell lung cancer", "ANATOMY", 33, 59], ["NSCLC", "ANATOMY", 61, 66], ["non-small cell lung cancer", "DISEASE", 33, 59], ["NSCLC", "DISEASE", 61, 66], ["NSCLC", "DISEASE", 205, 210], ["patients", "ORGANISM", 19, 27], ["non-small cell lung cancer", "CANCER", 33, 59], ["NSCLC", "CANCER", 61, 66], ["NSCLC", "CANCER", 205, 210], ["patients", "SPECIES", 19, 27], ["the same study", "TEST", 3, 17], ["non-small cell lung cancer", "PROBLEM", 33, 59], ["NSCLC", "PROBLEM", 61, 66], ["COVID", "TEST", 105, 110], ["NSCLC", "PROBLEM", 205, 210], ["non-small cell", "OBSERVATION", 33, 47], ["lung", "ANATOMY", 48, 52], ["cancer", "OBSERVATION", 53, 59], ["NSCLC", "OBSERVATION", 61, 66], ["higher", "OBSERVATION_MODIFIER", 85, 91], ["NSCLC", "OBSERVATION", 205, 210]]], ["According to another retrospective case study published by a Chinese team, cancer patients (most frequently, advanced lung cancer [28%]) were at higher risk of severe complications and unfavorable outcomes than hospitalized cancer-free patients (7) .", [["cancer", "ANATOMY", 75, 81], ["lung cancer", "ANATOMY", 118, 129], ["cancer", "ANATOMY", 224, 230], ["cancer", "DISEASE", 75, 81], ["lung cancer", "DISEASE", 118, 129], ["cancer", "DISEASE", 224, 230], ["cancer", "CANCER", 75, 81], ["patients", "ORGANISM", 82, 90], ["lung cancer", "CANCER", 118, 129], ["cancer", "CANCER", 224, 230], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 236, 244], ["advanced lung cancer", "PROBLEM", 109, 129], ["severe complications", "PROBLEM", 160, 180], ["cancer", "OBSERVATION", 75, 81], ["lung", "ANATOMY", 118, 122], ["cancer", "OBSERVATION", 123, 129], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["complications", "OBSERVATION", 167, 180]]], ["Smoking history also seems to increase the risk of complications by up to 1.4-fold, and by 2.4-fold that of death or need for mechanical ventilation due to COVID-19 (8, 9) .'", [["death", "DISEASE", 108, 113], ["COVID-19", "CHEMICAL", 156, 164], ["complications", "PROBLEM", 51, 64], ["death", "PROBLEM", 108, 113], ["mechanical ventilation", "TREATMENT", 126, 148], ["COVID", "TEST", 156, 161], ["complications", "OBSERVATION", 51, 64]]], ["LUNG CANCER AS A RISK FACTOR FOR COVID-19During a recent plenary session of the American Association for Cancer Research annual congress on ''COVID-19 and Cancer,'' an international team led by Dr. Marina Garassino presented initial data from TERAVOLT (Thoracic cancERs internAtional coVid 19 cOLlaboraTion) a global registry gathering information on patients with thoracic cancers infected with COVID-19in which a 34.6% mortality rate (66/191) among patients with thoracic cancer was reported.", [["Cancer", "ANATOMY", 105, 111], ["thoracic cancers", "ANATOMY", 365, 381], ["thoracic cancer", "ANATOMY", 465, 480], ["Cancer", "DISEASE", 105, 111], ["Cancer", "DISEASE", 155, 161], ["thoracic cancers infected", "DISEASE", 365, 390], ["COVID-19in", "CHEMICAL", 396, 406], ["thoracic cancer", "DISEASE", 465, 480], ["Cancer", "CANCER", 105, 111], ["Cancer", "CANCER", 155, 161], ["patients", "ORGANISM", 351, 359], ["thoracic cancers", "CANCER", 365, 381], ["patients", "ORGANISM", 451, 459], ["thoracic cancer", "CANCER", 465, 480], ["patients", "SPECIES", 351, 359], ["patients", "SPECIES", 451, 459], ["LUNG CANCER", "PROBLEM", 0, 11], ["thoracic cancers", "PROBLEM", 365, 381], ["COVID", "TEST", 396, 401], ["mortality rate", "TEST", 421, 435], ["thoracic cancer", "PROBLEM", 465, 480], ["CANCER", "OBSERVATION", 5, 11], ["Cancer", "OBSERVATION", 105, 111], ["Cancer", "OBSERVATION", 155, 161], ["Thoracic", "ANATOMY", 253, 261], ["thoracic", "ANATOMY", 365, 373], ["cancers", "OBSERVATION", 374, 381], ["thoracic", "ANATOMY", 465, 473], ["cancer", "OBSERVATION", 474, 480]]], ["In addition, the most common complications were pneumonia and pneumonitis (79.6%; 125/157), acute respiratory distress syndrome (26.8%; 42/157), multiple organ failure (7.6%; 12/157), and sepsis in (5.1%; 8/157).", [["respiratory", "ANATOMY", 98, 109], ["organ", "ANATOMY", 154, 159], ["pneumonia", "DISEASE", 48, 57], ["pneumonitis", "DISEASE", 62, 73], ["respiratory distress syndrome", "DISEASE", 98, 127], ["multiple organ failure", "DISEASE", 145, 167], ["sepsis", "DISEASE", 188, 194], ["organ", "ORGAN", 154, 159], ["the most common complications", "PROBLEM", 13, 42], ["pneumonia", "PROBLEM", 48, 57], ["pneumonitis", "PROBLEM", 62, 73], ["acute respiratory distress syndrome", "PROBLEM", 92, 127], ["multiple organ failure", "PROBLEM", 145, 167], ["sepsis", "PROBLEM", 188, 194], ["pneumonia", "OBSERVATION", 48, 57], ["pneumonitis", "OBSERVATION", 62, 73], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory distress syndrome", "OBSERVATION", 98, 127], ["multiple", "OBSERVATION_MODIFIER", 145, 153], ["organ", "ANATOMY", 154, 159], ["failure", "OBSERVATION", 160, 167], ["sepsis", "OBSERVATION", 188, 194]]], ["The cause of death in most of these patients was attributed to COVID-19 and not to cancer itself (10) .", [["cancer", "ANATOMY", 83, 89], ["death", "DISEASE", 13, 18], ["cancer", "DISEASE", 83, 89], ["patients", "ORGANISM", 36, 44], ["cancer", "CANCER", 83, 89], ["patients", "SPECIES", 36, 44], ["death", "PROBLEM", 13, 18], ["COVID", "TEST", 63, 68]]], ["For these reasons, lung cancer patients must be considered to be at greater risk of developing COVID-19 complications, regardless of the cancer staging.'", [["lung cancer", "ANATOMY", 19, 30], ["cancer", "ANATOMY", 137, 143], ["lung cancer", "DISEASE", 19, 30], ["COVID", "DISEASE", 95, 100], ["cancer", "DISEASE", 137, 143], ["lung cancer", "CANCER", 19, 30], ["patients", "ORGANISM", 31, 39], ["cancer", "CANCER", 137, 143], ["patients", "SPECIES", 31, 39], ["lung cancer", "PROBLEM", 19, 30], ["developing COVID-19 complications", "PROBLEM", 84, 117], ["the cancer staging", "PROBLEM", 133, 151], ["lung", "ANATOMY", 19, 23], ["cancer", "OBSERVATION", 24, 30], ["cancer", "OBSERVATION", 137, 143]]], ["RECOMMENDATION OF LUNG CANCER MANAGEMENT ACCORDING TO DISEASE STAGEDecisions about procedures, work-up, and treatment must be tailored by factors like disease stage, molecular and histology diagnosis, patient clinical status, local infrastructure, and pandemic characteristics.", [["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["LUNG CANCER MANAGEMENT", "TREATMENT", 18, 40], ["treatment", "TREATMENT", 108, 117], ["disease stage", "PROBLEM", 151, 164], ["histology diagnosis", "TEST", 180, 199], ["LUNG", "ANATOMY", 18, 22], ["CANCER", "OBSERVATION", 23, 29]]], ["In this regard, the following recommendations were adopted by the American College of Surgeons classification of phased units, based on disease burden and available facilities and resources (Table 1) (11).MANAGEMENT DURING DIAGNOSIS AND STAGINGGiven the high aggressiveness and mortality of lung cancer, decisions to postpone diagnostic procedures must be evaluated very carefully on a case-by-case basis, and patient and family expectations should be considered in the decision.", [["lung cancer", "ANATOMY", 291, 302], ["aggressiveness", "DISEASE", 259, 273], ["lung cancer", "DISEASE", 291, 302], ["lung cancer", "CANCER", 291, 302], ["patient", "ORGANISM", 410, 417], ["patient", "SPECIES", 410, 417], ["disease burden", "PROBLEM", 136, 150], ["the high aggressiveness", "PROBLEM", 250, 273], ["lung cancer", "PROBLEM", 291, 302], ["diagnostic procedures", "TEST", 326, 347], ["lung", "ANATOMY", 291, 295], ["cancer", "OBSERVATION", 296, 302]]], ["The risks of medical visits and procedures can vary, and depend on social isolation, exposition to contaminated patients or health staff in outpatient and inpatient units, invasive procedures to the airways and thorax, hospitalization, and immunosuppression.", [["airways", "ANATOMY", 199, 206], ["thorax", "ANATOMY", 211, 217], ["patients", "ORGANISM", 112, 120], ["airways", "MULTI-TISSUE_STRUCTURE", 199, 206], ["thorax", "ORGAN", 211, 217], ["patients", "SPECIES", 112, 120], ["procedures", "TREATMENT", 32, 42], ["social isolation", "TREATMENT", 67, 83], ["invasive procedures", "TREATMENT", 172, 191], ["hospitalization", "TREATMENT", 219, 234], ["immunosuppression", "TREATMENT", 240, 257], ["airways", "ANATOMY", 199, 206], ["thorax", "ANATOMY", 211, 217]]], ["In all situations, it is recommended to closely observe the current status and changes in the scenario of individual institutions in the face of the pandemic.", [["the pandemic", "PROBLEM", 145, 157], ["pandemic", "OBSERVATION", 149, 157]]], ["Whenever possible, patients should beINITIAL DISEASE MANAGEMENTThere is still paucity of data addressing initial lung cancer during COVID-19.", [["lung cancer", "ANATOMY", 113, 124], ["lung cancer", "DISEASE", 113, 124], ["patients", "ORGANISM", 19, 27], ["lung cancer", "CANCER", 113, 124], ["patients", "SPECIES", 19, 27], ["initial lung cancer", "PROBLEM", 105, 124], ["COVID", "TEST", 132, 137], ["lung", "ANATOMY", 113, 117], ["cancer", "OBSERVATION", 118, 124]]], ["In this subgroup, age was an important risk factor for complications, and the treatment complication rates appear to be higher in patients with advanced disease.", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["complications", "PROBLEM", 55, 68], ["the treatment complication rates", "PROBLEM", 74, 106], ["advanced disease", "PROBLEM", 144, 160]]], ["Therefore, when approaching a patient with initial disease, we must consider age, the presence of other comorbidities, contagion risk, potential treatment-related or primary immunosuppression, use of ventilation equipment, and intensive care unit (ICU) beds.", [["contagion", "DISEASE", 119, 128], ["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["initial disease", "PROBLEM", 43, 58], ["other comorbidities", "PROBLEM", 98, 117], ["primary immunosuppression", "TREATMENT", 166, 191], ["ventilation equipment", "TREATMENT", 200, 221], ["disease", "OBSERVATION", 51, 58]]], ["In this sense, we recommend, whenever possible, to transfer the patient to Phase 1 units and evaluate the following measures:LOCALLY ADVANCED DISEASE MANAGEMENTPatients with locally advanced disease may present in different stages and situations, and decisions should be made on a case-by-case basis.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["LOCALLY ADVANCED DISEASE MANAGEMENTPatients", "PROBLEM", 125, 168], ["locally advanced disease", "PROBLEM", 174, 198], ["ADVANCED", "OBSERVATION_MODIFIER", 133, 141], ["DISEASE", "OBSERVATION", 142, 149], ["locally", "OBSERVATION_MODIFIER", 174, 181], ["advanced", "OBSERVATION_MODIFIER", 182, 190], ["disease", "OBSERVATION", 191, 198], ["different stages", "OBSERVATION_MODIFIER", 214, 230]]], ["All previous recommendations regarding surgical and staging procedures should be followed.", [["surgical and staging procedures", "TREATMENT", 39, 70]]], ["Since locally advanced lung cancer is a high-risk disease, as a general rule, treatments should not be postponed, but adapted whenever possible, to deal with challenges brought by the pandemic.", [["lung cancer", "ANATOMY", 23, 34], ["lung cancer", "DISEASE", 23, 34], ["lung cancer", "CANCER", 23, 34], ["locally advanced lung cancer", "PROBLEM", 6, 34], ["a high-risk disease", "PROBLEM", 38, 57], ["treatments", "TREATMENT", 78, 88], ["locally", "OBSERVATION_MODIFIER", 6, 13], ["advanced", "OBSERVATION_MODIFIER", 14, 22], ["lung", "ANATOMY", 23, 27], ["cancer", "OBSERVATION", 28, 34], ["high-risk", "OBSERVATION_MODIFIER", 40, 49], ["disease", "OBSERVATION", 50, 57]]], ["We must take into account the presence of other comorbidities, age, performance status (PS), and treatment-related or primary immunosuppression, and try to reduce the contagion risk, number of visits to the treatment center, hospitalizations, use of ventilation equipment, and ICU beds.", [["other comorbidities", "PROBLEM", 42, 61], ["treatment", "TREATMENT", 97, 106], ["primary immunosuppression", "TREATMENT", 118, 143], ["ventilation equipment", "TREATMENT", 250, 271], ["ICU beds", "TREATMENT", 277, 285]]], ["We recommend, whenever possible, to transfer patients to Phase 1 hospitals and evaluate the following measures:ADVANCED DISEASE MANAGEMENTAlthough patients with advanced disease are at greater risk of complications from COVID-19, due to the severity of the neoplasia, treatments should generally not be postponed.", [["neoplasia", "ANATOMY", 257, 266], ["neoplasia", "DISEASE", 257, 266], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 147, 155], ["neoplasia", "CANCER", 257, 266], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 147, 155], ["advanced disease", "PROBLEM", 161, 177], ["complications", "PROBLEM", 201, 214], ["COVID", "TEST", 220, 225], ["the neoplasia", "PROBLEM", 253, 266], ["treatments", "TREATMENT", 268, 278], ["advanced", "OBSERVATION_MODIFIER", 161, 169], ["disease", "OBSERVATION", 170, 177], ["complications", "OBSERVATION", 201, 214], ["neoplasia", "OBSERVATION", 257, 266]]], ["We must consider the presence of other comorbidities, age, and PS, and try to reduce contagion risk, decrease the hospitalizations and the number of visits to the treatment center, reduce immunosuppression, and reduce use of equipment and ICU beds in hospitals.", [["other comorbidities", "PROBLEM", 33, 52], ["immunosuppression", "TREATMENT", 188, 205], ["ICU beds", "TREATMENT", 239, 247]]], ["We recommend, whenever possible, to transfer patients to Phase 1 hospitals and evaluate the following measures (12):ADVANCED DISEASE MANAGEMENT1.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["ADVANCED DISEASE MANAGEMENT1", "PROBLEM", 116, 144], ["DISEASE", "OBSERVATION", 125, 132]]], ["Prefer to start targeted therapy over CT/immunotherapy (IO), whenever possible.", [["targeted therapy", "TREATMENT", 16, 32], ["CT/immunotherapy", "TREATMENT", 38, 54]]], ["In patients already undergoing CT with partial response, a change to targeted therapy should be considered.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["CT", "TEST", 31, 33], ["targeted therapy", "TREATMENT", 69, 85]]], ["For patients with high PD-L1 expression (X50%): consider using IO as monotherapy, with adapted dosage (pembrolizumab 400 mg IV every 6 weeks).", [["patients", "ORGANISM", 4, 12], ["PD-L1", "GENE_OR_GENE_PRODUCT", 23, 28], ["patients", "SPECIES", 4, 12], ["high PD-L1 expression", "TREATMENT", 18, 39], ["IO", "TREATMENT", 63, 65], ["monotherapy", "TREATMENT", 69, 80], ["pembrolizumab", "TREATMENT", 103, 116]]], ["For patients undergoing IO, adapt the dosage (Nivolumab 480 mg IV every 4 weeks; Pembrolizumab 400 mg IV every 6 weeks).For patients undergoing maintenance CT (pemetrexed)and IO, consider pemetrexed suspension and maintenance of IO alone with an adapted dosage (pembrolizumab 400 mg IV every 6 weeks).", [["Nivolumab", "CHEMICAL", 46, 55], ["Pembrolizumab", "CHEMICAL", 81, 94], ["pemetrexed", "CHEMICAL", 160, 170], ["pemetrexed", "CHEMICAL", 188, 198], ["pembrolizumab", "CHEMICAL", 262, 275], ["pemetrexed", "CHEMICAL", 160, 170], ["pemetrexed", "CHEMICAL", 188, 198], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 124, 132], ["pemetrexed", "SIMPLE_CHEMICAL", 160, 170], ["pemetrexed", "SIMPLE_CHEMICAL", 188, 198], ["IO", "SIMPLE_CHEMICAL", 229, 231], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 124, 132], ["IO", "TREATMENT", 24, 26], ["Nivolumab", "TREATMENT", 46, 55], ["Pembrolizumab", "TREATMENT", 81, 94], ["maintenance CT (pemetrexed)", "TREATMENT", 144, 171], ["IO", "TREATMENT", 175, 177], ["pemetrexed suspension", "TREATMENT", 188, 209], ["IO", "TREATMENT", 229, 231], ["an adapted dosage (pembrolizumab", "TREATMENT", 243, 275]]], ["Avoid prescribing a third or fourth line of chemotherapy in patients with comorbidities.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["a third or fourth line of chemotherapy", "TREATMENT", 18, 56], ["comorbidities", "PROBLEM", 74, 87]]], ["Use G-CSF as primary prophylaxis to reduce the risk of hospitalization during CT, if the risk of febrile neutropenia is X10%.", [["neutropenia", "DISEASE", 105, 116], ["G-CSF", "GENE_OR_GENE_PRODUCT", 4, 9], ["G-CSF", "TREATMENT", 4, 9], ["primary prophylaxis", "TREATMENT", 13, 32], ["CT", "TEST", 78, 80], ["febrile neutropenia", "PROBLEM", 97, 116], ["febrile", "OBSERVATION_MODIFIER", 97, 104], ["neutropenia", "OBSERVATION", 105, 116]]], ["Adopt home administration for subcutaneous medications if feasible.For patients undergoing maintenance CT (pemetrexed)8.", [["subcutaneous", "ANATOMY", 30, 42], ["pemetrexed", "CHEMICAL", 107, 117], ["pemetrexed", "CHEMICAL", 107, 117], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["subcutaneous medications", "TREATMENT", 30, 54], ["maintenance CT (pemetrexed)", "TREATMENT", 91, 118]]], ["Postpone infusion of bisphosphonates (acid zolendronic every 3 months).", [["bisphosphonates", "CHEMICAL", 21, 36], ["bisphosphonates", "CHEMICAL", 21, 36], ["bisphosphonates", "SIMPLE_CHEMICAL", 21, 36], ["bisphosphonates (acid zolendronic", "TREATMENT", 21, 54]]], ["Prefer darbepoetin alfa 500 mg SC every 3 weeks for the treatment of anemia secondary to CT.", [["darbepoetin alfa", "CHEMICAL", 7, 23], ["anemia", "DISEASE", 69, 75], ["darbepoetin alfa", "SIMPLE_CHEMICAL", 7, 23], ["darbepoetin alfa", "TREATMENT", 7, 23], ["anemia", "PROBLEM", 69, 75], ["CT", "TEST", 89, 91], ["anemia", "OBSERVATION", 69, 75]]], ["Avoid blood transfusions.", [["blood", "ANATOMY", 6, 11], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["blood transfusions", "TREATMENT", 6, 24]]], ["When possible, postpone local treatment of oligometastasis.", [["oligometastasis", "DISEASE", 43, 58], ["postpone local treatment", "TREATMENT", 15, 39], ["oligometastasis", "PROBLEM", 43, 58], ["oligometastasis", "OBSERVATION", 43, 58]]], ["Prefer SABR and avoid surgical procedures in these cases.", [["SABR", "TREATMENT", 7, 11], ["surgical procedures", "TREATMENT", 22, 41]]], ["Brain metastases: prefer radiotherapy to surgery, and hypofractionated radiotherapy when possible.", [["Brain metastases", "ANATOMY", 0, 16], ["Brain metastases", "DISEASE", 0, 16], ["Brain", "ORGAN", 0, 5], ["Brain metastases", "PROBLEM", 0, 16], ["radiotherapy", "TREATMENT", 25, 37], ["surgery", "TREATMENT", 41, 48], ["hypofractionated radiotherapy", "TREATMENT", 54, 83], ["metastases", "OBSERVATION", 6, 16]]], ["Avoid radiation therapy or surgery if effective targeted therapy is available and the disease is oligo-or asymptomatic.", [["radiation therapy", "TREATMENT", 6, 23], ["surgery", "TREATMENT", 27, 34], ["effective targeted therapy", "TREATMENT", 38, 64], ["the disease is oligo", "PROBLEM", 82, 102], ["asymptomatic", "PROBLEM", 106, 118]]], ["Prophylactic CNS radiotherapy for SCLC should not be indicated.", [["CNS", "ANATOMY", 13, 16], ["SCLC", "ANATOMY", 34, 38], ["SCLC", "DISEASE", 34, 38], ["SCLC", "CANCER", 34, 38], ["Prophylactic CNS radiotherapy", "TREATMENT", 0, 29], ["SCLC", "PROBLEM", 34, 38]]], ["Consider follow-up with brain magnetic resonance imaging (MRI).ADVANCED DISEASE -PALLIATIVE CARE MANAGEMENTPatients with advanced lung cancer in palliative care are a major challenge in the face of the COVID-19 pandemic.", [["brain", "ANATOMY", 24, 29], ["lung cancer", "ANATOMY", 130, 141], ["lung cancer", "DISEASE", 130, 141], ["brain", "ORGAN", 24, 29], ["lung cancer", "CANCER", 130, 141], ["brain magnetic resonance imaging", "TEST", 24, 56], ["MRI", "TEST", 58, 61], ["ADVANCED DISEASE", "PROBLEM", 63, 79], ["PALLIATIVE CARE MANAGEMENTPatients", "TREATMENT", 81, 115], ["advanced lung cancer", "PROBLEM", 121, 141], ["palliative care", "TREATMENT", 145, 160], ["the COVID", "TEST", 198, 207], ["pandemic", "PROBLEM", 211, 219], ["DISEASE", "OBSERVATION", 72, 79], ["lung", "ANATOMY", 130, 134], ["cancer", "OBSERVATION", 135, 141]]], ["In this scenario, we must reduce contagion risk and family exposure, promote social isolation, try to reduce the use of ventilation equipment and ICU beds in hospitals, and provide psychological support to patients and their family.", [["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["social isolation", "TREATMENT", 77, 93], ["ventilation equipment", "TREATMENT", 120, 141], ["psychological support", "TREATMENT", 181, 202]]], ["Whenever possible, we recommend transferring the patient to Phase 1 hospitals and implementing the following measures:ADVANCED DISEASE -PALLIATIVE CARE MANAGEMENT1.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["DISEASE", "OBSERVATION", 127, 134]]], ["Discuss, for patients in exclusive palliative care, living wills and advance directives for medical decisions.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["exclusive palliative care", "TREATMENT", 25, 50]]], ["Define in medical records the level of support that can be administered in an emergency.", [["support", "TREATMENT", 39, 46]]], ["Allow and provide virtual contact with family and professionals for psychological support if isolation is recommended.MANAGEMENT OF PATIENTS IN FOLLOW-UPThe follow-up of lung cancer patients depends on the histological subtype (SCLC versus NSCLC) and the tumor stage (I and II versus III versus IV).", [["lung cancer", "ANATOMY", 170, 181], ["SCLC", "ANATOMY", 228, 232], ["NSCLC", "ANATOMY", 240, 245], ["tumor", "ANATOMY", 255, 260], ["lung cancer", "DISEASE", 170, 181], ["SCLC", "DISEASE", 228, 232], ["NSCLC", "DISEASE", 240, 245], ["tumor", "DISEASE", 255, 260], ["lung cancer", "CANCER", 170, 181], ["patients", "ORGANISM", 182, 190], ["SCLC", "CANCER", 228, 232], ["NSCLC", "CANCER", 240, 245], ["tumor", "CANCER", 255, 260], ["patients", "SPECIES", 182, 190], ["psychological support", "TREATMENT", 68, 89], ["isolation", "TREATMENT", 93, 102], ["lung cancer", "PROBLEM", 170, 181], ["the histological subtype (SCLC versus NSCLC", "PROBLEM", 202, 245], ["the tumor stage", "PROBLEM", 251, 266], ["lung", "ANATOMY", 170, 174], ["cancer", "OBSERVATION", 175, 181], ["SCLC", "OBSERVATION", 228, 232], ["NSCLC", "OBSERVATION", 240, 245], ["tumor", "OBSERVATION", 255, 260]]], ["In the current SARS-CoV-2 pandemic scenario we should seek to reduce the risk of patient contamination, promote social isolation, efficiently detect COVID-9 cases among cancer patients, monitor the patient's clinical status, minimize the risk of cancer progression, guarantee timely communication with the attending physician and the patient's cancer care team, and provide psychological support and reassurance (14) .MANAGEMENT OF PATIENTS IN FOLLOW-UPThe recommendations for lung cancer patients follow-up are as follows: ' FINAL CONSIDERATIONS COVID-19 is a very recently described disease.", [["cancer", "ANATOMY", 169, 175], ["cancer", "ANATOMY", 246, 252], ["cancer", "ANATOMY", 344, 350], ["lung cancer", "ANATOMY", 477, 488], ["cancer", "DISEASE", 169, 175], ["cancer", "DISEASE", 246, 252], ["cancer", "DISEASE", 344, 350], ["lung cancer", "DISEASE", 477, 488], ["patient", "ORGANISM", 81, 88], ["cancer", "CANCER", 169, 175], ["patients", "ORGANISM", 176, 184], ["patient", "ORGANISM", 198, 205], ["cancer", "CANCER", 246, 252], ["patient", "ORGANISM", 334, 341], ["cancer", "CANCER", 344, 350], ["lung cancer", "CANCER", 477, 488], ["patients", "ORGANISM", 489, 497], ["patient", "SPECIES", 81, 88], ["patients", "SPECIES", 176, 184], ["patient", "SPECIES", 198, 205], ["patient", "SPECIES", 334, 341], ["patients", "SPECIES", 489, 497], ["patient contamination", "PROBLEM", 81, 102], ["social isolation", "TREATMENT", 112, 128], ["cancer progression", "PROBLEM", 246, 264], ["psychological support", "TREATMENT", 374, 395], ["lung cancer", "PROBLEM", 477, 488], ["a very recently described disease", "PROBLEM", 559, 592], ["cancer", "OBSERVATION", 246, 252], ["lung", "ANATOMY", 477, 481], ["cancer", "OBSERVATION", 482, 488], ["disease", "OBSERVATION", 585, 592]]]], "PMC7377977": [["Funding sourceNone.DisclosuresNone.Declaration of competing interestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["Funding sourceNone", "TREATMENT", 0, 18]]]], "PMC7274940": [["IntroductionIn December 2019, China reported a pneumonia outbreak in Wuhan, a city with more than 11 million people [1].", [["pneumonia", "DISEASE", 47, 56], ["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115], ["a pneumonia outbreak", "PROBLEM", 45, 65], ["pneumonia", "OBSERVATION", 47, 56]]], ["A new coronavirus (COV) was identified as the causative organism\u2014namely, novel coronavirus, nCOV-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)\u2014and the disease was named as the Coronavirus Disease 2019 (COVID-19) [2].", [["coronavirus", "DISEASE", 79, 90], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 104, 142], ["coronavirus", "ORGANISM", 6, 17], ["COV", "CANCER", 19, 22], ["coronavirus", "ORGANISM", 79, 90], ["nCOV-Severe Acute Respiratory", "ORGANISM", 92, 121], ["SARS-CoV-2", "ORGANISM", 146, 156], ["coronavirus", "SPECIES", 79, 90], ["COV", "SPECIES", 19, 22], ["nCOV-Severe Acute Respiratory Syndrome Coronavirus 2", "SPECIES", 92, 144], ["SARS-CoV-2", "SPECIES", 146, 156], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 191, 225], ["A new coronavirus (COV)", "PROBLEM", 0, 23], ["the causative organism\u2014namely", "PROBLEM", 42, 71], ["novel coronavirus", "PROBLEM", 73, 90], ["nCOV", "TEST", 92, 96], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 97, 142], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["the disease", "PROBLEM", 162, 173], ["the Coronavirus Disease", "PROBLEM", 187, 210], ["COVID", "TEST", 217, 222], ["new", "OBSERVATION_MODIFIER", 2, 5], ["coronavirus", "OBSERVATION", 6, 17], ["Severe", "OBSERVATION_MODIFIER", 97, 103], ["Acute", "OBSERVATION_MODIFIER", 104, 109], ["Respiratory Syndrome", "OBSERVATION", 110, 130], ["disease", "OBSERVATION", 166, 173], ["Coronavirus Disease", "OBSERVATION", 191, 210]]], ["To date, COVID-19 has confirmed to affect a total of 115000 patients in Turkey with more than 3000 deaths.", [["deaths", "DISEASE", 99, 105], ["COVID-19", "CELL", 9, 17], ["patients", "ORGANISM", 60, 68], ["COVID-19", "DNA", 9, 17], ["patients", "SPECIES", 60, 68]]], ["Due to the life-threatening nature of its complications, most of the research about COVID-19 mainly focuses on respiratory system.", [["respiratory system", "ANATOMY", 111, 129], ["COVID-19", "CHEMICAL", 84, 92], ["its complications", "PROBLEM", 38, 55], ["COVID", "TEST", 84, 89], ["respiratory system", "ANATOMY", 111, 129]]], ["However, since other organ involvements might be alternative routes of transmissions, they must not be ignored.IntroductionSeven types of CoVs are known to infect humans: 229E, NL63, OC 43, HKU, MERS-CoV, SARS-CoV, and the recent SARS-CoV-2 [4].", [["organ", "ANATOMY", 21, 26], ["organ", "ORGAN", 21, 26], ["CoVs", "GENE_OR_GENE_PRODUCT", 138, 142], ["humans", "ORGANISM", 163, 169], ["229E", "GENE_OR_GENE_PRODUCT", 171, 175], ["NL63", "GENE_OR_GENE_PRODUCT", 177, 181], ["OC 43", "ORGANISM", 183, 188], ["HKU", "GENE_OR_GENE_PRODUCT", 190, 193], ["MERS-CoV", "ORGANISM", 195, 203], ["SARS-CoV", "ORGANISM", 205, 213], ["CoVs", "PROTEIN", 138, 142], ["humans", "SPECIES", 163, 169], ["humans", "SPECIES", 163, 169], ["MERS-CoV", "SPECIES", 195, 203], ["SARS-CoV", "SPECIES", 205, 213], ["SARS-CoV", "SPECIES", 230, 238], ["other organ involvements", "PROBLEM", 15, 39], ["CoVs", "PROBLEM", 138, 142], ["OC", "TEST", 183, 185], ["HKU", "TEST", 190, 193], ["MERS", "TEST", 195, 199], ["CoV", "TEST", 200, 203], ["SARS", "PROBLEM", 205, 209], ["CoV", "TEST", 210, 213], ["the recent SARS", "TEST", 219, 234], ["CoV", "TEST", 235, 238]]], ["Most of these CoVs cause infections in the respiratory tract but also known to have manifestations in the gastrointestinal system and ocular tissues [5, 6].", [["respiratory tract", "ANATOMY", 43, 60], ["gastrointestinal system", "ANATOMY", 106, 129], ["ocular tissues", "ANATOMY", 134, 148], ["infections in the respiratory tract", "DISEASE", 25, 60], ["CoVs", "GENE_OR_GENE_PRODUCT", 14, 18], ["respiratory tract", "ORGANISM_SUBDIVISION", 43, 60], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 106, 129], ["ocular tissues", "TISSUE", 134, 148], ["infections in the respiratory tract", "PROBLEM", 25, 60], ["manifestations in the gastrointestinal system and ocular tissues", "PROBLEM", 84, 148], ["CoVs", "OBSERVATION", 14, 18], ["infections", "OBSERVATION", 25, 35], ["respiratory tract", "ANATOMY", 43, 60], ["gastrointestinal system", "ANATOMY", 106, 129], ["ocular tissues", "ANATOMY", 134, 148]]], ["HCoV-NL63 and SARS-CoV are known to affect the ocular system.", [["ocular system", "ANATOMY", 47, 60], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["NL63", "GENE_OR_GENE_PRODUCT", 5, 9], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["ocular system", "MULTI-TISSUE_STRUCTURE", 47, 60], ["HCoV", "PROTEIN", 0, 4], ["HCoV", "SPECIES", 0, 4], ["SARS-CoV", "SPECIES", 14, 22], ["HCoV", "TEST", 0, 4], ["NL63", "PROBLEM", 5, 9], ["SARS", "PROBLEM", 14, 18], ["CoV", "PROBLEM", 19, 22], ["ocular system", "ANATOMY", 47, 60]]], ["There have been reports of cases with conjunctivitis and bronchiolitis between 2000 and 2003 with HCoV-NL63 [7].", [["conjunctivitis", "DISEASE", 38, 52], ["bronchiolitis", "DISEASE", 57, 70], ["conjunctivitis", "PROBLEM", 38, 52], ["bronchiolitis", "PROBLEM", 57, 70], ["HCoV", "TEST", 98, 102], ["conjunctivitis", "OBSERVATION", 38, 52], ["bronchiolitis", "OBSERVATION", 57, 70]]], ["In addition, in 2004, SARS-CoV-RNA was identified in tear samples of three patients suggesting that the virus can be present in tears [5].", [["tear samples", "ANATOMY", 53, 65], ["SARS-CoV", "ORGANISM", 22, 30], ["tear samples", "CANCER", 53, 65], ["patients", "ORGANISM", 75, 83], ["SARS-CoV-RNA", "RNA", 22, 34], ["patients", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV-RNA", "PROBLEM", 22, 34], ["tear samples", "TEST", 53, 65], ["the virus", "PROBLEM", 100, 109], ["virus", "OBSERVATION", 104, 109]]], ["Theories, including the conjunctiva being the direct inoculation site of pathogen-loaded droplets, migration of the infection from the respiratory tract through the nasolacrimal duct or even hematogenous infection of the lacrimal gland, were proposed [5].IntroductionGenomic and structural analyses show a similar receptor-binding motive between SARS-CoV and SARS-CoV-2 with resembling pathologic features and epidemiological characteristics [8, 9].", [["conjunctiva", "ANATOMY", 24, 35], ["droplets", "ANATOMY", 89, 97], ["respiratory tract", "ANATOMY", 135, 152], ["nasolacrimal duct", "ANATOMY", 165, 182], ["lacrimal gland", "ANATOMY", 221, 235], ["infection", "DISEASE", 116, 125], ["infection", "DISEASE", 204, 213], ["conjunctiva", "ORGAN", 24, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 135, 152], ["nasolacrimal duct", "MULTI-TISSUE_STRUCTURE", 165, 182], ["lacrimal gland", "ORGAN", 221, 235], ["SARS-CoV", "ORGANISM", 346, 354], ["SARS-CoV-2", "ORGANISM", 359, 369], ["SARS-CoV", "SPECIES", 346, 354], ["SARS-CoV", "SPECIES", 359, 367], ["the conjunctiva", "PROBLEM", 20, 35], ["pathogen-loaded droplets", "TREATMENT", 73, 97], ["the infection", "PROBLEM", 112, 125], ["the respiratory tract", "PROBLEM", 131, 152], ["the nasolacrimal duct", "PROBLEM", 161, 182], ["hematogenous infection of the lacrimal gland", "PROBLEM", 191, 235], ["IntroductionGenomic and structural analyses", "TEST", 255, 298], ["SARS", "PROBLEM", 346, 350], ["SARS", "PROBLEM", 359, 363], ["CoV", "TEST", 364, 367], ["resembling pathologic features", "PROBLEM", 375, 405], ["infection", "OBSERVATION", 116, 125], ["respiratory tract", "ANATOMY", 135, 152], ["nasolacrimal duct", "ANATOMY", 165, 182], ["hematogenous", "OBSERVATION_MODIFIER", 191, 203], ["infection", "OBSERVATION", 204, 213], ["lacrimal gland", "ANATOMY", 221, 235]]], ["As a result, a similar involvement of the ocular tissues has been suspected.", [["ocular tissues", "ANATOMY", 42, 56], ["ocular tissues", "TISSUE", 42, 56], ["a similar involvement of the ocular tissues", "PROBLEM", 13, 56], ["similar", "OBSERVATION_MODIFIER", 15, 22], ["involvement", "OBSERVATION", 23, 34], ["ocular tissues", "ANATOMY", 42, 56]]], ["Nevertheless, there have only been few reports about the ophthalmic manifestations of the recent SARS-CoV-2 [10, 11].", [["SARS", "DISEASE", 97, 101], ["SARS-CoV", "SPECIES", 97, 105], ["few", "OBSERVATION_MODIFIER", 35, 38]]], ["The purpose of our study is to investigate ocular findings and symptoms of clinically confirmed COVID-19 patients and assess the relationship with those findings and laboratory results.Materials and methodsThis cross-sectional study was conducted at the Kars Harakani State Hospital, Kars, Turkey, in accordance with the ethical standards of the Declaration of Helsinki.", [["ocular", "ANATOMY", 43, 49], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["our study", "TEST", 15, 24], ["ocular findings", "TEST", 43, 58], ["symptoms", "PROBLEM", 63, 71], ["COVID", "TEST", 96, 101], ["This cross-sectional study", "TEST", 206, 232]]], ["The study protocol was approved by the institutional board of the Okan University Medical Faculty ethics committee.Materials and methodsBetween March 11th and April 30th, 2020, 93 consecutive patients who were hospitalized in Kars Harakani State Hospital with the diagnosis of COVID-19 were included.", [["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["The study protocol", "TEST", 0, 18], ["COVID", "TEST", 277, 282]]], ["The COVID-19 diagnosis was made according to real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of respiratory specimens which revealed positive results for SARS-CoV-2 nucleic acid and thorax CT findings consistent with viral pneumonia [12].", [["respiratory specimens", "ANATOMY", 121, 142], ["viral pneumonia", "DISEASE", 242, 257], ["thorax", "ORGAN", 207, 213], ["COVID-19", "DNA", 4, 12], ["reverse transcriptase", "PROTEIN", 55, 76], ["SARS-CoV", "SPECIES", 179, 187], ["polymerase chain reaction", "TEST", 77, 102], ["RT-PCR", "TEST", 104, 110], ["respiratory specimens", "TEST", 121, 142], ["SARS", "TEST", 179, 183], ["CoV", "TEST", 184, 187], ["nucleic acid", "TEST", 190, 202], ["thorax CT", "TEST", 207, 216], ["viral pneumonia", "PROBLEM", 242, 257], ["respiratory", "ANATOMY", 121, 132], ["thorax", "ANATOMY", 207, 213], ["consistent with", "UNCERTAINTY", 226, 241], ["viral", "OBSERVATION_MODIFIER", 242, 247], ["pneumonia", "OBSERVATION", 248, 257]]], ["The COVID-19 diagnosis was confirmed with RT-PCR in all included patients in this study.", [["patients", "ORGANISM", 65, 73], ["COVID-19", "DNA", 4, 12], ["patients", "SPECIES", 65, 73], ["The COVID", "TEST", 0, 9], ["RT-PCR", "TEST", 42, 48], ["this study", "TEST", 77, 87]]], ["The patient symptoms, fever at presentation, thorax computerized tomography (CT) scans, neutrophil, lymphocyte and monocyte counts, C-reactive protein (CRP), pro-calcitonin (PCT), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), creatine kinase (CK), and d-dimer levels were recorded.", [["neutrophil", "ANATOMY", 88, 98], ["lymphocyte", "ANATOMY", 100, 110], ["monocyte", "ANATOMY", 115, 123], ["erythrocyte", "ANATOMY", 180, 191], ["fever", "DISEASE", 22, 27], ["lactate", "CHEMICAL", 218, 225], ["creatine", "CHEMICAL", 247, 255], ["lactate", "CHEMICAL", 218, 225], ["creatine", "CHEMICAL", 247, 255], ["patient", "ORGANISM", 4, 11], ["thorax", "ORGAN", 45, 51], ["neutrophil", "CELL", 88, 98], ["lymphocyte", "CELL", 100, 110], ["monocyte", "CELL", 115, 123], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 132, 150], ["CRP", "GENE_OR_GENE_PRODUCT", 152, 155], ["pro-calcitonin", "SIMPLE_CHEMICAL", 158, 172], ["PCT", "SIMPLE_CHEMICAL", 174, 177], ["erythrocyte", "CELL", 180, 191], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 218, 239], ["LDH", "SIMPLE_CHEMICAL", 241, 244], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 247, 262], ["CK", "GENE_OR_GENE_PRODUCT", 264, 266], ["d-dimer", "SIMPLE_CHEMICAL", 273, 280], ["neutrophil", "CELL_TYPE", 88, 98], ["C-reactive protein", "PROTEIN", 132, 150], ["CRP", "PROTEIN", 152, 155], ["pro-calcitonin", "PROTEIN", 158, 172], ["PCT", "PROTEIN", 174, 177], ["lactate dehydrogenase", "PROTEIN", 218, 239], ["LDH", "PROTEIN", 241, 244], ["creatine kinase", "PROTEIN", 247, 262], ["CK", "PROTEIN", 264, 266], ["patient", "SPECIES", 4, 11], ["The patient symptoms", "PROBLEM", 0, 20], ["fever", "PROBLEM", 22, 27], ["thorax computerized tomography", "TEST", 45, 75], ["CT) scans", "TEST", 77, 86], ["neutrophil", "TEST", 88, 98], ["lymphocyte", "TEST", 100, 110], ["monocyte counts", "TEST", 115, 130], ["C", "TEST", 132, 133], ["reactive protein", "TEST", 134, 150], ["CRP", "TEST", 152, 155], ["pro-calcitonin", "TEST", 158, 172], ["PCT", "TEST", 174, 177], ["erythrocyte sedimentation rate", "TEST", 180, 210], ["ESR", "TEST", 212, 215], ["lactate dehydrogenase", "TEST", 218, 239], ["LDH)", "TEST", 241, 245], ["creatine kinase", "TEST", 247, 262], ["CK", "TEST", 264, 266], ["d-dimer levels", "TEST", 273, 287], ["thorax", "ANATOMY", 45, 51], ["neutrophil", "ANATOMY", 88, 98], ["lymphocyte", "ANATOMY", 100, 110]]], ["Fever was classified as 37.3 \u00b0C or higher.Materials and methodsOcular findings and symptoms were evaluated at hospital admission.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["methodsOcular findings", "TEST", 56, 78], ["symptoms", "PROBLEM", 83, 91]]], ["Ophthalmological examination including ocular surface and anterior segment assessment was performed by the same experienced clinician using a binocular indirect ophthalmoscope.", [["ocular surface", "ANATOMY", 39, 53], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 39, 53], ["anterior segment", "MULTI-TISSUE_STRUCTURE", 58, 74], ["Ophthalmological examination", "TEST", 0, 28], ["ocular surface", "TEST", 39, 53], ["anterior segment assessment", "TEST", 58, 85], ["a binocular indirect ophthalmoscope", "TEST", 140, 175], ["ocular", "ANATOMY", 39, 45], ["anterior", "ANATOMY_MODIFIER", 58, 66]]], ["Ocular symptoms and findings were recorded.Materials and methodsStatistical analyses were performed with SPSS Statistics (Version 22.0, Armonk, NY: IBM Corp).", [["Ocular", "ANATOMY", 0, 6], ["Ocular", "ORGAN", 0, 6], ["Ocular symptoms", "PROBLEM", 0, 15], ["Statistical analyses", "TEST", 64, 84]]], ["The assumption of normal distribution of data was tested by the Kolmogorov-Smirnov test.", [["the Kolmogorov-Smirnov test", "TEST", 60, 87], ["normal", "OBSERVATION", 18, 24], ["distribution", "OBSERVATION_MODIFIER", 25, 37]]], ["Association of descriptive data was tested with the chi-square test.", [["descriptive data", "TEST", 15, 31], ["the chi-square test", "TEST", 48, 67]]], ["Differences in the outcomes between the groups were tested with the Mann\u2013Whitney U test.", [["the Mann\u2013Whitney U test", "TEST", 64, 87]]], ["A p value less than 0.05 was considered statistically significant.ResultsNinety-three patients with clinically confirmed COVID-19 were included in the study.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["A p value", "TEST", 0, 9], ["COVID", "TEST", 121, 126], ["the study", "TEST", 147, 156]]], ["Of the 93 patients, 54 (58.1%) were male and 39 (41.9%) were female.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Mean age of the patients was 39.4 \u00b1 21.9 (min 7, max 88) years.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["Mean age", "TEST", 0, 8]]], ["Ninety-two patients (98.9%) tested positive for SARS-CoV-2 by RT-PCR of nasopharyngeal swabs; while 1 (1.1%) was positive in the RT-PCR of the endotracheal aspirate.", [["nasopharyngeal swabs", "ANATOMY", 72, 92], ["endotracheal aspirate", "ANATOMY", 143, 164], ["SARS", "DISEASE", 48, 52], ["patients", "ORGANISM", 11, 19], ["nasopharyngeal swabs", "CANCER", 72, 92], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 143, 164], ["patients", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["RT", "TEST", 62, 64], ["PCR", "TEST", 65, 68], ["nasopharyngeal swabs", "TEST", 72, 92], ["the RT-PCR", "TEST", 125, 135], ["the endotracheal aspirate", "TEST", 139, 164], ["nasopharyngeal swabs", "ANATOMY", 72, 92], ["endotracheal", "ANATOMY", 143, 155], ["aspirate", "OBSERVATION", 156, 164]]], ["Twenty (21.5%) patients had fever, 18 (19.4%) patients had cough, 3 (3.2%) patients had respiratory distress, 2 (2.2%) patients had headache, and 50 (53.8%) patients had no symptoms at presentation to the hospital.", [["respiratory", "ANATOMY", 88, 99], ["fever", "DISEASE", 28, 33], ["cough", "DISEASE", 59, 64], ["respiratory distress", "DISEASE", 88, 108], ["headache", "DISEASE", 132, 140], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 157, 165], ["fever", "PROBLEM", 28, 33], ["cough", "PROBLEM", 59, 64], ["respiratory distress", "PROBLEM", 88, 108], ["headache", "PROBLEM", 132, 140], ["symptoms", "PROBLEM", 173, 181], ["respiratory", "ANATOMY", 88, 99], ["distress", "OBSERVATION", 100, 108]]], ["Fifty-eight (62.4%) patients had no sign of abnormality at thorax CT, whereas 23 (24.7%) patients had typical CT findings of SARS CoV-2 pneumonia, and 12 (12.9%) patients had possible SARS CoV-2 pneumonia according to the CT findings.", [["thorax", "ANATOMY", 59, 65], ["SARS", "DISEASE", 125, 129], ["pneumonia", "DISEASE", 136, 145], ["pneumonia", "DISEASE", 195, 204], ["patients", "ORGANISM", 20, 28], ["thorax", "ORGAN", 59, 65], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 162, 170], ["SARS CoV", "SPECIES", 125, 133], ["sign of abnormality", "PROBLEM", 36, 55], ["thorax CT", "TEST", 59, 68], ["typical CT", "TEST", 102, 112], ["SARS CoV-2 pneumonia", "PROBLEM", 125, 145], ["SARS CoV", "PROBLEM", 184, 192], ["2 pneumonia", "PROBLEM", 193, 204], ["the CT findings", "TEST", 218, 233], ["no sign of", "UNCERTAINTY", 33, 43], ["abnormality", "OBSERVATION", 44, 55], ["thorax", "ANATOMY", 59, 65], ["SARS CoV", "OBSERVATION", 125, 133], ["pneumonia", "OBSERVATION", 136, 145], ["possible", "UNCERTAINTY", 175, 183], ["SARS CoV", "OBSERVATION", 184, 192], ["pneumonia", "OBSERVATION", 195, 204]]], ["Five patients were intubated due to respiratory distress and 4 of them died due to SARS CoV-2 pneumonia and comorbidities.ResultsTable 1 represents age, fever, and the laboratory findings of the patients with and without ocular involvement.", [["respiratory", "ANATOMY", 36, 47], ["ocular", "ANATOMY", 221, 227], ["respiratory distress", "DISEASE", 36, 56], ["SARS", "DISEASE", 83, 87], ["pneumonia", "DISEASE", 94, 103], ["fever", "DISEASE", 153, 158], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 195, 203], ["ocular", "ORGAN", 221, 227], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 195, 203], ["intubated", "TREATMENT", 19, 28], ["respiratory distress", "PROBLEM", 36, 56], ["SARS CoV", "PROBLEM", 83, 91], ["pneumonia", "PROBLEM", 94, 103], ["comorbidities", "PROBLEM", 108, 121], ["fever", "PROBLEM", 153, 158], ["ocular involvement", "PROBLEM", 221, 239], ["respiratory", "ANATOMY", 36, 47], ["distress", "OBSERVATION", 48, 56], ["pneumonia", "OBSERVATION", 94, 103], ["without", "UNCERTAINTY", 213, 220], ["ocular", "ANATOMY", 221, 227], ["involvement", "OBSERVATION", 228, 239]]], ["Mean neutrophil count, neutrophil to lymphocyte ratio, CRP, PCT, and ESR levels were significantly higher in patients with ocular involvement; whereas, mean lymphocyte count was significantly lower.", [["neutrophil", "ANATOMY", 5, 15], ["neutrophil", "ANATOMY", 23, 33], ["lymphocyte", "ANATOMY", 37, 47], ["ocular", "ANATOMY", 123, 129], ["lymphocyte", "ANATOMY", 157, 167], ["neutrophil", "CELL", 5, 15], ["neutrophil", "CELL", 23, 33], ["lymphocyte", "CELL", 37, 47], ["CRP", "GENE_OR_GENE_PRODUCT", 55, 58], ["PCT", "GENE_OR_GENE_PRODUCT", 60, 63], ["ESR", "GENE_OR_GENE_PRODUCT", 69, 72], ["patients", "ORGANISM", 109, 117], ["ocular", "ORGAN", 123, 129], ["lymphocyte", "CELL", 157, 167], ["CRP", "PROTEIN", 55, 58], ["PCT", "PROTEIN", 60, 63], ["ESR", "PROTEIN", 69, 72], ["patients", "SPECIES", 109, 117], ["Mean neutrophil count", "TEST", 0, 21], ["neutrophil", "TEST", 23, 33], ["lymphocyte ratio", "TEST", 37, 53], ["CRP", "TEST", 55, 58], ["PCT", "TEST", 60, 63], ["ESR levels", "TEST", 69, 79], ["ocular involvement", "PROBLEM", 123, 141], ["mean lymphocyte count", "TEST", 152, 173], ["neutrophil count", "OBSERVATION", 5, 21], ["ocular", "ANATOMY", 123, 129], ["lymphocyte count", "OBSERVATION", 157, 173], ["lower", "OBSERVATION_MODIFIER", 192, 197]]], ["No significant difference was observed between patients with and without ocular involvement regarding mean monocyte count, LDH, CK, and d-dimer levels.ResultsTable 2 represents ocular findings and symptoms of the patients.", [["ocular", "ANATOMY", 73, 79], ["monocyte", "ANATOMY", 107, 115], ["ocular", "ANATOMY", 177, 183], ["patients", "ORGANISM", 47, 55], ["ocular", "ORGAN", 73, 79], ["monocyte", "CELL", 107, 115], ["LDH", "GENE_OR_GENE_PRODUCT", 123, 126], ["CK", "GENE_OR_GENE_PRODUCT", 128, 130], ["d-dimer", "GENE_OR_GENE_PRODUCT", 136, 143], ["ocular", "ORGAN", 177, 183], ["patients", "ORGANISM", 213, 221], ["LDH", "PROTEIN", 123, 126], ["CK", "PROTEIN", 128, 130], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 213, 221], ["ocular involvement", "PROBLEM", 73, 91], ["mean monocyte count", "TEST", 102, 121], ["LDH", "TEST", 123, 126], ["CK", "TEST", 128, 130], ["d-dimer levels", "TEST", 136, 150], ["ocular findings", "PROBLEM", 177, 192], ["symptoms", "PROBLEM", 197, 205], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["Hyperemia was found to be associated with high fever (p = 0.006), typical radiological findings of SARS CoV-2 pneumonia (p = 0.046), high ESR and CRP (p < 0.001 for all), PCT levels (p = 0.001) and neutrophil to lymphocyte ratio (NTL) (p < 0.001).", [["neutrophil", "ANATOMY", 198, 208], ["lymphocyte", "ANATOMY", 212, 222], ["Hyperemia", "DISEASE", 0, 9], ["fever", "DISEASE", 47, 52], ["SARS", "DISEASE", 99, 103], ["pneumonia", "DISEASE", 110, 119], ["CRP", "GENE_OR_GENE_PRODUCT", 146, 149], ["neutrophil", "CELL", 198, 208], ["lymphocyte", "CELL", 212, 222], ["ESR", "PROTEIN", 138, 141], ["CRP", "PROTEIN", 146, 149], ["PCT", "PROTEIN", 171, 174], ["Hyperemia", "PROBLEM", 0, 9], ["high fever", "PROBLEM", 42, 52], ["SARS CoV", "PROBLEM", 99, 107], ["pneumonia", "PROBLEM", 110, 119], ["high ESR", "PROBLEM", 133, 141], ["CRP", "TEST", 146, 149], ["PCT levels", "TEST", 171, 181], ["p", "TEST", 183, 184], ["neutrophil", "TEST", 198, 208], ["lymphocyte ratio", "TEST", 212, 228], ["high", "OBSERVATION_MODIFIER", 42, 46], ["fever", "OBSERVATION", 47, 52], ["SARS CoV", "OBSERVATION", 99, 107], ["pneumonia", "OBSERVATION", 110, 119]]], ["Epiphora and increased secretion were found to be associated with high fever (p = 0.012, p = 0.006, respectively), high ESR (p = 0.001, p = 0.023, respectively), CRP (p < 0.001, p = 0.001 respectively), PCT (p = 0.002, p = 0.004 respectively), and NTL (p = 0.001, p < 0.001 respectively).", [["fever", "DISEASE", 71, 76], ["CRP", "GENE_OR_GENE_PRODUCT", 162, 165], ["CRP", "PROTEIN", 162, 165], ["Epiphora", "PROBLEM", 0, 8], ["increased secretion", "PROBLEM", 13, 32], ["high fever", "PROBLEM", 66, 76], ["p", "TEST", 89, 90], ["high ESR", "PROBLEM", 115, 123], ["p", "TEST", 136, 137], ["CRP", "TEST", 162, 165], ["PCT", "TEST", 203, 206], ["p", "TEST", 219, 220], ["NTL", "TEST", 248, 251], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["secretion", "OBSERVATION", 23, 32]]], ["Chemosis was positively correlated with high CRP (p = 0.017), PCT (p = 0.39), and NTL (p = 0.008).", [["CRP", "GENE_OR_GENE_PRODUCT", 45, 48], ["CRP", "PROTEIN", 45, 48], ["Chemosis", "PROBLEM", 0, 8], ["high CRP", "PROBLEM", 40, 48], ["PCT", "TEST", 62, 65], ["NTL", "TEST", 82, 85]]], ["Follicular conjunctivitis was also correlated with high fever (p = 0.037), high neutrophil count (p < 0.001), ESR (p = 0.001), and CRP (p < 0.001), PCT (p = 0.001) and high NTL (p = 0.001).", [["Follicular", "ANATOMY", 0, 10], ["neutrophil", "ANATOMY", 80, 90], ["Follicular conjunctivitis", "DISEASE", 0, 25], ["fever", "DISEASE", 56, 61], ["neutrophil", "CELL", 80, 90], ["CRP", "GENE_OR_GENE_PRODUCT", 131, 134], ["ESR", "PROTEIN", 110, 113], ["CRP", "PROTEIN", 131, 134], ["Follicular conjunctivitis", "PROBLEM", 0, 25], ["high fever", "PROBLEM", 51, 61], ["high neutrophil count", "TEST", 75, 96], ["ESR", "TEST", 110, 113], ["CRP", "TEST", 131, 134], ["PCT", "TEST", 148, 151], ["high NTL", "TREATMENT", 168, 176], ["conjunctivitis", "OBSERVATION", 11, 25]]], ["Episcleritis was found to be associated with higher d-dimer (p = 0.017), PCT (p = 0.045), and CRP (p = 0.020).", [["Episcleritis", "DISEASE", 0, 12], ["CRP", "GENE_OR_GENE_PRODUCT", 94, 97], ["CRP", "PROTEIN", 94, 97], ["Episcleritis", "PROBLEM", 0, 12], ["higher d-dimer", "PROBLEM", 45, 59], ["PCT", "TEST", 73, 76], ["CRP", "TEST", 94, 97]]], ["No ocular finding was associated with gender, LDH or CK levels, and monocyte count (p > 0.05 for all).DiscussionOcular involvement with Coronavirus family has been shown in various publications [10, 13, 14].", [["ocular", "ANATOMY", 3, 9], ["monocyte", "ANATOMY", 68, 76], ["LDH", "GENE_OR_GENE_PRODUCT", 46, 49], ["CK", "GENE_OR_GENE_PRODUCT", 53, 55], ["monocyte", "CELL", 68, 76], ["CK", "PROTEIN", 53, 55], ["ocular finding", "PROBLEM", 3, 17], ["LDH", "TEST", 46, 49], ["CK levels", "TEST", 53, 62], ["monocyte count", "TEST", 68, 82], ["p", "TEST", 84, 85], ["ocular", "ANATOMY", 3, 9]]], ["On January 22, 2020, when a visiting doctor in Wuhan developed conjunctivitis, and later yielded positive for SARS-CoV-2, call for research on ocular transmission and involvement of SARS-CoV-2 was made [14].", [["ocular", "ANATOMY", 143, 149], ["conjunctivitis", "DISEASE", 63, 77], ["SARS", "DISEASE", 110, 114], ["ocular transmission", "DISEASE", 143, 162], ["SARS", "DISEASE", 182, 186], ["ocular", "ORGAN", 143, 149], ["SARS-CoV", "SPECIES", 110, 118], ["SARS-CoV", "SPECIES", 182, 190], ["conjunctivitis", "PROBLEM", 63, 77], ["SARS", "PROBLEM", 110, 114], ["CoV", "TEST", 115, 118], ["ocular transmission", "TEST", 143, 162], ["SARS", "PROBLEM", 182, 186], ["conjunctivitis", "OBSERVATION", 63, 77]]], ["In a prospective study by Xia et al. [10], tear and conjunctival secretions of 30 COVID-19 patients were collected, and the presence of the virus was evaluated by RT-PCR [10].", [["tear", "ANATOMY", 43, 47], ["conjunctival secretions", "ANATOMY", 52, 75], ["tear", "TISSUE", 43, 47], ["conjunctival secretions", "MULTI-TISSUE_STRUCTURE", 52, 75], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["a prospective study", "TEST", 3, 22], ["tear and conjunctival secretions", "TEST", 43, 75], ["the virus", "PROBLEM", 136, 145], ["PCR", "TEST", 166, 169], ["conjunctival", "ANATOMY", 52, 64], ["virus", "OBSERVATION", 140, 145]]], ["Virus was detected in only one patient\u2019s conjunctival scrapes who had conjunctivitis at the time of specimen collection; therefore, it was proposed that the virus only existed in the tear and conjunctiva of the patients with conjunctivitis.", [["conjunctival scrapes", "ANATOMY", 41, 61], ["specimen", "ANATOMY", 100, 108], ["tear", "ANATOMY", 183, 187], ["conjunctiva", "ANATOMY", 192, 203], ["conjunctivitis", "DISEASE", 70, 84], ["conjunctivitis", "DISEASE", 225, 239], ["Virus", "ORGANISM", 0, 5], ["patient", "ORGANISM", 31, 38], ["conjunctival scrapes", "PATHOLOGICAL_FORMATION", 41, 61], ["tear", "TISSUE", 183, 187], ["conjunctiva", "ORGAN", 192, 203], ["patients", "ORGANISM", 211, 219], ["patient", "SPECIES", 31, 38], ["patients", "SPECIES", 211, 219], ["Virus", "PROBLEM", 0, 5], ["conjunctivitis", "PROBLEM", 70, 84], ["specimen collection", "TEST", 100, 119], ["the virus", "PROBLEM", 153, 162], ["conjunctivitis", "PROBLEM", 225, 239], ["conjunctival", "ANATOMY", 41, 53], ["scrapes", "OBSERVATION", 54, 61], ["conjunctivitis", "OBSERVATION", 70, 84], ["collection", "OBSERVATION", 109, 119], ["virus", "OBSERVATION", 157, 162], ["tear", "OBSERVATION", 183, 187], ["conjunctiva", "ANATOMY", 192, 203], ["conjunctivitis", "OBSERVATION", 225, 239]]], ["On the other hand, in the same study, it was stated that the sample volume of tear and conjunctival secretion might be insufficient for RT-PCR detection, and therefore, the possibility of viral particles\u2019 presence in tears and conjunctiva should not be ignored in patients without conjunctivitis.[10]DiscussionIn the present study, we reported the ocular findings and symptoms of COVID-19 patients and risk factors associated with those ocular manifestations.DiscussionResults of our study suggest that 20.5% of the COVID patients had at least one ocular abnormality.", [["sample", "ANATOMY", 61, 67], ["tear", "ANATOMY", 78, 82], ["conjunctival", "ANATOMY", 87, 99], ["tears", "ANATOMY", 217, 222], ["conjunctiva", "ANATOMY", 227, 238], ["ocular", "ANATOMY", 348, 354], ["ocular", "ANATOMY", 437, 443], ["ocular", "ANATOMY", 548, 554], ["conjunctivitis", "DISEASE", 281, 295], ["COVID", "DISEASE", 380, 385], ["COVID", "DISEASE", 516, 521], ["ocular abnormality", "DISEASE", 548, 566], ["tear", "TISSUE", 78, 82], ["conjunctival", "ORGAN", 87, 99], ["tears", "PATHOLOGICAL_FORMATION", 217, 222], ["conjunctiva", "ORGAN", 227, 238], ["patients", "ORGANISM", 264, 272], ["patients", "ORGANISM", 389, 397], ["patients", "ORGANISM", 522, 530], ["ocular", "ORGAN", 548, 554], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 389, 397], ["patients", "SPECIES", 522, 530], ["the same study", "TEST", 22, 36], ["the sample volume", "TEST", 57, 74], ["tear", "PROBLEM", 78, 82], ["conjunctival secretion", "PROBLEM", 87, 109], ["RT-PCR detection", "TEST", 136, 152], ["viral particles", "PROBLEM", 188, 203], ["tears and conjunctiva", "PROBLEM", 217, 238], ["conjunctivitis", "PROBLEM", 281, 295], ["the ocular findings", "PROBLEM", 344, 363], ["symptoms", "PROBLEM", 368, 376], ["COVID", "TEST", 380, 385], ["risk factors", "PROBLEM", 402, 414], ["those ocular manifestations", "PROBLEM", 431, 458], ["our study", "TEST", 480, 489], ["ocular abnormality", "PROBLEM", 548, 566], ["tear", "OBSERVATION", 78, 82], ["conjunctival secretion", "OBSERVATION", 87, 109], ["possibility of", "UNCERTAINTY", 173, 187], ["viral particles", "OBSERVATION", 188, 203], ["tears", "OBSERVATION", 217, 222], ["conjunctiva", "ANATOMY", 227, 238], ["conjunctivitis", "OBSERVATION", 281, 295], ["ocular", "ANATOMY", 348, 354], ["ocular", "ANATOMY", 548, 554], ["abnormality", "OBSERVATION", 555, 566]]], ["Mean age, fever, neutrophil count, CRP, PCT, and ESR levels were significantly higher in patients with ocular involvement; whereas, mean lymphocyte count was significantly lower.DiscussionThe aggressive inflammatory response is a significant component in the pathophysiology of SARS-CoV-2 infection, strongly implicated in the resulting airway damage [15].", [["neutrophil", "ANATOMY", 17, 27], ["ocular", "ANATOMY", 103, 109], ["lymphocyte", "ANATOMY", 137, 147], ["airway", "ANATOMY", 337, 343], ["fever", "DISEASE", 10, 15], ["SARS", "DISEASE", 278, 282], ["infection", "DISEASE", 289, 298], ["airway damage", "DISEASE", 337, 350], ["neutrophil", "CELL", 17, 27], ["CRP", "GENE_OR_GENE_PRODUCT", 35, 38], ["PCT", "GENE_OR_GENE_PRODUCT", 40, 43], ["patients", "ORGANISM", 89, 97], ["ocular", "ORGAN", 103, 109], ["lymphocyte", "CELL", 137, 147], ["SARS-CoV-2", "ORGANISM", 278, 288], ["airway", "MULTI-TISSUE_STRUCTURE", 337, 343], ["CRP", "PROTEIN", 35, 38], ["PCT", "PROTEIN", 40, 43], ["ESR", "PROTEIN", 49, 52], ["patients", "SPECIES", 89, 97], ["SARS-CoV-2", "SPECIES", 278, 288], ["Mean age", "TEST", 0, 8], ["fever", "PROBLEM", 10, 15], ["neutrophil count", "TEST", 17, 33], ["CRP", "TEST", 35, 38], ["PCT", "TEST", 40, 43], ["ESR levels", "TEST", 49, 59], ["ocular involvement", "PROBLEM", 103, 121], ["mean lymphocyte count", "TEST", 132, 153], ["The aggressive inflammatory response", "PROBLEM", 188, 224], ["a significant component", "PROBLEM", 228, 251], ["SARS", "PROBLEM", 278, 282], ["CoV-2 infection", "PROBLEM", 283, 298], ["neutrophil count", "OBSERVATION", 17, 33], ["ocular", "ANATOMY", 103, 109], ["lymphocyte count", "OBSERVATION", 137, 153], ["lower", "OBSERVATION_MODIFIER", 172, 177], ["aggressive", "OBSERVATION_MODIFIER", 192, 202], ["inflammatory", "OBSERVATION", 203, 215], ["significant", "OBSERVATION_MODIFIER", 230, 241], ["component", "OBSERVATION_MODIFIER", 242, 251], ["SARS", "OBSERVATION", 278, 282], ["infection", "OBSERVATION", 289, 298], ["airway", "ANATOMY", 337, 343]]], ["Severity of the disease is reported to be not only due to the viral infection but also the host response [16].", [["infection", "DISEASE", 68, 77], ["the disease", "PROBLEM", 12, 23], ["the viral infection", "PROBLEM", 58, 77], ["disease", "OBSERVATION", 16, 23], ["viral", "OBSERVATION_MODIFIER", 62, 67], ["infection", "OBSERVATION", 68, 77]]], ["There are many studies highlighting the role of inflammatory markers such as ESR, CRP, and PCT to predict the onset of an inflammatory process or infection [17].", [["infection", "DISEASE", 146, 155], ["CRP", "GENE_OR_GENE_PRODUCT", 82, 85], ["inflammatory markers", "PROTEIN", 48, 68], ["ESR", "PROTEIN", 77, 80], ["CRP", "PROTEIN", 82, 85], ["PCT", "PROTEIN", 91, 94], ["many studies", "TEST", 10, 22], ["inflammatory markers", "TEST", 48, 68], ["ESR", "TEST", 77, 80], ["CRP", "TEST", 82, 85], ["PCT", "TEST", 91, 94], ["an inflammatory process", "PROBLEM", 119, 142], ["infection", "PROBLEM", 146, 155], ["inflammatory", "OBSERVATION", 48, 60], ["inflammatory", "OBSERVATION", 122, 134], ["infection", "OBSERVATION", 146, 155]]], ["In the case of SARS-CoV-2 infection, many studies demonstrated that most of the patients present with elevated levels of acute immune markers [18, 19].DiscussionC-reactive protein begins to rise within 4\u20136 h in settings of inflammation and has a half-life of 4\u20137 h [20].", [["SARS-CoV-2 infection", "DISEASE", 15, 35], ["inflammation", "DISEASE", 223, 235], ["SARS-CoV-2", "ORGANISM", 15, 25], ["patients", "ORGANISM", 80, 88], ["acute immune markers", "PROTEIN", 121, 141], ["DiscussionC-reactive protein", "PROTEIN", 151, 179], ["patients", "SPECIES", 80, 88], ["SARS-CoV-2", "SPECIES", 15, 25], ["SARS", "PROBLEM", 15, 19], ["CoV-2 infection", "PROBLEM", 20, 35], ["many studies", "TEST", 37, 49], ["elevated levels", "PROBLEM", 102, 117], ["acute immune markers", "PROBLEM", 121, 141], ["reactive protein", "PROBLEM", 163, 179], ["inflammation", "PROBLEM", 223, 235], ["SARS", "OBSERVATION", 15, 19], ["infection", "OBSERVATION", 26, 35], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["immune markers", "OBSERVATION", 127, 141], ["reactive protein", "OBSERVATION", 163, 179], ["inflammation", "OBSERVATION", 223, 235]]], ["Therefore, serum level of CRP is considered to be a measure of active inflammation.", [["serum", "ANATOMY", 11, 16], ["inflammation", "DISEASE", 70, 82], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["CRP", "GENE_OR_GENE_PRODUCT", 26, 29], ["CRP", "PROTEIN", 26, 29], ["serum level", "TEST", 11, 22], ["CRP", "TEST", 26, 29], ["active inflammation", "PROBLEM", 63, 82], ["active", "OBSERVATION_MODIFIER", 63, 69], ["inflammation", "OBSERVATION", 70, 82]]], ["CRP levels were found to be positively correlated with the diameter of lung lesions and severity of the presentation in COVID-19 patients [21].", [["lung lesions", "ANATOMY", 71, 83], ["lung lesions", "DISEASE", 71, 83], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["lung lesions", "CANCER", 71, 83], ["patients", "ORGANISM", 129, 137], ["CRP", "PROTEIN", 0, 3], ["patients", "SPECIES", 129, 137], ["CRP levels", "TEST", 0, 10], ["lung lesions", "PROBLEM", 71, 83], ["COVID", "TEST", 120, 125], ["diameter", "OBSERVATION_MODIFIER", 59, 67], ["lung", "ANATOMY", 71, 75], ["lesions", "OBSERVATION", 76, 83], ["severity", "OBSERVATION_MODIFIER", 88, 96]]], ["In our study, all of the ocular findings were correlated with high CRP levels which may indicate active inflammatory response and severity of the disease.DiscussionProcalcitonin is a peptide precursor of calcitonin, released primarily by lung and intestine, in response to bacterial toxins and cytokines.", [["ocular", "ANATOMY", 25, 31], ["lung", "ANATOMY", 238, 242], ["intestine", "ANATOMY", 247, 256], ["calcitonin", "CHEMICAL", 204, 214], ["ocular", "ORGAN", 25, 31], ["CRP", "GENE_OR_GENE_PRODUCT", 67, 70], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 164, 177], ["calcitonin", "GENE_OR_GENE_PRODUCT", 204, 214], ["lung", "ORGAN", 238, 242], ["intestine", "ORGAN", 247, 256], ["CRP", "PROTEIN", 67, 70], ["cytokines", "PROTEIN", 294, 303], ["our study", "TEST", 3, 12], ["the ocular findings", "TEST", 21, 40], ["high CRP levels", "PROBLEM", 62, 77], ["active inflammatory response", "PROBLEM", 97, 125], ["the disease", "PROBLEM", 142, 153], ["Procalcitonin", "TREATMENT", 164, 177], ["a peptide precursor of calcitonin", "TREATMENT", 181, 214], ["bacterial toxins", "PROBLEM", 273, 289], ["cytokines", "PROBLEM", 294, 303], ["ocular", "ANATOMY", 25, 31], ["may indicate", "UNCERTAINTY", 84, 96], ["active", "OBSERVATION_MODIFIER", 97, 103], ["inflammatory", "OBSERVATION", 104, 116], ["disease", "OBSERVATION", 146, 153], ["lung", "ANATOMY", 238, 242], ["intestine", "ANATOMY", 247, 256], ["bacterial toxins", "OBSERVATION", 273, 289]]], ["Production of PCT is amplified during bacterial infections but downregulated during viral infections which make it a particularly interesting acute inflammatory marker [22].", [["infections", "DISEASE", 48, 58], ["viral infections", "DISEASE", 84, 100], ["PCT", "GENE_OR_GENE_PRODUCT", 14, 17], ["PCT", "PROTEIN", 14, 17], ["Production of PCT", "PROBLEM", 0, 17], ["bacterial infections", "PROBLEM", 38, 58], ["viral infections", "PROBLEM", 84, 100], ["bacterial", "OBSERVATION_MODIFIER", 38, 47], ["infections", "OBSERVATION", 48, 58], ["viral infections", "OBSERVATION", 84, 100], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["inflammatory", "OBSERVATION", 148, 160]]], ["Levels of PCT become detectable in patient\u2019s serum in 3\u20136 h after onset of inflammation and remain elevated for 12\u201336 h after resolution [22].", [["serum", "ANATOMY", 45, 50], ["inflammation", "DISEASE", 75, 87], ["PCT", "GENE_OR_GENE_PRODUCT", 10, 13], ["patient", "ORGANISM", 35, 42], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["PCT", "PROTEIN", 10, 13], ["patient", "SPECIES", 35, 42], ["Levels of PCT", "TEST", 0, 13], ["patient\u2019s serum", "TEST", 35, 50], ["inflammation", "PROBLEM", 75, 87], ["inflammation", "OBSERVATION", 75, 87], ["elevated", "OBSERVATION", 99, 107]]], ["A metaanalysis of the literature suggests that serial PCT measurement may be beneficial to evaluate progression towards a more severe form [23].", [["serial PCT measurement", "TEST", 47, 69]]], ["The production of PCT is inhibited by interferon-\u03b3, whose concentration increases during viral infections [24].", [["interferon-\u03b3", "CHEMICAL", 38, 50], ["viral infections", "DISEASE", 89, 105], ["PCT", "GENE_OR_GENE_PRODUCT", 18, 21], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 38, 50], ["PCT", "PROTEIN", 18, 21], ["interferon-\u03b3", "PROTEIN", 38, 50], ["PCT", "TEST", 18, 21], ["interferon", "TREATMENT", 38, 48], ["viral infections", "PROBLEM", 89, 105]]], ["PCT levels remain within the reference range in several patients with noncomplicated SARS-CoV-2 infection, whereas substantially increase in the severe form of the disease, possibly secondary to a bacterial coinfection which contributes to complicate the clinical picture.", [["SARS-CoV-2 infection", "DISEASE", 85, 105], ["coinfection", "DISEASE", 207, 218], ["PCT", "GENE_OR_GENE_PRODUCT", 0, 3], ["patients", "ORGANISM", 56, 64], ["CoV-2", "ORGANISM", 90, 95], ["PCT", "PROTEIN", 0, 3], ["patients", "SPECIES", 56, 64], ["PCT levels", "TEST", 0, 10], ["noncomplicated SARS", "PROBLEM", 70, 89], ["CoV-2 infection", "PROBLEM", 90, 105], ["the disease", "PROBLEM", 160, 171], ["a bacterial coinfection", "PROBLEM", 195, 218], ["the clinical picture", "PROBLEM", 251, 271], ["infection", "OBSERVATION", 96, 105], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["disease", "OBSERVATION", 164, 171], ["bacterial", "OBSERVATION_MODIFIER", 197, 206], ["coinfection", "OBSERVATION", 207, 218]]], ["Procalcitonine levels of the patients with ocular symptoms were higher than the patients without ocular involvement, which may also be indicative for the severity of the disease in those individuals.DiscussionPatients with ocular manifestations had higher ESR levels according to the results of our study.", [["ocular", "ANATOMY", 43, 49], ["ocular", "ANATOMY", 97, 103], ["ocular", "ANATOMY", 223, 229], ["Procalcitonine", "CHEMICAL", 0, 14], ["ocular symptoms", "DISEASE", 43, 58], ["Procalcitonine", "CHEMICAL", 0, 14], ["Procalcitonine", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 29, 37], ["ocular", "ORGAN", 43, 49], ["patients", "ORGANISM", 80, 88], ["ocular", "ORGAN", 97, 103], ["ESR", "PROTEIN", 256, 259], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 80, 88], ["Procalcitonine levels", "TEST", 0, 21], ["ocular symptoms", "PROBLEM", 43, 58], ["ocular involvement", "PROBLEM", 97, 115], ["the disease in those individuals", "PROBLEM", 166, 198], ["ocular manifestations", "PROBLEM", 223, 244], ["higher ESR levels", "PROBLEM", 249, 266], ["our study", "TEST", 295, 304], ["ocular", "ANATOMY", 97, 103], ["involvement", "OBSERVATION", 104, 115], ["may also be indicative for", "UNCERTAINTY", 123, 149], ["disease", "OBSERVATION", 170, 177]]], ["Erythrocyte sedimentation rate typically begins to increase within 24 h after the onset of inflammation.", [["Erythrocyte", "ANATOMY", 0, 11], ["inflammation", "DISEASE", 91, 103], ["Erythrocyte", "CELL", 0, 11], ["Erythrocyte sedimentation rate", "TEST", 0, 30], ["inflammation", "PROBLEM", 91, 103], ["sedimentation rate", "OBSERVATION", 12, 30], ["inflammation", "OBSERVATION", 91, 103]]], ["ESR can be a useful tool to aid in the diagnosis and management of certain specific situations, like inflammation or infection, but like CRP it lacks specificity [25].DiscussionElder patients seemed to be at certain risk for developing ocular symptoms.", [["ocular", "ANATOMY", 236, 242], ["inflammation", "DISEASE", 101, 113], ["infection", "DISEASE", 117, 126], ["ocular symptoms", "DISEASE", 236, 251], ["CRP", "GENE_OR_GENE_PRODUCT", 137, 140], ["patients", "ORGANISM", 183, 191], ["ocular", "ORGAN", 236, 242], ["CRP", "PROTEIN", 137, 140], ["patients", "SPECIES", 183, 191], ["ESR", "TEST", 0, 3], ["management", "TREATMENT", 53, 63], ["certain specific situations", "PROBLEM", 67, 94], ["inflammation", "PROBLEM", 101, 113], ["infection", "PROBLEM", 117, 126], ["CRP", "TEST", 137, 140], ["developing ocular symptoms", "PROBLEM", 225, 251], ["inflammation", "OBSERVATION", 101, 113], ["infection", "OBSERVATION", 117, 126]]], ["This may be secondary to the already existing age related changes in the ocular tissues of the older population such as dry eye disease, meibomian gland dysfunction, or demodex infestation [26].", [["ocular tissues", "ANATOMY", 73, 87], ["eye", "ANATOMY", 124, 127], ["meibomian gland", "ANATOMY", 137, 152], ["dry eye disease", "DISEASE", 120, 135], ["meibomian gland dysfunction", "DISEASE", 137, 164], ["ocular tissues", "TISSUE", 73, 87], ["eye", "ORGAN", 124, 127], ["meibomian gland", "ORGAN", 137, 152], ["dry eye disease", "PROBLEM", 120, 135], ["meibomian gland dysfunction", "PROBLEM", 137, 164], ["demodex infestation", "PROBLEM", 169, 188], ["may be", "UNCERTAINTY", 5, 11], ["ocular tissues", "ANATOMY", 73, 87], ["eye", "ANATOMY", 124, 127], ["disease", "OBSERVATION", 128, 135], ["meibomian gland", "ANATOMY", 137, 152]]], ["It may be expected that ocular problems would be exacerbated in older adults, where the communication between innate and adaptive immunity is known to be compromised [27].DiscussionThe pathogenesis and organ manifestations of SARS-CoV-2 virus are not fully understood [28].", [["ocular", "ANATOMY", 24, 30], ["organ", "ANATOMY", 202, 207], ["ocular problems", "DISEASE", 24, 39], ["SARS", "DISEASE", 226, 230], ["organ", "ORGAN", 202, 207], ["SARS-CoV-2 virus", "ORGANISM", 226, 242], ["CoV-2 virus", "SPECIES", 231, 242], ["SARS-CoV-2 virus", "SPECIES", 226, 242], ["ocular problems", "PROBLEM", 24, 39], ["SARS", "PROBLEM", 226, 230], ["CoV", "TEST", 231, 234], ["2 virus", "PROBLEM", 235, 242], ["may be expected", "UNCERTAINTY", 3, 18]]], ["Cytokine storm and viral evasion of cellular immune responses are considered to have crucial roles in the severity of COVID-19 [29].", [["cellular", "ANATOMY", 36, 44], ["COVID-19", "CHEMICAL", 118, 126], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["cellular", "CELL", 36, 44], ["Cytokine storm", "TREATMENT", 0, 14], ["COVID", "TEST", 118, 123]]], ["In this study, patients with COVID-19 who had ocular manifestations had significantly high levels of CRP, PCT, and ESR, perhaps as a result of the active immune response of the host and disease severity.", [["ocular", "ANATOMY", 46, 52], ["patients", "ORGANISM", 15, 23], ["CRP", "GENE_OR_GENE_PRODUCT", 101, 104], ["PCT", "GENE_OR_GENE_PRODUCT", 106, 109], ["CRP", "PROTEIN", 101, 104], ["PCT", "PROTEIN", 106, 109], ["ESR", "PROTEIN", 115, 118], ["patients", "SPECIES", 15, 23], ["this study", "TEST", 3, 13], ["COVID", "TEST", 29, 34], ["ocular manifestations", "PROBLEM", 46, 67], ["CRP", "TEST", 101, 104], ["PCT", "TEST", 106, 109], ["ESR", "TEST", 115, 118], ["disease severity", "PROBLEM", 186, 202], ["active", "OBSERVATION_MODIFIER", 147, 153], ["immune response", "OBSERVATION", 154, 169]]], ["This may partly explain the positive association between high fever and ocular manifestations.DiscussionLymphocytopenia and increased levels of neutrophils have been reported to reflect an enhanced inflammatory process and suggest a poor prognosis in COVID-19 [28].", [["ocular", "ANATOMY", 72, 78], ["neutrophils", "ANATOMY", 144, 155], ["fever", "DISEASE", 62, 67], ["ocular manifestations", "DISEASE", 72, 93], ["ocular", "ORGAN", 72, 78], ["neutrophils", "CELL", 144, 155], ["neutrophils", "CELL_TYPE", 144, 155], ["high fever", "PROBLEM", 57, 67], ["ocular manifestations", "PROBLEM", 72, 93], ["DiscussionLymphocytopenia", "PROBLEM", 94, 119], ["increased levels of neutrophils", "PROBLEM", 124, 155], ["an enhanced inflammatory process", "PROBLEM", 186, 218], ["COVID", "TEST", 251, 256], ["may partly explain", "UNCERTAINTY", 5, 23], ["positive", "OBSERVATION", 28, 36], ["high", "OBSERVATION_MODIFIER", 57, 61], ["fever", "OBSERVATION", 62, 67], ["ocular manifestations", "OBSERVATION", 72, 93], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["levels", "OBSERVATION_MODIFIER", 134, 140], ["neutrophils", "OBSERVATION", 144, 155], ["enhanced", "OBSERVATION_MODIFIER", 189, 197], ["inflammatory", "OBSERVATION", 198, 210]]], ["In our group, patients with higher neutrophil-to-lymphocyte ratio seemed to be in higher risk for developing ocular manifestations.", [["neutrophil", "ANATOMY", 35, 45], ["lymphocyte", "ANATOMY", 49, 59], ["ocular", "ANATOMY", 109, 115], ["ocular manifestations", "DISEASE", 109, 130], ["patients", "ORGANISM", 14, 22], ["neutrophil", "CELL", 35, 45], ["lymphocyte", "CELL", 49, 59], ["ocular", "ORGAN", 109, 115], ["patients", "SPECIES", 14, 22], ["higher neutrophil", "TEST", 28, 45], ["developing ocular manifestations", "PROBLEM", 98, 130], ["ocular manifestations", "OBSERVATION", 109, 130]]], ["This can also be secondary to the severity of the disease with generalized aggressive inflammatory response.DiscussionLimited sample size and absence of conjunctival RT-PCR evaluation are the limitations of our study.", [["conjunctival", "ANATOMY", 153, 165], ["the disease", "PROBLEM", 46, 57], ["generalized aggressive inflammatory response", "PROBLEM", 63, 107], ["conjunctival RT-PCR evaluation", "TEST", 153, 183], ["our study", "TEST", 207, 216], ["disease", "OBSERVATION", 50, 57], ["generalized", "OBSERVATION_MODIFIER", 63, 74], ["aggressive", "OBSERVATION_MODIFIER", 75, 85], ["inflammatory response", "OBSERVATION", 86, 107], ["size", "OBSERVATION_MODIFIER", 133, 137], ["conjunctival", "ANATOMY", 153, 165]]], ["A larger cohort study of patients with COVID-19 from multiple centers would help to further define the ocular manifestations and risk factors of the disease.", [["ocular", "ANATOMY", 103, 109], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["A larger cohort study", "TEST", 0, 21], ["COVID", "TEST", 39, 44], ["the ocular manifestations", "PROBLEM", 99, 124], ["the disease", "PROBLEM", 145, 156], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["ocular", "ANATOMY", 103, 109], ["disease", "OBSERVATION", 149, 156]]], ["Regardless, the findings of our study are the preliminary results shared in an effort to serve as a starting platform for research into ocular involvement immunological responses of COVID-19.DiscussionOlder age, high fever, increased neutrophil/lymphocyte ratio, and high levels of acute phase reactants were associated with greater risk of developing ocular manifestations.", [["ocular", "ANATOMY", 136, 142], ["neutrophil", "ANATOMY", 234, 244], ["lymphocyte", "ANATOMY", 245, 255], ["ocular", "ANATOMY", 352, 358], ["fever", "DISEASE", 217, 222], ["ocular manifestations", "DISEASE", 352, 373], ["ocular", "ORGAN", 136, 142], ["neutrophil", "CELL", 234, 244], ["lymphocyte", "CELL", 245, 255], ["ocular", "ORGAN", 352, 358], ["neutrophil", "CELL_TYPE", 234, 244], ["our study", "TEST", 28, 37], ["COVID", "TEST", 182, 187], ["high fever", "PROBLEM", 212, 222], ["increased neutrophil/lymphocyte ratio", "PROBLEM", 224, 261], ["acute phase reactants", "PROBLEM", 282, 303], ["developing ocular manifestations", "PROBLEM", 341, 373], ["increased", "OBSERVATION_MODIFIER", 224, 233], ["neutrophil", "OBSERVATION", 234, 244], ["lymphocyte", "OBSERVATION", 245, 255], ["acute", "OBSERVATION_MODIFIER", 282, 287], ["ocular manifestations", "OBSERVATION", 352, 373]]], ["Care must be taken when evaluating patients with those characteristics to prevent ocular complications and viral spread, since other organ involvements might be alternative routes of transmissions.", [["ocular", "ANATOMY", 82, 88], ["organ", "ANATOMY", 133, 138], ["ocular complications", "DISEASE", 82, 102], ["patients", "ORGANISM", 35, 43], ["organ", "ORGAN", 133, 138], ["patients", "SPECIES", 35, 43], ["ocular complications", "PROBLEM", 82, 102], ["viral spread", "PROBLEM", 107, 119], ["other organ involvements", "PROBLEM", 127, 151], ["ocular", "ANATOMY", 82, 88], ["complications", "OBSERVATION", 89, 102]]], ["As the current pandemic continues, a better understanding of both the transmission routes and manifestations of COVID-19 will emerge.", [["COVID", "TREATMENT", 112, 117]]]], "abfde8b86ffacb5af8405d8b9ef42b5a0331741a": [["IntroductionOn December 30, 2019, the Municipal Health Commission in Wuhan (Hubei Province, China) reports a cluster of unexplained pneumonia cases (Ren et al., 2020) .", [["pneumonia", "DISEASE", 132, 141], ["unexplained pneumonia cases", "PROBLEM", 120, 147], ["pneumonia", "OBSERVATION", 132, 141]]], ["On January, 2020, a betacoronavirus, named the severe acute respiratory syndrome coronavirus (SARS-CoV-2) was identified (Chang et al., 2020 ; Zhou et al., 2020) .", [["betacoronavirus", "CHEMICAL", 20, 35], ["acute respiratory syndrome coronavirus", "DISEASE", 54, 92], ["SARS-CoV-2", "ORGANISM", 94, 104], ["severe acute respiratory syndrome coronavirus", "SPECIES", 47, 92], ["SARS-CoV-2", "SPECIES", 94, 104], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 43, 92], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["respiratory syndrome coronavirus", "OBSERVATION", 60, 92]]], ["The disease causes by the SARS-CoV-2 was named coronavirus infectious disease 2019 .", [["SARS", "DISEASE", 26, 30], ["coronavirus infectious disease", "DISEASE", 47, 77], ["SARS-CoV-2", "ORGANISM", 26, 36], ["coronavirus", "ORGANISM", 47, 58], ["coronavirus", "SPECIES", 47, 58], ["SARS-CoV", "SPECIES", 26, 34], ["The disease", "PROBLEM", 0, 11], ["the SARS", "TEST", 22, 30], ["coronavirus infectious disease", "PROBLEM", 47, 77], ["disease", "OBSERVATION", 4, 11]]], ["COVID-19 is a highly infectious disease and following the first cases in China, the virus spread rapidly worldwide.", [["COVID-19", "CHEMICAL", 0, 8], ["infectious disease", "DISEASE", 21, 39], ["COVID-19", "SPECIES", 0, 8], ["a highly infectious disease", "PROBLEM", 12, 39], ["the virus spread", "PROBLEM", 80, 96], ["highly", "OBSERVATION_MODIFIER", 14, 20], ["infectious", "OBSERVATION", 21, 31], ["virus", "OBSERVATION", 84, 89]]], ["Reasons for the rapid spread of SARS-CoV-2 include high transmissibility of the virus (Li et al., 2020a) , asymptomatic or paucisymptomatic carriers (Bai et al., 2020) , and the lack of any apparent cross-protective immunity from related viral infections (Loos et al., 2020) .", [["SARS", "DISEASE", 32, 36], ["viral infections", "DISEASE", 238, 254], ["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["the virus", "PROBLEM", 76, 85], ["asymptomatic", "PROBLEM", 107, 119], ["paucisymptomatic carriers", "PROBLEM", 123, 148], ["viral infections", "PROBLEM", 238, 254]]], ["As of September 4th, 2020, the number of SARS-CoV-2 confirmed cases exceeds 26 million and more than 800,000 deaths had been reported.", [["SARS", "DISEASE", 41, 45], ["deaths", "DISEASE", 109, 115], ["SARS-CoV", "SPECIES", 41, 49], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49]]], ["The socioeconomic impact of the COVID-19 pandemic has also been significant, with lockdown drastically reducing the mobility and productivity of much of the world's population worldwide (WHO, 2020) .IntroductionIn France, the SARS-CoV-2 epidemic period ranged from 2020w09 (24) (25) (26) (27) (28) (29) to 2020w19 (4-10 May), with an epidemic peak at 2020w13 (23-29 March) and a positivity rate of up to 30% affecting mostly the Paris region and the Northeastern of the country (Sant\u00e9 Publique France, 2020).", [["SARS", "DISEASE", 226, 230], ["the COVID", "TEST", 28, 37], ["the SARS", "TEST", 222, 230], ["CoV", "TEST", 231, 234], ["an epidemic peak", "TEST", 331, 347], ["a positivity rate", "TEST", 377, 394], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["mobility", "OBSERVATION_MODIFIER", 116, 124]]], ["These measures have reduced the number of incident cases and the stress on the health care system.", [["reduced", "OBSERVATION_MODIFIER", 20, 27]]], ["After the epidemic period, it has been projected that in France, 3.7 million (range: 2.3-6.7) people, i.e., 5.7% of the population, will have been infected (Salje et al., 2020) .IntroductionCorsica, a French Mediterranean island, was affected by the COVID-19 pandemic like continental France, at the beginning of March.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100], ["a French Mediterranean island", "TREATMENT", 199, 228]]], ["The SARS-CoV-2, positivity rate ranged from 3.5% (2020w09) to 2.0% (2020w19), and peaked on 2020w13 at 14% (ARS, 2020).", [["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["positivity rate", "TEST", 16, 31]]], ["Until May 12th, 55 people died (46 in South Corsica, 9 in Haute-Corse) of COVID-19 in hospital (mortality rate = 0.0002% and lethality rate = 21.6%).IntroductionThese epidemiological data included only a fraction of the real number of SARS-CoV-2 infections, since not all infected patients were symptomatic, required hospitalizations, or .", [["SARS", "DISEASE", 235, 239], ["infections", "DISEASE", 246, 256], ["people", "ORGANISM", 19, 25], ["SARS-CoV-2", "ORGANISM", 235, 245], ["patients", "ORGANISM", 281, 289], ["people", "SPECIES", 19, 25], ["patients", "SPECIES", 281, 289], ["SARS-CoV", "SPECIES", 235, 243], ["COVID", "TEST", 74, 79], ["mortality rate", "TEST", 96, 110], ["lethality rate", "TEST", 125, 139], ["SARS", "PROBLEM", 235, 239], ["CoV-2 infections", "PROBLEM", 240, 256], ["symptomatic", "PROBLEM", 295, 306]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Introductionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 30, 2020 . . https://doi.org/10.1101 provided specimens for laboratory testing (Mizumoto et al., 2020) .", [["specimens", "ANATOMY", 340, 349], ["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 307, 330], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["laboratory testing", "TEST", 354, 372], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 128, 131]]], ["The capacity to estimate the spread of SARS-CoV-2 depends on our knowledge of the immune status against SARS-CoV-2 in the population.IntroductionThe primary outcome of this study was to estimate for the first time the prevalence of IgG antibodies against SARS-CoV-2 in Corsican population in order to improve epidemiological knowledge of the virus spread and to estimate what part of the Corsican population has been infected by the SARS-CoV-2.", [["SARS", "DISEASE", 39, 43], ["SARS", "DISEASE", 433, 437], ["SARS-CoV-2", "ORGANISM", 39, 49], ["SARS-CoV-2", "ORGANISM", 104, 114], ["SARS-CoV-2", "ORGANISM", 255, 265], ["SARS-CoV-2", "ORGANISM", 433, 443], ["IgG antibodies", "PROTEIN", 232, 246], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 104, 112], ["SARS-CoV", "SPECIES", 255, 263], ["SARS-CoV", "SPECIES", 433, 441], ["The capacity", "PROBLEM", 0, 12], ["SARS", "PROBLEM", 39, 43], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["this study", "TEST", 168, 178], ["IgG antibodies", "TEST", 232, 246], ["SARS", "PROBLEM", 255, 259], ["CoV", "TEST", 260, 263], ["Corsican population", "TREATMENT", 269, 288], ["the virus spread", "PROBLEM", 338, 354], ["the SARS", "TEST", 429, 437], ["virus", "OBSERVATION", 342, 347], ["infected", "OBSERVATION", 417, 425]]], ["The secondary outcome was to estimate neutralizing antibodies against SARS-CoV-2 by using an in-house virus neutralization test (VNT) currently considered as the most specific and sensitive serological assay capable of evaluating and detecting, functional neutralizing antibodies.", [["SARS-CoV-2", "ORGANISM", 70, 80], ["neutralizing antibodies", "PROTEIN", 38, 61], ["neutralizing antibodies", "PROTEIN", 256, 279], ["SARS-CoV", "SPECIES", 70, 78], ["neutralizing antibodies", "TEST", 38, 61], ["SARS", "PROBLEM", 70, 74], ["serological assay", "TEST", 190, 207], ["functional neutralizing antibodies", "PROBLEM", 245, 279], ["neutralizing antibodies", "OBSERVATION", 256, 279]]], ["Monitoring of seroprevalence can guide public health measures to fight the pandemic.Study area and populationThe study was conducted in the French Mediterranean island of Corsica (8,680 km2) located south-east of mainland France.", [["public health measures", "TREATMENT", 39, 61], ["Study area", "TEST", 84, 94], ["The study", "TEST", 109, 118], ["Corsica", "ANATOMY_MODIFIER", 171, 178]]], ["The population of the island was estimated at 344,679 as of January 1, 2019 (INSEE, 2020) .", [["population", "OBSERVATION_MODIFIER", 4, 14], ["island", "OBSERVATION_MODIFIER", 22, 28]]], ["The age and sex distribution by age groups of the Corsican population was obtained from the French national institute of statistics and economic studies (INSEE, 2020) (Appendix 1; Fig 1A) .Sample sizeThe sample size was calculated according to Epidemiological Calculation Tools (Epitools, 2018) .", [["economic studies", "TEST", 136, 152], ["Appendix", "TEST", 168, 176], ["The sample size", "TEST", 200, 215], ["size", "OBSERVATION_MODIFIER", 196, 200], ["size", "OBSERVATION_MODIFIER", 211, 215]]], ["A minimum sample size of 1814 was calculated assuming an a priori 5% IgG anti-SARS-CoV-2 seroprevalence (Salje et al., 2020) , a confidence in the estimate of 95%, a maximum allowable error in the prevalence of 1%, and a Corsican population size of 344,679 habitants based on the latest French census data (INSEE, 2020).Studied populationThe sampling plan was established taking into account the minimum estimated sample size and the actual distribution of the Corsican population by age group and sex.", [["IgG", "PROTEIN", 69, 72], ["A minimum sample size", "TEST", 0, 21], ["a Corsican population size", "TEST", 219, 245], ["size", "OBSERVATION_MODIFIER", 17, 21], ["size", "OBSERVATION_MODIFIER", 241, 245], ["size", "OBSERVATION_MODIFIER", 421, 425]]], ["Information about the distribution of the studied population and the general population of Corsica by age group and sex is available in the Appendix ( Figure A1A and A1B). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintStudied populationThe copyright holder for this this version posted September 30, 2020 . . https://doi.org/10.1101 Between 16th April and 15thJune 2020, 2,312 residual sera were collected from patients having carried out a blood analysis in one of the two participating laboratories (Figure 1 ).Studied populationThe conditions of exclusion were the following: one or more samples from the same person (only one sample included in the study), sample with missing information on age and/or gender and/or invalid serology result (insufficient serum volume or invalid result).", [["sera", "ANATOMY", 472, 476], ["blood", "ANATOMY", 527, 532], ["serum", "ANATOMY", 845, 850], ["https://doi.org/10.1101", "CHEMICAL", 395, 418], ["sera", "ORGANISM_SUBSTANCE", 472, 476], ["patients", "ORGANISM", 497, 505], ["blood", "ORGANISM_SUBSTANCE", 527, 532], ["serum", "ORGANISM_SUBSTANCE", 845, 850], ["patients", "SPECIES", 497, 505], ["person", "SPECIES", 699, 705], ["the studied population", "PROBLEM", 38, 60], ["a blood analysis", "TEST", 525, 541], ["the study", "TEST", 735, 744], ["invalid serology", "TEST", 807, 823], ["serum volume", "TEST", 845, 857], ["Appendix", "ANATOMY", 140, 148], ["med", "ANATOMY", 210, 213]]], ["Ajaccio is one of the two largest cities of Corsica (south-west) and corresponds to the area of the island where the vast majority of COVID-19 cases were detected during the SARS-CoV-2 epidemic.", [["SARS", "DISEASE", 174, 178], ["COVID", "GENE_OR_GENE_PRODUCT", 134, 139], ["SARS-CoV", "SPECIES", 174, 182], ["COVID", "TEST", 134, 139], ["the SARS", "TEST", 170, 178], ["CoV", "TEST", 179, 182], ["epidemic", "PROBLEM", 185, 193], ["one", "OBSERVATION_MODIFIER", 11, 14], ["two", "OBSERVATION_MODIFIER", 22, 25], ["largest", "OBSERVATION_MODIFIER", 26, 33], ["Corsica", "OBSERVATION_MODIFIER", 44, 51], ["island", "ANATOMY_MODIFIER", 100, 106]]], ["The laboratory located in Ajaccio, is one of the main laboratory of the island and analyze samples coming from the south and north-western of the island.", [["main", "OBSERVATION_MODIFIER", 49, 53], ["island", "OBSERVATION", 72, 78], ["island", "OBSERVATION", 146, 152]]], ["The laboratory of Corte analyzes samples from the center of Corsica.Serological analysesResidual sera obtained from persons of all ages were tested for the presence of anti-SARS-CoV-2 IgG using the EUROIMMUN enzyme immunoassay kit for semiquantitative detection of IgG antibodies against S1 domain of viral spike protein (ELISA-S) (reference: In all samples with a ratio \u2265 0.8, neutralizing antibodies were detected using a VNT as previously described (Gallian et al., 2020) .", [["samples", "ANATOMY", 33, 40], ["sera", "ANATOMY", 97, 101], ["samples", "ANATOMY", 350, 357], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["persons", "ORGANISM", 116, 123], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 168, 187], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 265, 279], ["anti-SARS-CoV-2 IgG", "PROTEIN", 168, 187], ["IgG antibodies", "PROTEIN", 265, 279], ["S1 domain", "PROTEIN", 288, 297], ["viral spike protein", "PROTEIN", 301, 320], ["ELISA-S", "PROTEIN", 322, 329], ["neutralizing antibodies", "PROTEIN", 378, 401], ["persons", "SPECIES", 116, 123], ["Serological analyses", "TEST", 68, 88], ["Residual sera", "TEST", 88, 101], ["anti-SARS", "TEST", 168, 177], ["CoV", "TEST", 178, 181], ["the EUROIMMUN enzyme immunoassay", "TEST", 194, 226], ["semiquantitative detection", "TEST", 235, 261], ["IgG antibodies", "TEST", 265, 279], ["viral spike protein", "TEST", 301, 320], ["ELISA", "TEST", 322, 327], ["a ratio", "TEST", 363, 370], ["neutralizing antibodies", "TEST", 378, 401], ["Corsica", "OBSERVATION", 60, 67], ["viral spike", "OBSERVATION", 301, 312]]], ["VeroE6 cells cultured in 96-well microplates, 100 TCID50 of the SARS-CoV-2 strain BavPat1 (courtesy of Pr.", [["VeroE6 cells", "ANATOMY", 0, 12], ["VeroE6 cells", "CELL", 0, 12], ["BavPat1", "ORGANISM", 82, 89], ["VeroE6 cells", "CELL_LINE", 0, 12], ["SARS-CoV", "SPECIES", 64, 72], ["VeroE6 cells", "TEST", 0, 12], ["the SARS", "TEST", 60, 68], ["CoV", "TEST", 69, 72]]], ["Drosten, Berlin) and serial dilutions of serum (1/20-1/160) were used.", [["serum", "ANATOMY", 41, 46], ["Drosten", "SIMPLE_CHEMICAL", 0, 7], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["serial dilutions of serum", "TEST", 21, 46]]], ["Dilutions associated with cytopathic effect (CPE) were considered as negative (no neutralization) and those with no CPE at day 4 post-infection were considered positive (complete neutralization), respectively.", [["CPE", "CHEMICAL", 116, 119], ["infection", "DISEASE", 134, 143], ["Dilutions", "TREATMENT", 0, 9], ["cytopathic effect (CPE", "PROBLEM", 26, 48], ["neutralization", "PROBLEM", 82, 96], ["CPE", "PROBLEM", 116, 119], ["infection", "PROBLEM", 134, 143], ["cytopathic", "OBSERVATION_MODIFIER", 26, 36], ["infection", "OBSERVATION", 134, 143]]], ["The neutralization titer referred to the highest dilution of serum with a positive result.", [["serum", "ANATOMY", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["The neutralization titer", "TEST", 0, 24]]], ["Specimens with a VNT titer \u226540 were considered positive (Gallian et al., 2020) (Figure 1 ).Ethical statementNo nominative or sensitive data on participant people have been collected.", [["Specimens", "ANATOMY", 0, 9], ["people", "ORGANISM", 155, 161], ["participant", "SPECIES", 143, 154], ["people", "SPECIES", 155, 161], ["Specimens", "TEST", 0, 9], ["a VNT titer", "TEST", 15, 26]]], ["This is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintEthical statementThe copyright holder for this this version posted September 30, 2020. . https://doi.org/10.1101/2020.09.29.20201368 doi: medRxiv preprintCollection data and statistical analysisAccording to French Reference Methodology MR-004 regulation on research projects concerning tube bottoms, only the age, sex, date and laboratory place of collection could be collected for each sample.", [["tube", "ANATOMY", 423, 427], ["tube", "TISSUE", 423, 427], ["MR", "PROTEIN", 373, 375], ["Methodology MR", "TEST", 361, 375], ["tube bottoms", "TREATMENT", 423, 435], ["collection", "PROBLEM", 485, 495], ["med", "ANATOMY", 43, 46], ["tube bottoms", "OBSERVATION", 423, 435]]], ["The statistical analyses have been realized for these variables.Collection data and statistical analysisDescriptive statistic methods were performed for age and sex.", [["The statistical analyses", "TEST", 0, 24], ["Collection data", "TEST", 64, 79], ["statistical analysisDescriptive statistic methods", "TEST", 84, 133]]], ["All categorical data were reported as percentages.", [["All categorical data", "TEST", 0, 20]]], ["IgG anti-SARS-CoV-2 seroprevalences and its 95% exact binomial confidence intervals (CIs) were estimated.", [["IgG anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 19], ["IgG", "TEST", 0, 3], ["anti-SARS", "TEST", 4, 13], ["CoV", "TEST", 14, 17]]], ["Associations of the presence of anti-SARS-CoV-2 IgG with sex and age and location were analyzed and tested using the \u03c72 test or Fisher's exact test.", [["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 32, 51], ["anti-SARS", "PROTEIN", 32, 41], ["CoV", "PROTEIN", 42, 45], ["IgG", "PROTEIN", 48, 51], ["anti-SARS", "TEST", 32, 41], ["CoV", "TEST", 42, 45], ["the \u03c72 test", "TEST", 113, 124], ["Fisher's exact test", "TEST", 128, 147]]], ["Statistical significance was set at a p value < 0.05.", [["a p value", "TEST", 36, 45]]], ["The odds ratio (ORs) was used to describe the risk of different gae groups and gender in positive ELISA-S serums compared with non-positive ELISA-S serums.", [["different gae groups", "PROBLEM", 54, 74], ["positive ELISA", "TEST", 89, 103], ["S serums", "TEST", 104, 112], ["non-positive ELISA", "TEST", 127, 145]]], ["Seroprevalence by age group and sex will be adjusted according to the proportions observed in the real population (INSEE, 2020) .", [["Seroprevalence", "TREATMENT", 0, 14]]], ["The following R packages were used for the statistical analysis: questionr; car; stats; survey; FactoMineR and ade4.", [["The following R packages", "TREATMENT", 0, 24], ["the statistical analysis", "TEST", 39, 63], ["FactoMineR", "TREATMENT", 96, 106]]], ["All statistical analyses were performed using R software version 3.6.1 (R Foundation, Vienna, Austria).Collection data and statistical analysis.", [["All statistical analyses", "TEST", 0, 24], ["R software version", "TEST", 46, 64], ["Collection data", "TEST", 103, 118], ["statistical analysis", "TEST", 123, 143]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Collection data and statistical analysisis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintCollection data and statistical analysisThe copyright holder for this this version posted September 30, 2020. . https://doi.org/10.1101/2020.09.29.20201368 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintCollection data and statistical analysisThe copyright holder for this this version posted September 30, 2020. . https://doi.org/10.1101/2020.09.29.20201368 doi: medRxiv preprintResultsA total of 1,973 serums of patients were included from the two participating private medical laboratories between late April and June 2020.", [["CC", "CHEMICAL", 0, 2], ["serums", "ORGANISM", 761, 767], ["patients", "ORGANISM", 771, 779], ["patients", "SPECIES", 771, 779], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Collection data", "TEST", 78, 93], ["Collection data", "TEST", 250, 265], ["statistical analysis", "TEST", 270, 290], ["Collection data", "TEST", 560, 575], ["statistical analysis", "TEST", 580, 600], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 156, 159], ["med", "ANATOMY", 466, 469]]], ["People included ranged in age from 6 months to 101 years including 1,187 women (60.2%) and 786 men (39.8%).", [["People", "ORGANISM", 0, 6], ["women", "ORGANISM", 73, 78], ["men", "ORGANISM", 95, 98], ["People", "SPECIES", 0, 6], ["women", "SPECIES", 73, 78], ["men", "SPECIES", 95, 98]]], ["The weighted population according to sex and age groups, showed that the mean age was 44 years, including 51.7% of women and 48.3% of men.CoV-2The Table 1 and Figure 2 described the overall seroprevalence and the seroprevalence rates estimated by age groups and gender in the included and in the weighted population.", [["women", "ORGANISM", 115, 120], ["men", "ORGANISM", 134, 137], ["women", "SPECIES", 115, 120], ["men", "SPECIES", 134, 137], ["CoV", "TEST", 138, 141], ["the seroprevalence rates", "TREATMENT", 209, 233]]], ["One is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintCoV-2The copyright holder for this this version posted September 30, 2020. . https://doi.org/10.1101/2020.09.29.20201368 doi: medRxiv preprintResults of VNT assayAmong the 140 samples with an ELISA ratio \u2265 0.80 (Table 2) , 104 samples showed a ratio >1.1 and 36 a ratio ranging from 0.8 to 1.1.", [["samples", "ANATOMY", 312, 319], ["samples", "ANATOMY", 363, 370], ["an ELISA ratio", "TEST", 325, 339], ["a ratio", "TEST", 378, 385], ["a ratio", "TEST", 398, 405], ["med", "ANATOMY", 42, 45]]], ["Forty-two percent (n=59) of 140 samples had a positive neutralization antibody titer (VNT titer \u2265 40) ( Table 2) .DiscussionTo the best of our knowledge this is the first study describing the prevalence of SARS-CoV-2 antibodies in a representative sample of Corsican patients having carried out a blood analysis in biological laboratories after the COVID19 epidemic period.DiscussionThe seroprevalence value estimated in the present study with ELISA-S (5.46% [4.51-6.57]; approximately 18,800 of people ) was in line with an estimation that 3.7 million (range:Discussion2.3-6.7) people, i.e., 5.7% of the French population, will have been infected during the epidemic period (Salje et al., 2020) .", [["samples", "ANATOMY", 32, 39], ["blood", "ANATOMY", 297, 302], ["SARS", "DISEASE", 206, 210], ["samples", "CANCER", 32, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 206, 216], ["patients", "ORGANISM", 267, 275], ["blood", "ORGANISM_SUBSTANCE", 297, 302], ["people", "ORGANISM", 496, 502], ["people", "ORGANISM", 579, 585], ["SARS-CoV-2 antibodies", "PROTEIN", 206, 227], ["patients", "SPECIES", 267, 275], ["people", "SPECIES", 496, 502], ["people", "SPECIES", 579, 585], ["SARS-CoV", "SPECIES", 206, 214], ["a positive neutralization antibody titer", "PROBLEM", 44, 84], ["VNT titer", "TEST", 86, 95], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214], ["a blood analysis", "TEST", 295, 311], ["The seroprevalence value", "TEST", 383, 407], ["ELISA", "TEST", 444, 449], ["an estimation", "TEST", 522, 535], ["neutralization antibody", "OBSERVATION", 55, 78], ["infected", "OBSERVATION", 639, 647]]], ["The rate of seroprevalence reported in Corsica was closer to the rate reported by a similar study in a French region with low proportion of COVID-19Discussioncases during the epidemic period (3%), than those reported in two regions with the highest rates (9-10%) (Carrat et al., 2020) .The observed seroprevalence in our population was in line with ELISA-S values reported in Spain, New York city and in different subcohorts of Wuhan .", [["COVID-19Discussioncases", "CHEMICAL", 140, 163], ["COVID", "TEST", 140, 145], ["low", "OBSERVATION_MODIFIER", 122, 125], ["highest", "OBSERVATION_MODIFIER", 241, 248], ["rates", "OBSERVATION_MODIFIER", 249, 254]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Discussionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintDiscussionThe copyright holder for this this version posted September 30, 2020. . https://doi.org/10.1101/2020.09.29.20201368 doi: medRxiv preprint (Pollan et al., 2020) , United States (Havers et al., 2020) and China (Xu et al., 2020) but lower than values reported in heavily affected areas such as Swiss (Stringhini et al., 2020) , NorthernDiscussionItaly (Vena et al., 2020) and the urban areas around Madrid (Soriano et al., 2020) .DiscussionIn the present study we did not observed a significantly distribution of seroprevalence values between males and females, in agreement with previous reports in Spain (Pollan et al., 2020) , Dutch blood donors (Slot, 2020) and French blood donors (Gallian et al., 2020) .", [["blood", "ANATOMY", 863, 868], ["blood", "ANATOMY", 900, 905], ["CC", "CHEMICAL", 0, 2], ["blood", "ORGANISM_SUBSTANCE", 863, 868], ["blood", "ORGANISM_SUBSTANCE", 900, 905], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["French blood donors", "TREATMENT", 893, 912], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 126, 129], ["Vena", "ANATOMY", 580, 584]]], ["This is in line with sex-disaggregated data for COVID-19 in several European countries showing a similar number of cases between the sexes, but more severe outcomes in aged men (Gebhard et al., 2020) .", [["men", "ORGANISM", 173, 176], ["men", "SPECIES", 173, 176], ["COVID", "TEST", 48, 53], ["severe", "OBSERVATION_MODIFIER", 149, 155]]], ["We observed that seroprevalence values differed significantly among age groups.", [["seroprevalence values", "TEST", 17, 38]]], ["Individuals aged less than 50 years old showed a seroprevalence rate significantly higher than people aged more than 50 years old.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["a seroprevalence rate", "TEST", 47, 68]]], ["In our sample seroprevalence values suggest that infection was less prevalent in children than in adolescents during the epidemic period.", [["infection", "DISEASE", 49, 58], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89], ["our sample seroprevalence values", "TEST", 3, 35], ["infection", "PROBLEM", 49, 58], ["infection", "OBSERVATION", 49, 58], ["less prevalent", "OBSERVATION_MODIFIER", 63, 77]]], ["The lower prevalence in children might be in part related to lower nasal gene expression of angiotensinconverting enzyme 2 (Bunyavanich et al., 2020) .DiscussionBecause it is possible that the ELISA assay could exhibit cross-reactivity with antibodies to other seasonal human coronaviruses, some results may represent false-positives leading to overestimation of seroprevalence data (Takahashi et al., 2020) .", [["nasal", "ANATOMY", 67, 72], ["children", "ORGANISM", 24, 32], ["nasal", "ORGANISM_SUBDIVISION", 67, 72], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 92, 122], ["human", "ORGANISM", 270, 275], ["coronaviruses", "ORGANISM", 276, 289], ["antibodies", "PROTEIN", 241, 251], ["children", "SPECIES", 24, 32], ["human", "SPECIES", 270, 275], ["human coronaviruses", "SPECIES", 270, 289], ["the ELISA assay", "TEST", 189, 204], ["cross-reactivity with antibodies to other seasonal human coronaviruses", "PROBLEM", 219, 289], ["false-positives", "PROBLEM", 318, 333], ["lower prevalence", "OBSERVATION_MODIFIER", 4, 20], ["lower", "ANATOMY_MODIFIER", 61, 66], ["nasal", "ANATOMY", 67, 72]]], ["The EUROIMMUN assay used in this study was evaluated in different studies showing a specificity ranging from 96.2% to 100% and sensitivity ranging from 86.4% to 100% (Beavis et al., 2020 ; Kohmer et al., 2020 ; Kruttgen et al., 2020) .", [["The EUROIMMUN assay", "TEST", 0, 19], ["this study", "TEST", 28, 38], ["different studies", "TEST", 56, 73], ["a specificity", "TEST", 82, 95], ["sensitivity", "TEST", 127, 138]]], ["The sensitivity and specificity of the ELISA can vary considerably depending on the timing of the sample, in particular from samples collected \u22654 days, after COVID-19 diagnosis by PCR.", [["sample", "ANATOMY", 98, 104], ["samples", "ANATOMY", 125, 132], ["The sensitivity", "TEST", 0, 15], ["the ELISA", "TEST", 35, 44], ["the sample", "TEST", 94, 104], ["PCR", "TEST", 180, 183]]], ["The sensitivity can increase from 67% to 100% between samples analyzed at the time of PCR and them analyzed at least four days later (Beavis et al., 2020) .", [["samples", "ANATOMY", 54, 61], ["The sensitivity", "TEST", 0, 15], ["samples", "TEST", 54, 61], ["PCR", "TEST", 86, 89], ["increase", "OBSERVATION_MODIFIER", 20, 28]]], ["Virus neutralization test, currently considered as the gold standard, is the most specific serological assay capable of detecting true positive cases and functional neutralizing antibodies (Algaissi A, 2020) .", [["Virus", "ORGANISM", 0, 5], ["neutralizing antibodies", "PROTEIN", 165, 188], ["Virus neutralization test", "TEST", 0, 25], ["true positive cases", "PROBLEM", 130, 149]]], ["The positivity of a titer \u226540 for the VNT assay used in the present study is an indicator of strong specificity (100%) (Gallian et al., 2020) .DiscussionAround half of the samples showing ELISA results \u22650.8 half showed a VNT\u226540 in line with a previous study (Carrat et al., 2020) .", [["samples", "ANATOMY", 172, 179], ["samples", "CANCER", 172, 179], ["VNT", "PROTEIN", 38, 41], ["the VNT assay", "TEST", 34, 47], ["the samples", "TEST", 168, 179], ["ELISA", "TEST", 188, 193], ["a previous study", "TEST", 241, 257]]], ["The prevalence value based on our VNT analysis revealed that at least 3% of the included samples have been exposed to the virus and had .", [["samples", "ANATOMY", 89, 96], ["samples", "CANCER", 89, 96], ["VNT", "DNA", 34, 37], ["our VNT analysis", "TEST", 30, 46], ["the virus", "PROBLEM", 118, 127]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Discussionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintDiscussionThe copyright holder for this this version posted September 30, 2020 . . https://doi.org/10.1101 developed a titer of neutralizing antibodies \u226540.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 303, 326], ["neutralizing antibodies", "PROTEIN", 348, 371], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["neutralizing antibodies", "TEST", 348, 371], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 126, 129]]], ["This value is in line with the low value of 2.7% observed with the same VNT assay in blood donors collected during the last week of March or the first week of April 2020 in four French departments (Gallian et al., 2020) and in the adult general population of a region with low prevalence (Carrat et al., 2020) .DiscussionSeroprevalence data based on ELISA assay provided information about previous exposure to SARS-CoV-2 but not about protection.", [["blood", "ANATOMY", 85, 90], ["SARS", "DISEASE", 410, 414], ["blood donors", "ORGANISM_SUBSTANCE", 85, 97], ["SARS-CoV", "SPECIES", 410, 418], ["This value", "TEST", 0, 10], ["blood donors", "TEST", 85, 97], ["Seroprevalence data", "TEST", 321, 340], ["ELISA assay", "TEST", 350, 361], ["low", "OBSERVATION_MODIFIER", 31, 34]]], ["In the present study we also estimated SARS-CoV-2 neutralizing antibodies titers among serum samples with dubious (\u22650.8 and <1.1) and positive (\u2265 1.1) results.", [["serum samples", "ANATOMY", 87, 100], ["CoV-2", "GENE_OR_GENE_PRODUCT", 44, 49], ["serum samples", "ORGANISM_SUBSTANCE", 87, 100], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["neutralizing antibodies titers", "TEST", 50, 80], ["serum samples", "TEST", 87, 100]]], ["About half of these samples had neutralizing antibodies with a titer \u226540.", [["samples", "ANATOMY", 20, 27], ["samples", "CANCER", 20, 27], ["neutralizing antibodies", "PROTEIN", 32, 55], ["these samples", "TEST", 14, 27], ["neutralizing antibodies", "TEST", 32, 55], ["a titer", "TEST", 61, 68]]], ["This represents a preliminary approach to protection against re-infection, but it should be underlined that no precise correlate of protection is available yet (Wu, 2020) .DiscussionThere are several limitations in our study.", [["re-infection", "PROBLEM", 61, 73], ["our study", "TEST", 215, 224], ["re-infection", "OBSERVATION", 61, 73]]], ["Firstly, residual sera from screening or routine care provided by private medical biology laboratories, are more likely to come from people needing to monitor their health status for chronic medical conditions.", [["sera", "ANATOMY", 18, 22], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139], ["residual sera from screening", "TEST", 9, 37], ["routine care", "TREATMENT", 41, 53], ["chronic medical conditions", "PROBLEM", 183, 209]]], ["Additionally, no data concerning clinical features, chronic disease, or possible COVID-19 exposures were available potentially biasing results.", [["chronic disease", "DISEASE", 52, 67], ["clinical features", "PROBLEM", 33, 50], ["chronic disease", "PROBLEM", 52, 67], ["COVID-19 exposures", "PROBLEM", 81, 99], ["no", "UNCERTAINTY", 14, 16], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["disease", "OBSERVATION", 60, 67]]], ["Moreover, this lack of information on the COVID-19 status of the persons included could also influence the specificity and sensitivity of the ELISA test (timing of the sample in relation to the infection).", [["infection", "DISEASE", 194, 203], ["persons", "ORGANISM", 65, 72], ["persons", "SPECIES", 65, 72], ["the COVID", "TEST", 38, 47], ["the ELISA test", "TEST", 138, 152], ["the sample", "TEST", 164, 174], ["the infection", "PROBLEM", 190, 203], ["infection", "OBSERVATION", 194, 203]]], ["As we tested by seroneutralization samples with an ELISA-S test optical density \u22650.8 and not all samples, seoprevalence could be slightly underestimated.DiscussionThe strengths of this study were the size of the sample and its representativity in terms of age and gender.", [["samples", "ANATOMY", 35, 42], ["samples", "ANATOMY", 97, 104], ["an ELISA", "TEST", 48, 56], ["this study", "TEST", 180, 190], ["slightly", "OBSERVATION_MODIFIER", 129, 137], ["underestimated", "OBSERVATION", 138, 152]]], ["Samples have been analysed by combining ELISA and neutralization methods to strengthen results.DiscussionIn conclusion the present study showed that a low seroprevalence for COVID-19 in Corsica in accordance with values reported for other French regions in which the impact of the pandemic was low.", [["Samples", "ANATOMY", 0, 7], ["COVID-19", "CHEMICAL", 174, 182], ["Samples", "TEST", 0, 7], ["combining ELISA", "TEST", 30, 45], ["neutralization methods", "TEST", 50, 72], ["the present study", "TEST", 119, 136], ["COVID", "TEST", 174, 179]]], ["This regional study is particularly important in Corsica, as the island situation cannot be extrapolated from neighboring regions.Discussion.", [["This regional study", "TEST", 0, 19]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Discussionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintDiscussionThe copyright holder for this this version posted September 30, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 126, 129]]], ["1101 Author Contributions: Conceptualization: A.F., M-H.S., J.C., R.C. and L.C.; Investigation:DiscussionM-H.S. and J.C.; Funding acquisition: A.F.; methodology: R.C., A.F. and X.d.L, writing original draft preparation: L.C. and A.F.; Writing-review and editing: X.d.L., R.C. and A.F.;DiscussionLaboratory analyses: S.M., N.A., S.P. and L.C.; Statistical analyses: L.C.; Supervision: A.F., M-H.S., J.C., R.C. and X.d.L.DiscussionFunding: This research received no external funding.Conflicts of Interest:The authors declare no conflict of interest.Conflicts of Interest:.", [["external funding", "TREATMENT", 464, 480]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Conflicts of Interest:is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintConflicts of Interest:The copyright holder for this this version posted September 30, 2020. . https://doi.org/10.1101/2020.09.29.20201368 doi: medRxiv preprint Figure A1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 138, 141]]], ["Age and sex repartition pyramid among Corsican population (A1A) and studied population (A1B). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintConflicts of Interest:The copyright holder for this this version posted September 30, 2020. . https://doi.org/10.", [["A1B", "CANCER", 88, 91], ["med", "ANATOMY", 132, 135]]]], "25871630e68f1dca6c9746592cbf8994461a8c37": [["INTRODUCTIONThe SARS-CoV-2 is an emerging human coronavirus discovered in Wuhan, China, in December 2019.", [["SARS-CoV-2", "ORGANISM", 16, 26], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["SARS-CoV-2", "SPECIES", 16, 26], ["human coronavirus", "SPECIES", 42, 59]]], ["It causes the COVID-19 disease, which developed into a pandemic in early 2020: on May 24 , 2020, more than 5 million persons had been infected and more than 340,000 died.", [["persons", "ORGANISM", 117, 124], ["persons", "SPECIES", 117, 124], ["the COVID-19 disease", "PROBLEM", 10, 30], ["19 disease", "OBSERVATION", 20, 30], ["pandemic", "OBSERVATION_MODIFIER", 55, 63], ["infected", "OBSERVATION", 134, 142]]], ["In the past four months, more than 12,400 articles have been published and scientific data collected from thousands of patients have been released.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127]]], ["This impressive research and clinical work made it possible to better understand the disease and its different phases.", [["the disease", "PROBLEM", 81, 92]]], ["Numerous clinical trials are currently investigating multiple therapeutic candidates and strategies (1) , including prophylaxis (2) .INTRODUCTIONProphylaxis refers to measures taken to prevent the onset of the disease.", [["prophylaxis", "TREATMENT", 116, 127], ["the disease", "PROBLEM", 206, 217], ["disease", "OBSERVATION", 210, 217]]], ["For infectious diseases it includes for example drugs aimed at blocking the infectious cycle of the pathogen or drugs that can reinforce the host immunity.", [["infectious diseases", "DISEASE", 4, 23], ["infectious diseases", "PROBLEM", 4, 23], ["example drugs", "TREATMENT", 40, 53], ["drugs", "TREATMENT", 112, 117]]], ["There are two main categories of prophylaxis: pre-exposure prophylaxis (PrEP), where individuals who did not yet encounter the pathogen are treated, and post-exposure prophylaxis (PEP), where individuals who may have been infected (for example through contact with patients) but did not yet develop symptoms are treated.", [["individuals", "ORGANISM", 192, 203], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["pre-exposure prophylaxis", "TREATMENT", 46, 70], ["the pathogen", "PROBLEM", 123, 135], ["symptoms", "PROBLEM", 299, 307], ["two", "OBSERVATION_MODIFIER", 10, 13], ["main", "OBSERVATION_MODIFIER", 14, 18], ["prophylaxis", "OBSERVATION", 33, 44]]], ["Both strategies have been extensively studied with HIV infections (3) .", [["HIV infections", "DISEASE", 51, 65], ["HIV", "SPECIES", 51, 54], ["HIV infections", "PROBLEM", 51, 65]]], ["According to these studies, PrEP with tenofovir disoproxil fumarate-emtricitabine can reduce the risk of HIV transmission by more than 90 percent in patients who are at high risk of acquiring HIV, depending on the level of adherence (4, 5) .INTRODUCTIONProphylaxis is an interesting strategy for COVID-19 since it could both contain the spread of the SARS-CoV-2 and prevent the development of COVID-19, especially in patients at risk of severe forms.", [["tenofovir disoproxil fumarate", "CHEMICAL", 38, 67], ["emtricitabine", "CHEMICAL", 68, 81], ["HIV transmission", "DISEASE", 105, 121], ["HIV", "DISEASE", 192, 195], ["SARS", "DISEASE", 351, 355], ["tenofovir disoproxil fumarate", "CHEMICAL", 38, 67], ["emtricitabine", "CHEMICAL", 68, 81], ["PrEP", "SIMPLE_CHEMICAL", 28, 32], ["tenofovir disoproxil fumarate-emtricitabine", "SIMPLE_CHEMICAL", 38, 81], ["HIV", "ORGANISM", 105, 108], ["patients", "ORGANISM", 149, 157], ["HIV", "ORGANISM", 192, 195], ["SARS-CoV-2", "ORGANISM", 351, 361], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 417, 425], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 192, 195], ["SARS-CoV", "SPECIES", 351, 359], ["these studies", "TEST", 13, 26], ["PrEP", "TREATMENT", 28, 32], ["tenofovir disoproxil fumarate", "TREATMENT", 38, 67], ["emtricitabine", "TREATMENT", 68, 81], ["HIV transmission", "PROBLEM", 105, 121], ["acquiring HIV", "PROBLEM", 182, 195], ["COVID", "TREATMENT", 296, 301], ["the SARS", "TEST", 347, 355], ["COVID", "TEST", 393, 398], ["severe", "OBSERVATION", 437, 443]]], ["In this review we discuss the current approaches for COVID-19 prophylaxis and the therapeutic perspectives they raise.METHODSA review of currently registered clinical trials was performed to identify relevant studies.", [["COVID-19", "CHEMICAL", 53, 61], ["COVID-19 prophylaxis", "TREATMENT", 53, 73]]], ["A search was conducted on April 27 on the clinicaltrials.gov repository (6), the EudraCT repository (7), the anticovid platform (8), the covid-nma platform (9) and the covid-trials platform (10), using the keywords \"prophylaxis\", \"PrEP\" and \"prevention\", except in the covid-nma platform where the keywords \"healthy\" and \"exposed\" were searched in the data file.", [["the EudraCT repository", "TEST", 77, 99], ["the anticovid platform", "TREATMENT", 105, 127], ["the covid-nma platform", "TREATMENT", 133, 155], ["the covid-trials platform", "TREATMENT", 164, 189], ["prophylaxis", "TREATMENT", 216, 227]]], ["A search on pubmed on May 14 with the key words \"COVID-19 prophylaxis\", \"COVID-19 prophylax\" did not reveal any published clinical trial result.METHODSThe eligibility criteria were developed using the Patient Intervention Comparison Outcomes Study type (PICOS) framework (11) .METHODSInclusion criteria were: -Population: any population -Intervention/Comparator: any antiviral agent or drug.", [["COVID", "TEST", 49, 54], ["COVID", "TEST", 73, 78], ["the Patient Intervention", "TREATMENT", 197, 221], ["any antiviral agent", "TREATMENT", 363, 382]]], ["We excluded trials evaluating therapeutic strategies whose description was not sufficient to identify a specific drug.METHODS-Outcomes: any outcome evaluating the infection with SARS-CoV-2 -Study type: interventional clinical trial.Number of studies.", [["infection", "DISEASE", 163, 172], ["SARS", "DISEASE", 178, 182], ["therapeutic strategies", "TREATMENT", 30, 52], ["the infection", "PROBLEM", 159, 172], ["SARS", "TEST", 178, 182], ["interventional clinical trial", "TREATMENT", 202, 231], ["studies", "TEST", 242, 249], ["infection", "OBSERVATION", 163, 172]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)We found 309 studies on the clinicaltrials.gov repository, 32 on the EudraCT repository, 508 on the anticovid platform, 69 on the covid-nma platform and 101 on the covid-trials platform.", [["CC", "CHEMICAL", 0, 2], ["the covid-trials platform", "TREATMENT", 358, 383], ["med", "ANATOMY", 102, 105]]], ["After eliminating the duplicates and the studies that were not testing prophylaxis (n=951), 68 relevant clinical trials were identified (Figure 1 ), summarized in Table 1 .", [["the studies", "TEST", 37, 48]]], ["Most trials were focused on hydroxychloroquine (n=46, 68%), followed by BCG vaccine (n=5, 7%) and lopinavir/ritonavir (n=3, 4%).", [["hydroxychloroquine", "CHEMICAL", 28, 46], ["lopinavir/ritonavir", "CHEMICAL", 98, 117], ["hydroxychloroquine", "CHEMICAL", 28, 46], ["lopinavir", "CHEMICAL", 98, 107], ["ritonavir", "CHEMICAL", 108, 117], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 28, 46], ["lopinavir", "SIMPLE_CHEMICAL", 98, 107], ["ritonavir", "SIMPLE_CHEMICAL", 108, 117], ["hydroxychloroquine", "TREATMENT", 28, 46], ["BCG vaccine", "TREATMENT", 72, 83], ["lopinavir", "TREATMENT", 98, 107], ["ritonavir", "TREATMENT", 108, 117]]], ["The most frequently evaluated routes of administration were oral (n=51, 75%), intradermal for vaccines (n=6, 9%) and inhaled (n=4, 6%).", [["oral", "ANATOMY", 60, 64], ["oral", "ORGANISM_SUBDIVISION", 60, 64], ["oral (n", "TREATMENT", 60, 67], ["intradermal for vaccines", "TREATMENT", 78, 102]]], ["Both pre-and post-exposure prophylaxis were investigated, with a substantial number of trials on PrEP for exposed medical workers, as could be expected from the current emphasis on protecting medical workers in order to keep health systems functional through the pandemic.", [["Both pre-and post-exposure prophylaxis", "TREATMENT", 0, 38], ["PrEP", "TREATMENT", 97, 101]]], ["Chloroquine derivatives, most notably hydroxychloroquine sulfate, inhibit coronavirus membrane fusion through an increase in endosomal pH and disrupt the glycosylation of their glycoproteins (13) They were suggested to be efficient against SARS-CoV-2 in vitro (12) (13) (14) and allegedly improved the disease in COVID-19 patients (17, 18) , although these reports are questioned and side effects are suspected (17, 18) .", [["membrane", "ANATOMY", 86, 94], ["endosomal", "ANATOMY", 125, 134], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 38, 56], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine sulfate", "CHEMICAL", 38, 64], ["Chloroquine derivatives", "SIMPLE_CHEMICAL", 0, 23], ["hydroxychloroquine sulfate", "SIMPLE_CHEMICAL", 38, 64], ["coronavirus", "ORGANISM", 74, 85], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["endosomal", "CELLULAR_COMPONENT", 125, 134], ["SARS-CoV-2", "ORGANISM", 240, 250], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 322, 330], ["SARS-CoV", "SPECIES", 240, 248], ["Chloroquine derivatives", "TREATMENT", 0, 23], ["hydroxychloroquine sulfate", "TREATMENT", 38, 64], ["coronavirus membrane fusion", "TREATMENT", 74, 101], ["an increase in endosomal pH", "PROBLEM", 110, 137], ["SARS", "PROBLEM", 240, 244], ["CoV", "TEST", 245, 248], ["the disease", "PROBLEM", 298, 309], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["endosomal pH", "OBSERVATION", 125, 137], ["disease", "OBSERVATION", 302, 309]]], ["These early results and the ease to produce and administer hydroxychloroquine in high quantities may explain why it is the most investigated prophylaxis against COVID-19, with 68% (46/68) of all clinical trials analysed in this review, and involving more than 150,000 subjects in total (Supplementary Table 1 ).", [["hydroxychloroquine", "CHEMICAL", 59, 77], ["hydroxychloroquine", "CHEMICAL", 59, 77], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 59, 77], ["hydroxychloroquine", "TREATMENT", 59, 77], ["COVID", "TEST", 161, 166]]], ["Chloroquine derivatives are administered orally at doses ranging from 400mg per week to 600mg per day, with a loading dose the first day (or occasionally the first 4 days) of 200 to 1200mg.", [["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine derivatives", "SIMPLE_CHEMICAL", 0, 23], ["Chloroquine derivatives", "TREATMENT", 0, 23]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . post-exposure prophylaxis were represented, the former included trials conducted over 65 (IQR=58-90) days in median, while the median duration of the latter was 5 (IQR=5-5) days after exposure.InterferonsType 1 interferons (IFN) are cytokines with pro-inflammatory and unspecific antiviral properties.", [["CC", "CHEMICAL", 0, 2], ["Type 1 interferons", "GENE_OR_GENE_PRODUCT", 477, 495], ["IFN", "GENE_OR_GENE_PRODUCT", 497, 500], ["InterferonsType 1 interferons", "PROTEIN", 466, 495], ["IFN", "PROTEIN", 497, 500], ["cytokines", "PROTEIN", 506, 515], ["The copyright holder", "TREATMENT", 198, 218], ["post-exposure prophylaxis", "TREATMENT", 273, 298], ["InterferonsType 1 interferons (IFN)", "TREATMENT", 466, 501], ["cytokines", "PROBLEM", 506, 515], ["pro-inflammatory and unspecific antiviral properties", "TREATMENT", 521, 573], ["med", "ANATOMY", 102, 105], ["antiviral properties", "OBSERVATION", 553, 573]]], ["Although they are produced by the organism when an infection occurs, treating COVID-19 patients with additional IFN is thought to be protective in the early phases of infection, when an acceleration in the recruitment of adaptive immunity can facilitate viral clearance (21) .", [["infection", "DISEASE", 51, 60], ["IFN", "CHEMICAL", 112, 115], ["infection", "DISEASE", 167, 176], ["patients", "ORGANISM", 87, 95], ["IFN", "GENE_OR_GENE_PRODUCT", 112, 115], ["IFN", "PROTEIN", 112, 115], ["patients", "SPECIES", 87, 95], ["an infection", "PROBLEM", 48, 60], ["COVID", "TREATMENT", 78, 83], ["additional IFN", "TREATMENT", 101, 115], ["infection", "PROBLEM", 167, 176], ["an acceleration", "PROBLEM", 183, 198], ["adaptive immunity", "TREATMENT", 221, 238], ["viral clearance", "TEST", 254, 269], ["infection", "OBSERVATION", 51, 60], ["thought to be", "UNCERTAINTY", 119, 132], ["protective", "OBSERVATION", 133, 143], ["early phases", "OBSERVATION_MODIFIER", 151, 163], ["infection", "OBSERVATION", 167, 176]]], ["Therefore, type 1 interferons appear suited to prophylaxis or early disease treatment, and to immunocompromized patients (22) .", [["type 1 interferons", "GENE_OR_GENE_PRODUCT", 11, 29], ["patients", "ORGANISM", 112, 120], ["type 1 interferons", "PROTEIN", 11, 29], ["patients", "SPECIES", 112, 120], ["type 1 interferons", "TREATMENT", 11, 29], ["prophylaxis", "TREATMENT", 47, 58], ["early disease treatment", "TREATMENT", 62, 85]]], ["In late stages of the disease, an excessive immune response could be deleterious and the role of interferons is more debated.", [["interferons", "GENE_OR_GENE_PRODUCT", 97, 108], ["interferons", "PROTEIN", 97, 108], ["the disease", "PROBLEM", 18, 29], ["an excessive immune response", "PROBLEM", 31, 59], ["late stages", "OBSERVATION_MODIFIER", 3, 14], ["disease", "OBSERVATION", 22, 29], ["excessive", "OBSERVATION_MODIFIER", 34, 43], ["immune response", "OBSERVATION", 44, 59]]], ["In macaques, prophylactic pegylated IFN\u03b12b administered intramuscularly one on two days at 3mg/kg decreased SARS-CoV replication and lung damage (23) .", [["lung", "ANATOMY", 133, 137], ["pegylated IFN\u03b12b", "CHEMICAL", 26, 42], ["lung damage", "DISEASE", 133, 144], ["macaques", "ORGANISM", 3, 11], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 108, 116], ["lung", "ORGAN", 133, 137], ["IFN", "PROTEIN", 36, 39], ["macaques", "SPECIES", 3, 11], ["SARS-CoV", "SPECIES", 108, 116], ["prophylactic pegylated IFN\u03b12b", "TREATMENT", 13, 42], ["CoV replication", "TREATMENT", 113, 128], ["lung damage", "PROBLEM", 133, 144], ["lung", "ANATOMY", 133, 137]]], ["As a therapy, IFN\u03b12b has been reported to reduce SARS-CoV-2 infection duration (24) in a small-scale, non-randomised clinical trial.", [["IFN\u03b12b", "CHEMICAL", 14, 20], ["infection", "DISEASE", 60, 69], ["IFN\u03b12b", "GENE_OR_GENE_PRODUCT", 14, 20], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["IFN\u03b12b", "PROTEIN", 14, 20], ["a therapy", "TREATMENT", 3, 12], ["IFN\u03b12b", "TREATMENT", 14, 20], ["SARS", "PROBLEM", 49, 53], ["2 infection duration", "PROBLEM", 58, 78]]], ["Recently, IFN\u03b11b was used as a prophylaxis on hundreds of health care workers, many of whom directly exposed to COVID-19 patients, and administered by nasal drops, in combination or not with thymosin-\u03b11 (a putative enhancer of cellular innate immunity) (25) .", [["nasal", "ANATOMY", 151, 156], ["cellular", "ANATOMY", 227, 235], ["IFN\u03b11b", "CHEMICAL", 10, 16], ["thymosin-\u03b11", "CHEMICAL", 191, 202], ["IFN\u03b11b", "GENE_OR_GENE_PRODUCT", 10, 16], ["patients", "ORGANISM", 121, 129], ["nasal", "ORGANISM_SUBDIVISION", 151, 156], ["thymosin-\u03b11", "GENE_OR_GENE_PRODUCT", 191, 202], ["cellular", "CELL", 227, 235], ["IFN", "PROTEIN", 10, 13], ["thymosin", "PROTEIN", 191, 199], ["\u03b11", "PROTEIN", 200, 202], ["patients", "SPECIES", 121, 129], ["nasal drops", "TREATMENT", 151, 162]]], ["No COVID-19 case was reported in the individuals who received the prophylaxis.", [["COVID", "TEST", 3, 8], ["the prophylaxis", "TREATMENT", 62, 77]]], ["Although very promising, this result must be further confirmed, since it stems from a non-randomised clinical trial.", [["a non-randomised clinical trial", "TREATMENT", 84, 115]]], ["Different modes of IFN administration are studied, notably subcutaneous pegylated IFN\u03bb1a in a phase 2 clinical trial (NCT04344600).Lopinavir/ritonavirLopinavir/ritonavir (LPV/RTV), a protease inhibitor, was reported to improve SARS (26) , although this study was criticized due to biases in patients' assignment (27) .", [["IFN", "CHEMICAL", 19, 22], ["pegylated IFN\u03bb1a", "CHEMICAL", 72, 88], ["Lopinavir", "CHEMICAL", 131, 140], ["ritonavirLopinavir/ritonavir", "CHEMICAL", 141, 169], ["LPV/RTV", "CHEMICAL", 171, 178], ["SARS", "DISEASE", 227, 231], ["Lopinavir", "CHEMICAL", 131, 140], ["ritonavirLopinavir", "CHEMICAL", 141, 159], ["ritonavir", "CHEMICAL", 160, 169], ["LPV", "CHEMICAL", 171, 174], ["RTV", "CHEMICAL", 175, 178], ["IFN", "GENE_OR_GENE_PRODUCT", 19, 22], ["Lopinavir", "SIMPLE_CHEMICAL", 131, 140], ["ritonavirLopinavir", "SIMPLE_CHEMICAL", 141, 159], ["ritonavir", "SIMPLE_CHEMICAL", 160, 169], ["LPV", "SIMPLE_CHEMICAL", 171, 174], ["RTV", "SIMPLE_CHEMICAL", 175, 178], ["patients", "ORGANISM", 291, 299], ["IFN", "PROTEIN", 19, 22], ["subcutaneous pegylated IFN\u03bb1a", "PROTEIN", 59, 88], ["patients", "SPECIES", 291, 299], ["IFN administration", "TREATMENT", 19, 37], ["subcutaneous pegylated IFN", "TREATMENT", 59, 85], ["Lopinavir", "TREATMENT", 131, 140], ["ritonavirLopinavir", "TREATMENT", 141, 159], ["ritonavir (LPV/RTV)", "TREATMENT", 160, 179], ["a protease inhibitor", "TREATMENT", 181, 201], ["this study", "TEST", 248, 258], ["subcutaneous", "ANATOMY", 59, 71]]], ["Its safety profile is ascertained by its widespread use against HIV (28) .", [["HIV", "ORGANISM", 64, 67], ["HIV", "SPECIES", 64, 67], ["HIV", "SPECIES", 64, 67], ["HIV", "PROBLEM", 64, 67]]], ["LPV/RTV is investigated as COVID-19 post-exposure prophylaxis in the CORIPREV-LR trial (NCT04321174) and the COPEP trial (NCT04364022), during respectively 14 or 5 days following exposure to a COVID-19 patient.", [["LPV", "CHEMICAL", 0, 3], ["RTV", "CHEMICAL", 4, 7], ["RTV", "CHEMICAL", 4, 7], ["RTV", "SIMPLE_CHEMICAL", 4, 7], ["patient", "ORGANISM", 202, 209], ["patient", "SPECIES", 202, 209], ["LPV/RTV", "TREATMENT", 0, 7], ["COVID", "TEST", 27, 32], ["the COPEP trial", "TREATMENT", 105, 120], ["RTV", "OBSERVATION", 4, 7]]], ["It is administered orally twice daily at doses of 400mg lopinavir + 100mg ritonavir in CORIPREV-LR, versus 200mg lopinavir + 50mg ritonavir in COPEP.", [["lopinavir", "CHEMICAL", 56, 65], ["ritonavir", "CHEMICAL", 74, 83], ["CORIPREV-LR", "CHEMICAL", 87, 98], ["lopinavir", "CHEMICAL", 113, 122], ["ritonavir", "CHEMICAL", 130, 139], ["COPEP", "CHEMICAL", 143, 148], ["lopinavir", "CHEMICAL", 56, 65], ["ritonavir", "CHEMICAL", 74, 83], ["lopinavir", "CHEMICAL", 113, 122], ["ritonavir", "CHEMICAL", 130, 139], ["lopinavir", "SIMPLE_CHEMICAL", 56, 65], ["ritonavir", "SIMPLE_CHEMICAL", 74, 83], ["CORIPREV-LR", "SIMPLE_CHEMICAL", 87, 98], ["lopinavir", "SIMPLE_CHEMICAL", 113, 122], ["ritonavir", "SIMPLE_CHEMICAL", 130, 139], ["COPEP", "SIMPLE_CHEMICAL", 143, 148], ["lopinavir", "TREATMENT", 56, 65], ["ritonavir", "TREATMENT", 74, 83], ["LR", "TREATMENT", 96, 98], ["lopinavir", "TREATMENT", 113, 122], ["ritonavir in COPEP", "TREATMENT", 130, 148]]], ["In the trial COVIDAXIS (NCT04328285), it is used as PrEP, administered orally twice daily at doses of 200mg lopinavir + 50mg ritonavir for 2 months.NitazoxanideNitazoxanide is a broad-spectrum antiviral that amplifies cytoplasmic RNA sensing and type 1 IFN signaling.", [["cytoplasmic", "ANATOMY", 218, 229], ["lopinavir", "CHEMICAL", 108, 117], ["ritonavir", "CHEMICAL", 125, 134], ["Nitazoxanide", "CHEMICAL", 148, 160], ["Nitazoxanide", "CHEMICAL", 160, 172], ["lopinavir", "CHEMICAL", 108, 117], ["ritonavir", "CHEMICAL", 125, 134], ["Nitazoxanide", "CHEMICAL", 148, 160], ["Nitazoxanide", "CHEMICAL", 160, 172], ["lopinavir", "SIMPLE_CHEMICAL", 108, 117], ["ritonavir", "SIMPLE_CHEMICAL", 125, 134], ["Nitazoxanide", "SIMPLE_CHEMICAL", 148, 160], ["Nitazoxanide", "SIMPLE_CHEMICAL", 160, 172], ["cytoplasmic", "ORGANISM_SUBSTANCE", 218, 229], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 246, 256], ["IFN", "PROTEIN", 253, 256], ["PrEP", "TREATMENT", 52, 56], ["lopinavir", "TREATMENT", 108, 117], ["ritonavir", "TREATMENT", 125, 134], ["NitazoxanideNitazoxanide", "TREATMENT", 148, 172], ["a broad-spectrum antiviral", "TREATMENT", 176, 202], ["cytoplasmic RNA sensing", "TREATMENT", 218, 241], ["type 1 IFN signaling", "PROBLEM", 246, 266]]], ["It inhibits SARS-CoV-2 replication in vitro (14) and is tested as a PrEP for 600 elderly people in special care institutions in the trial NCT04343248, and for 800 medical workers in the trial NCT04359680.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["SARS", "PROBLEM", 12, 16], ["CoV", "TEST", 17, 20]]], ["It is administered orally twice a day at doses of 600mg in both studies.Nitric oxideNitric oxide, a signaling molecule and unspecific antimicrobial, inhibits SARS-CoV replication in vitro (29) and is investigated as a PrEP for medical workers in contact with COVID-19 patients in the trial NCT04312243.", [["Nitric oxideNitric oxide", "CHEMICAL", 72, 96], ["Nitric oxideNitric oxide", "CHEMICAL", 72, 96], ["Nitric oxideNitric oxide", "SIMPLE_CHEMICAL", 72, 96], ["SARS-CoV", "ORGANISM", 158, 166], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["SARS-CoV", "SPECIES", 158, 166], ["Nitric oxideNitric oxide", "TREATMENT", 72, 96], ["a signaling molecule", "PROBLEM", 98, 118], ["unspecific antimicrobial", "TREATMENT", 123, 147]]], ["It is administered twice daily through a 15 minutes long inhalation of a gas containing 160ppm of nitric oxide.", [["nitric oxide", "CHEMICAL", 98, 110], ["nitric oxide", "CHEMICAL", 98, 110], ["nitric oxide", "SIMPLE_CHEMICAL", 98, 110], ["a gas", "TREATMENT", 71, 76], ["nitric oxide", "TREATMENT", 98, 110]]], ["In the NCT04337918 trial, it is used both as PrEP for medical workers and as post-exposure prophylaxis.", [["medical workers", "TREATMENT", 54, 69], ["post-exposure prophylaxis", "TREATMENT", 77, 102]]], ["Several modes of administration are investigated: gargle, nasopharyngeal irrigation and nasal spray.Convalescent serum.", [["nasopharyngeal", "ANATOMY", 58, 72], ["nasal", "ANATOMY", 88, 93], ["serum", "ANATOMY", 113, 118], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 58, 72], ["nasal", "ORGANISM_SUBDIVISION", 88, 93], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["gargle", "TREATMENT", 50, 56], ["nasopharyngeal irrigation", "TREATMENT", 58, 83], ["nasal spray", "TREATMENT", 88, 99], ["Convalescent serum", "TEST", 100, 118], ["nasopharyngeal", "ANATOMY", 58, 72]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.30.20117937 doi: medRxiv preprint Convalescent serum intravenous administration has been proposed as a passive antibody prophylaxis or therapy against COVID-19 (30) following the hypothesis that antibodies developed by the donor, who had been infected by SARS-CoV-2 and recovered, could protect the recipient against potential infection.", [["serum", "ANATOMY", 352, 357], ["intravenous", "ANATOMY", 358, 369], ["CC", "CHEMICAL", 0, 2], ["COVID-19", "CHEMICAL", 456, 464], ["SARS", "DISEASE", 560, 564], ["infection", "DISEASE", 632, 641], ["serum", "ORGANISM_SUBSTANCE", 352, 357], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 358, 369], ["SARS-CoV-2", "ORGANISM", 560, 570], ["antibodies", "PROTEIN", 500, 510], ["SARS-CoV", "SPECIES", 560, 568], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 322, 329], ["Convalescent serum intravenous administration", "TREATMENT", 339, 384], ["a passive antibody prophylaxis", "TREATMENT", 406, 436], ["therapy", "TREATMENT", 440, 447], ["COVID", "TEST", 456, 461], ["CoV", "TEST", 565, 568], ["potential infection", "PROBLEM", 622, 641], ["med", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 632, 641]]], ["Convalescent serum has already been used as a therapy against MERS-CoV (31), SARS-CoV (32, 33) and SARS-CoV-2 (34), and resulted in improved prognosis, but has not yet been tested as a prophylaxis.", [["serum", "ANATOMY", 13, 18], ["SARS-CoV", "DISEASE", 77, 85], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["MERS-CoV", "ORGANISM", 62, 70], ["SARS-CoV", "ORGANISM", 77, 85], ["SARS-CoV-2", "ORGANISM", 99, 109], ["MERS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 77, 85], ["SARS-CoV", "SPECIES", 99, 107], ["Convalescent serum", "TEST", 0, 18], ["a therapy", "TREATMENT", 44, 53], ["MERS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["SARS-CoV", "TEST", 77, 85], ["SARS-CoV", "TEST", 99, 107], ["a prophylaxis", "TREATMENT", 183, 196]]], ["The number of recovered patients is already very high and is expected to grow further: thus, if the pool of potential donors is efficiently harnessed, large quantities of convalescent serum could be produced and convalescent plasma may become a good candidate for large-scale prophylaxis.", [["serum", "ANATOMY", 184, 189], ["plasma", "ANATOMY", 225, 231], ["patients", "ORGANISM", 24, 32], ["donors", "ORGANISM", 118, 124], ["convalescent", "ORGANISM", 171, 183], ["serum", "ORGANISM_SUBSTANCE", 184, 189], ["plasma", "ORGANISM_SUBSTANCE", 225, 231], ["patients", "SPECIES", 24, 32], ["potential donors", "PROBLEM", 108, 124], ["convalescent serum", "TEST", 171, 189], ["convalescent plasma", "TEST", 212, 231], ["large-scale prophylaxis", "TREATMENT", 264, 287]]], ["Therefore, convalescent serum has been included in the guidelines of the Infectious Diseases Society of America (35) for both pre-and post-exposure prophylaxis.", [["serum", "ANATOMY", 24, 29], ["Infectious Diseases", "DISEASE", 73, 92], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["convalescent serum", "TEST", 11, 29], ["both pre-and post-exposure prophylaxis", "TREATMENT", 121, 159], ["Infectious", "OBSERVATION_MODIFIER", 73, 83]]], ["This treatment will be tested as a post-exposure prophylaxis, with 150 individuals belonging to categories highly susceptible to develop a severe disease, in a phase 2 clinical trial (NCT04323800).", [["This treatment", "TREATMENT", 0, 14], ["a post-exposure prophylaxis", "TREATMENT", 33, 60], ["a severe disease", "PROBLEM", 137, 153], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["disease", "OBSERVATION", 146, 153]]], ["However, the most relevant dose of convalescent serum has yet to be determined, and convalescent serum treatment raises the risk of antibody-dependant enhancement of infection (ADE), a process observed in a few coronaviruses (36) .", [["serum", "ANATOMY", 48, 53], ["serum", "ANATOMY", 97, 102], ["infection", "DISEASE", 166, 175], ["ADE", "DISEASE", 177, 180], ["convalescent", "ORGANISM", 35, 47], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["convalescent serum", "TEST", 35, 53], ["convalescent serum treatment", "TREATMENT", 84, 112], ["antibody", "PROBLEM", 132, 140], ["dependant enhancement of infection", "PROBLEM", 141, 175], ["dependant enhancement", "OBSERVATION_MODIFIER", 141, 162], ["infection", "OBSERVATION", 166, 175]]], ["Consequently, investigations aiming to determine if convalescent antibodies for SARS-CoV-2 could induce ADE are warranted.", [["SARS", "DISEASE", 80, 84], ["ADE", "DISEASE", 104, 107], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["convalescent antibodies", "PROTEIN", 52, 75], ["SARS-CoV", "SPECIES", 80, 88], ["investigations", "TEST", 14, 28], ["convalescent antibodies", "TEST", 52, 75], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88]]], ["An alternative to convalescent serum prophylaxis is the use of antibody preparations, which are already being developed, but we did not find clinical trials investigating them.Tuberculosis or measles vaccinesThe BCG tuberculosis vaccine is known to have non-specific protective effects against respiratory infections.", [["serum", "ANATOMY", 31, 36], ["respiratory", "ANATOMY", 294, 305], ["Tuberculosis", "DISEASE", 176, 188], ["tuberculosis", "DISEASE", 216, 228], ["respiratory infections", "DISEASE", 294, 316], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["BCG tuberculosis", "ORGANISM", 212, 228], ["convalescent serum prophylaxis", "TREATMENT", 18, 48], ["antibody preparations", "TREATMENT", 63, 84], ["Tuberculosis", "PROBLEM", 176, 188], ["measles vaccines", "TREATMENT", 192, 208], ["The BCG tuberculosis vaccine", "TREATMENT", 208, 236], ["respiratory infections", "PROBLEM", 294, 316], ["tuberculosis", "OBSERVATION", 216, 228], ["infections", "OBSERVATION", 306, 316]]], ["Moreover, the geographical distribution of BCG vaccination is negatively correlated with the prevalence and mortality of COVID-19 (37, 38) , although the significance of this correlation is debated (39, 40) .", [["COVID-19", "SPECIES", 121, 129], ["BCG vaccination", "PROBLEM", 43, 58], ["COVID", "TEST", 121, 126], ["geographical", "OBSERVATION_MODIFIER", 14, 26], ["distribution", "OBSERVATION_MODIFIER", 27, 39], ["BCG", "OBSERVATION", 43, 46]]], ["5 clinical trials of BCG vaccination on medical workers exposed to COVID-19 are being conducted (NCT04328441, NCT04327206, NCT04348370, NCT04350931, NCT04362124) and involve together 8810 subjects.", [["NCT04328441", "CHEMICAL", 97, 108], ["BCG vaccination", "TREATMENT", 21, 36]]], ["Similarly, Mycobacterium w, another tuberculosis vaccine, is tested as anti COVID-19 prophylaxis (both pre-and post-exposure) in the trial NCT04353518.", [["tuberculosis", "DISEASE", 36, 48], ["COVID-19", "CHEMICAL", 76, 84], ["Mycobacterium w", "GENE_OR_GENE_PRODUCT", 11, 26], ["Mycobacterium w", "PROBLEM", 11, 26], ["another tuberculosis vaccine", "TREATMENT", 28, 56], ["anti COVID", "TREATMENT", 71, 81], ["Mycobacterium", "OBSERVATION", 11, 24]]], ["An in silico comparison of SARS-CoV-2 proteins with those of the measles, mumps and rubella viruses suggested that the antigens of the MMR vaccine may immunise patients against SARS-CoV-2 epitopes (41) .", [["measles", "DISEASE", 65, 72], ["mumps and rubella viruses", "DISEASE", 74, 99], ["SARS", "DISEASE", 177, 181], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["measles", "ORGANISM", 65, 72], ["mumps", "ORGANISM", 74, 79], ["rubella viruses", "ORGANISM", 84, 99], ["patients", "ORGANISM", 160, 168], ["SARS-CoV-2", "ORGANISM", 177, 187], ["SARS-CoV-2 proteins", "PROTEIN", 27, 46], ["patients", "SPECIES", 160, 168], ["SARS-CoV", "SPECIES", 27, 35], ["rubella viruses", "SPECIES", 84, 99], ["SARS-CoV", "SPECIES", 177, 185], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["the measles", "PROBLEM", 61, 72], ["mumps", "PROBLEM", 74, 79], ["rubella viruses", "PROBLEM", 84, 99], ["the MMR vaccine", "TREATMENT", 131, 146], ["SARS", "PROBLEM", 177, 181], ["CoV", "TEST", 182, 185]]], ["Although this hypothesis has not yet been tested in vitro or in vivo, it prompted the launch of the NCT04357028 trial, where the MMR vaccine is used as PrEP for medical workers.Levamisole and isoprinosineLevamisole is a stimulator of T helper type 1 immune response (42) , used as vaccine adjuvant.", [["Levamisole", "CHEMICAL", 177, 187], ["isoprinosineLevamisole", "CHEMICAL", 192, 214], ["Levamisole", "CHEMICAL", 177, 187], ["isoprinosineLevamisole", "CHEMICAL", 192, 214], ["Levamisole", "SIMPLE_CHEMICAL", 177, 187], ["isoprinosineLevamisole", "SIMPLE_CHEMICAL", 192, 214], ["T helper type 1", "GENE_OR_GENE_PRODUCT", 234, 249], ["the MMR vaccine", "TREATMENT", 125, 140], ["Levamisole", "TREATMENT", 177, 187], ["isoprinosineLevamisole", "TREATMENT", 192, 214], ["a stimulator", "TREATMENT", 218, 230], ["vaccine adjuvant", "TREATMENT", 281, 297]]], ["Isoprinosine is also an immunostimulator and has antiviral properties whose mechanism is unclear (43) .", [["Isoprinosine", "CHEMICAL", 0, 12], ["Isoprinosine", "CHEMICAL", 0, 12], ["Isoprinosine", "SIMPLE_CHEMICAL", 0, 12], ["Isoprinosine", "TREATMENT", 0, 12], ["an immunostimulator", "TREATMENT", 21, 40], ["antiviral properties", "TREATMENT", 49, 69]]], ["These two drugs are tested in combination in the trial NCT04360122, as a PrEP for medical workers.", [["These two drugs", "TREATMENT", 0, 15], ["drugs", "OBSERVATION", 10, 15]]], ["They are administered orally at doses of 150mg levamisole twice a week and 1g isoprinosine three times a day.Other treatmentsOther compounds are investigated in combination with hydroxychloroquine.", [["levamisole", "CHEMICAL", 47, 57], ["isoprinosine", "CHEMICAL", 78, 90], ["hydroxychloroquine", "CHEMICAL", 178, 196], ["levamisole", "CHEMICAL", 47, 57], ["isoprinosine", "CHEMICAL", 78, 90], ["hydroxychloroquine", "CHEMICAL", 178, 196], ["levamisole", "SIMPLE_CHEMICAL", 47, 57], ["isoprinosine", "SIMPLE_CHEMICAL", 78, 90], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 178, 196], ["levamisole", "TREATMENT", 47, 57], ["1g isoprinosine", "TREATMENT", 75, 90], ["Other treatments", "TREATMENT", 109, 125], ["hydroxychloroquine", "TREATMENT", 178, 196]]], ["Umifenovir (arbidol) is a broad-spectrum antiviral approved in Russia and China which impairs viral membrane fusion (44) and displays anti SARS-CoV-2 effects.", [["membrane", "ANATOMY", 100, 108], ["Umifenovir", "CHEMICAL", 0, 10], ["arbidol", "CHEMICAL", 12, 19], ["Umifenovir", "CHEMICAL", 0, 10], ["arbidol", "CHEMICAL", 12, 19], ["Umifenovir", "SIMPLE_CHEMICAL", 0, 10], ["arbidol", "SIMPLE_CHEMICAL", 12, 19], ["CoV-2", "GENE_OR_GENE_PRODUCT", 144, 149], ["Umifenovir (arbidol)", "TREATMENT", 0, 20], ["a broad-spectrum antiviral", "TREATMENT", 24, 50], ["viral membrane fusion", "TREATMENT", 94, 115], ["anti SARS", "TEST", 134, 143]]], ["It was correlated with improvements in COVID-19 in a small-scale (16 patients in the arbidol group), non-randomised clinical trial (45) .", [["arbidol", "CHEMICAL", 85, 92], ["arbidol", "CHEMICAL", 85, 92], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 39, 44]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . prophylaxis in the trials ChiCTR2000029803 and ChiCTR2000029592.", [["CC", "CHEMICAL", 0, 2], ["ChiCTR2000029803", "CHEMICAL", 299, 315], ["ChiCTR2000029592", "CHEMICAL", 320, 336], ["The copyright holder", "TREATMENT", 198, 218], ["prophylaxis", "TREATMENT", 273, 284], ["med", "ANATOMY", 102, 105]]], ["Azithromycine is an antibiotic and antiviral reported to synergize with hydroxychloroquine against COVID-19 in the controversial report of Gautret et al. (18) .", [["Azithromycine", "CHEMICAL", 0, 13], ["hydroxychloroquine", "CHEMICAL", 72, 90], ["COVID-19", "CHEMICAL", 99, 107], ["Azithromycine", "CHEMICAL", 0, 13], ["hydroxychloroquine", "CHEMICAL", 72, 90], ["COVID-19", "CHEMICAL", 99, 107], ["Azithromycine", "SIMPLE_CHEMICAL", 0, 13], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 72, 90], ["Azithromycine", "TREATMENT", 0, 13], ["an antibiotic", "TREATMENT", 17, 30], ["antiviral", "TREATMENT", 35, 44], ["hydroxychloroquine", "TREATMENT", 72, 90], ["COVID", "TREATMENT", 99, 104]]], ["It is compared with hydroxychloroquine as PrEP for medical workers in the trials NCT04344379 and NCT04354597, with an oral administration of respectively 250mg per day and 500mg per week.", [["oral", "ANATOMY", 118, 122], ["hydroxychloroquine", "CHEMICAL", 20, 38], ["hydroxychloroquine", "CHEMICAL", 20, 38], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 20, 38], ["oral", "ORGANISM_SUBDIVISION", 118, 122], ["hydroxychloroquine", "TREATMENT", 20, 38]]], ["Mefloquine, an anti-malarial drug, was identified as a potent in vitro inhibitor of SARS-CoV-2 (46) and other coronaviruses (47, 48) , and is currently evaluated as a post-exposure prophylaxis in the 2020-001194-69 clinical trial on 200 individuals, with an oral administration of 250mg/day for a month.", [["oral", "ANATOMY", 258, 262], ["Mefloquine", "CHEMICAL", 0, 10], ["Mefloquine", "CHEMICAL", 0, 10], ["Mefloquine", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV-2", "ORGANISM", 84, 94], ["coronaviruses", "ORGANISM", 110, 123], ["oral", "ORGANISM_SUBDIVISION", 258, 262], ["SARS-CoV-2", "SPECIES", 84, 94], ["Mefloquine", "TREATMENT", 0, 10], ["an anti-malarial drug", "TREATMENT", 12, 33], ["CoV", "TEST", 89, 92], ["a post-exposure prophylaxis", "TREATMENT", 165, 192], ["an oral administration", "TREATMENT", 255, 277], ["anti-malarial drug", "OBSERVATION", 15, 33]]], ["In the NCT04334928 trial, both tenofovir disoproxil and emtricitabine are tested.", [["tenofovir disoproxil", "CHEMICAL", 31, 51], ["emtricitabine", "CHEMICAL", 56, 69], ["tenofovir disoproxil", "CHEMICAL", 31, 51], ["emtricitabine", "CHEMICAL", 56, 69], ["tenofovir disoproxil", "SIMPLE_CHEMICAL", 31, 51], ["emtricitabine", "SIMPLE_CHEMICAL", 56, 69], ["both tenofovir disoproxil", "TREATMENT", 26, 51], ["emtricitabine", "TREATMENT", 56, 69]]], ["These are nucleoside inhibitors of HIV reverse transcriptase.", [["nucleoside", "CHEMICAL", 10, 20], ["nucleoside", "CHEMICAL", 10, 20], ["nucleoside", "SIMPLE_CHEMICAL", 10, 20], ["HIV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 35, 60], ["HIV reverse transcriptase", "PROTEIN", 35, 60], ["HIV", "SPECIES", 35, 38], ["nucleoside inhibitors", "TREATMENT", 10, 31], ["HIV reverse transcriptase", "TREATMENT", 35, 60]]], ["Their use against COVID-19 was probably prompted by the discovery that tenofovir binds SARS-CoV-2 RdRp (49), suggesting an antiviral effect.", [["COVID-19", "CHEMICAL", 18, 26], ["tenofovir", "CHEMICAL", 71, 80], ["COVID-19", "CHEMICAL", 18, 26], ["tenofovir", "CHEMICAL", 71, 80], ["tenofovir", "SIMPLE_CHEMICAL", 71, 80], ["SARS-CoV-2", "ORGANISM", 87, 97], ["COVID", "TEST", 18, 23], ["tenofovir binds SARS", "PROBLEM", 71, 91], ["CoV", "TEST", 92, 95], ["an antiviral effect", "PROBLEM", 120, 139], ["antiviral effect", "OBSERVATION", 123, 139]]], ["Bromhexine is a potent and specific inhibitor of the TMPRSS2 protease involved in SARS-CoV-2 spike protein maturation (50) .", [["Bromhexine", "CHEMICAL", 0, 10], ["Bromhexine", "CHEMICAL", 0, 10], ["Bromhexine", "SIMPLE_CHEMICAL", 0, 10], ["TMPRSS2 protease", "GENE_OR_GENE_PRODUCT", 53, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["TMPRSS2 protease", "PROTEIN", 53, 69], ["Bromhexine", "TREATMENT", 0, 10], ["specific inhibitor", "TREATMENT", 27, 45], ["the TMPRSS2 protease", "TREATMENT", 49, 69], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["protein maturation", "TEST", 99, 117]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Both pre and post exposure prophylaxis are investigated.", [["Both pre and post exposure prophylaxis", "TREATMENT", 0, 38]]], ["PrEP strategies targeted at-risk individuals (such as elderly or with chronic medical conditions such as obesity (12)) or, in most cases, medical workers highly exposed to infectious patients, on the protection of whom a special emphasis is put in order to keep health systems functional through the pandemic.", [["obesity", "DISEASE", 105, 112], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["PrEP strategies", "TREATMENT", 0, 15], ["chronic medical conditions", "PROBLEM", 70, 96], ["obesity", "PROBLEM", 105, 112]]], ["Most trials were focused on (hydroxy)chloroquine (68%), which explains the prevalence of orally administered treatments.", [["hydroxy", "CHEMICAL", 29, 36], ["chloroquine", "CHEMICAL", 37, 48], ["(hydroxy)chloroquine", "CHEMICAL", 28, 48], ["(hydroxy)chloroquine", "SIMPLE_CHEMICAL", 28, 48], ["chloroquine", "TREATMENT", 37, 48], ["orally administered treatments", "TREATMENT", 89, 119]]], ["Numerous trials on hydroxychloroquine or BCG vaccine are redundant because they follow identical or very similar protocols.(which was not certified by peer review)An important challenge with prophylactic treatments is that they must be pursued or repeated until the recipient is immunized or falls out of the priority categories, because the protective effects are shortlived: from a few hours with interferon nasal drops (25) to a few weeks with convalescent serum (30) .The long duration of treatments and the fact that they are targeted on healthy individuals make it essential to propose treatments easily administered on an outpatient basis and with an excellent tolerance.", [["nasal", "ANATOMY", 410, 415], ["serum", "ANATOMY", 460, 465], ["hydroxychloroquine", "CHEMICAL", 19, 37], ["hydroxychloroquine", "CHEMICAL", 19, 37], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 19, 37], ["serum", "ORGANISM_SUBSTANCE", 460, 465], ["interferon", "PROTEIN", 399, 409], ["hydroxychloroquine", "TREATMENT", 19, 37], ["BCG vaccine", "TREATMENT", 41, 52], ["prophylactic treatments", "TREATMENT", 191, 214], ["interferon nasal drops", "TREATMENT", 399, 421], ["convalescent serum", "TEST", 447, 465], ["treatments", "TREATMENT", 493, 503], ["long duration", "OBSERVATION_MODIFIER", 476, 489]]], ["Compared with therapeutic treatments, more risks are taken and less advantages are expected, which may lead to exclude treatments such as hydroxychloroquine for which side effects have been reported.(which was not certified by peer review)Naturally, the prophylactic strategies evaluated are centered on the early antiviral action of drugs or the a b(which was not certified by peer review).", [["hydroxychloroquine", "CHEMICAL", 138, 156], ["hydroxychloroquine", "CHEMICAL", 138, 156], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 138, 156], ["therapeutic treatments", "TREATMENT", 14, 36], ["hydroxychloroquine", "TREATMENT", 138, 156], ["the prophylactic strategies", "TREATMENT", 250, 277], ["drugs", "TREATMENT", 334, 339]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . stimulation of the immune system, e.g. with interferons or convalescent antibodies.", [["immune system", "ANATOMY", 333, 346], ["CC", "CHEMICAL", 0, 2], ["interferons", "PROTEIN", 358, 369], ["convalescent antibodies", "PROTEIN", 373, 396], ["The copyright holder", "TREATMENT", 239, 259], ["the immune system", "TEST", 329, 346], ["interferons", "TREATMENT", 358, 369], ["convalescent antibodies", "PROBLEM", 373, 396], ["med", "ANATOMY", 102, 105]]], ["The antiinflammatory strategies that have been described elsewhere are reserved for patients with severe disease and an excessive immune response to the virus (51).(which was not certified by peer review)We only included trials that were registered up to April 27, 2020 but new approaches could be tested in future trials, notably antivirals that demonstrated prophylactic efficiency against coronaviruses, such as EIDD-2801 (52) .CONCLUSIONNumerous strategies of prophylaxis against COVID-19 are currently investigated, and target different steps of the virus life cycle or the patient immune system.", [["coronaviruses", "DISEASE", 392, 405], ["EIDD-2801", "CHEMICAL", 415, 424], ["COVID-19", "CHEMICAL", 484, 492], ["EIDD-2801", "CHEMICAL", 415, 424], ["patients", "ORGANISM", 84, 92], ["coronaviruses", "ORGANISM", 392, 405], ["patient", "ORGANISM", 579, 586], ["patients", "SPECIES", 84, 92], ["patient", "SPECIES", 579, 586], ["EIDD-2801", "SPECIES", 415, 424], ["The antiinflammatory strategies", "TREATMENT", 0, 31], ["severe disease", "PROBLEM", 98, 112], ["an excessive immune response", "PROBLEM", 117, 145], ["the virus", "TEST", 149, 158], ["trials", "TREATMENT", 221, 227], ["antivirals", "TREATMENT", 331, 341], ["prophylactic efficiency", "TREATMENT", 360, 383], ["coronaviruses", "PROBLEM", 392, 405], ["EIDD", "TEST", 415, 419], ["prophylaxis", "TREATMENT", 464, 475], ["COVID", "TEST", 484, 489], ["the virus life cycle", "TREATMENT", 551, 571], ["antiinflammatory strategies", "OBSERVATION", 4, 31]]], ["(Hydroxy)chloroquine is being evaluated in 68% of the registered clinical trials that we found, while numerous prophylactic strategies were investigated in a small number of trials.", [["Hydroxy", "CHEMICAL", 1, 8], ["chloroquine", "CHEMICAL", 9, 20], ["(Hydroxy)chloroquine", "CHEMICAL", 0, 20], ["Hydroxy)chloroquine", "SIMPLE_CHEMICAL", 1, 20], ["(Hydroxy)chloroquine", "TREATMENT", 0, 20], ["numerous prophylactic strategies", "TREATMENT", 102, 134]]], ["This discrepancy highlights the need to increase the number of treatments investigated in order to achieve an extensive cover of all promising candidate treatments against COVID-19.", [["treatments", "TREATMENT", 63, 73], ["COVID", "TEST", 172, 177]]]], "PMC7340910": [["In fact, more than 80% of company and organization data is in the form of documents.", [["organization data", "TEST", 38, 55]]], ["Multimedia documents are characterized by a rich content and complex structures, which complicates access to specific granules in such documents and therefore makes the document retrieval a tedious task.", [["granules", "ANATOMY", 118, 126], ["granules", "CELLULAR_COMPONENT", 118, 126], ["a rich content and complex structures", "PROBLEM", 42, 79], ["rich content", "OBSERVATION", 44, 56], ["complex", "OBSERVATION_MODIFIER", 61, 68]]], ["Graph is the most effective representation model, which allow the representation of complex and connected data, such as multimedia document.", [["most effective", "OBSERVATION_MODIFIER", 13, 27]]], ["The graph theory could be of great interest in the evaluation of the structural similarity.IntroductionIn general, comparing two graphs leads to find the better matching between them.", [["the evaluation", "TEST", 47, 61]]], ["In such applications, graph similarity based on exact matching is not appropriate.", [["graph similarity", "TEST", 22, 38]]], ["For this purpose, approximate error-tolerant graph matching based on finding the maximum common subgraph or on the calculation of the graph editing distance has been proposed in [8, 9, 17].", [["approximate error-tolerant graph matching", "TREATMENT", 18, 59]]], ["In the context of image, finding visual information granularity in an image, requires the use of special techniques in order to respond to user\u2019s need.", [["special techniques", "TREATMENT", 97, 115]]], ["Indeed, Image Retrieval can be based either on the text or on the visual content.", [["Image Retrieval", "TREATMENT", 8, 23]]], ["However, a key limitation of traditional image retrieval system is the ignorance of semantic aspect.", [["traditional image retrieval system", "TEST", 29, 63]]], ["In [1], graphs are rich data structures with the ability to represent complex and structured objects.IntroductionIn this paper, we present the basic concepts of Image Retrieval and image retrieval techniques.", [["Image Retrieval", "TREATMENT", 161, 176], ["image retrieval techniques", "TEST", 181, 207], ["complex", "OBSERVATION", 70, 77], ["structured objects", "OBSERVATION", 82, 100]]], ["Also, a comparative study of image retrieval techniques has been carried out to present their advantages, and drawbacks.", [["a comparative study", "TEST", 6, 25], ["image retrieval techniques", "TEST", 29, 55]]], ["Section 2, describes the concept of Image Retrieval and the techniques of Image Retrieval, and presents advantages and limits of using each type of techniques.", [["Image Retrieval", "TREATMENT", 36, 51], ["Image Retrieval", "TREATMENT", 74, 89]]], ["Section 3 presents a comparative study on graph-based Image Retrieval and outlines the integration of semantic aspect in graph-based approaches.", [["a comparative study", "TEST", 19, 38], ["Image Retrieval", "TREATMENT", 54, 69]]], ["4 discusses our issue focused on graph-based semantic Image Retrieval.Image Retrieval Techniques ::: Image RetrievalImage Retrieval (ImR) is the area studying the way to find images in image collection.", [["Image RetrievalImage Retrieval", "TREATMENT", 101, 131], ["images in image collection", "TEST", 175, 201]]], ["ImR attracts the attention of many researchers in the field of: digital libraries, remote sensing, astronomy, etc. It has been a very active field since the 1970s.", [["ImR", "GENE_OR_GENE_PRODUCT", 0, 3], ["ImR", "PROTEIN", 0, 3], ["very", "OBSERVATION_MODIFIER", 129, 133], ["active", "OBSERVATION_MODIFIER", 134, 140]]], ["ImR systems can be classified into three techniques [20]:Text-based Image Retrieval (TBIR), is the system for retrieving images by text queries.", [["retrieving images", "TEST", 110, 127]]], ["The extraction of an image similar to a user query is based on indexation process, which proposes to attach to an image, a set of descriptors.", [["The extraction", "TREATMENT", 0, 14], ["an image", "TEST", 18, 26], ["an image", "TEST", 111, 119]]], ["This technique use the textual indexation of an image, its metadata or the textual elements attached to the image.", [["an image", "TEST", 45, 53]]], ["A lot of research has been done on TBIR, but are very ancient due to the great importance given to the other types of ImR.", [["TBIR", "SIMPLE_CHEMICAL", 35, 39], ["ImR", "GENE_OR_GENE_PRODUCT", 118, 121], ["ImR", "PROTEIN", 118, 121], ["TBIR", "TREATMENT", 35, 39]]], ["TBIR can be based on annotation [15].", [["TBIR", "PROTEIN", 0, 4]]], ["The major drawback of this approach is that for a descriptive annotation, it must be manual, hence, the complexity of the task.", [["a descriptive annotation", "TEST", 48, 72]]], ["One of the first examples of TBIR is [36], it presents a framework that performs annotations to images using text and then uses text-based databases.Content-based Retrieval (CBIR): over the last decades, a big interest in images collection has grown with the development of image acquisition devices, storage capacities and the availability of high-quality digitization techniques.", [["TBIR", "DNA", 29, 33], ["images collection", "TEST", 222, 239], ["image acquisition devices", "TREATMENT", 274, 299]]], ["Indeed, CBIR is a system based on colors, textures, shapes, and other characteristics (depending on the user\u2019s needs).", [["CBIR", "PROTEIN", 8, 12], ["shapes", "OBSERVATION_MODIFIER", 52, 58]]], ["This technique responds to many needs in the field of ImR and overcomes the limitations of TBIR.", [["TBIR", "SIMPLE_CHEMICAL", 91, 95], ["TBIR", "TREATMENT", 91, 95]]], ["An image can be described by a weighting function that reflects the importance of the features and varies widely according to the system and the objectives.", [["An image", "TEST", 0, 8]]], ["Work [34] presents an effective content-based visual ImR system, by extracting color histogram and spatial information.", [["color histogram", "TEST", 79, 94]]], ["Work [14] presents CBIR approach using a computational visual attention model, based on saliency regions and energy features of the gray-level co-occurrence and saliency structure histogram.", [["CBIR approach", "TREATMENT", 19, 32], ["the gray", "TEST", 128, 136], ["saliency structure histogram", "TEST", 161, 189]]], ["Work [16] presents an approach using local visual attention feature, based on fast and performant salient point detector, and the salient point expansion.Semantic-based Image Retrieval (SBIR), is the technique that defines image using semantic terms to determine the significance conveyed in the image.", [["an approach", "TREATMENT", 19, 30]]], ["SBIR can be obtained by extracting visual descriptors from the image in order to identify significant and interesting regions of the image, followed by a process for extracting knowledge in order to obtain a semantic description of the image.", [["SBIR", "PROTEIN", 0, 4], ["the image", "TEST", 59, 68]]], ["This technique is performed by several factors.", [["This technique", "TREATMENT", 0, 14]]]], "e884eacb75a71ac7b6e9ffd1e6fd895580487a33": [["Less than a month has passed since the World Health organization (WHO) was first alerted regarding a mysterious viral respiratory illness spreading across the city of Wuhan in the Hubei province of China that painted an eerily familiar picture to the severe respiratory syndrome (SARS) epidemic.", [["respiratory", "ANATOMY", 118, 129], ["viral respiratory illness", "DISEASE", 112, 137], ["respiratory syndrome", "DISEASE", 258, 278], ["SARS", "DISEASE", 280, 284], ["a mysterious viral respiratory illness", "PROBLEM", 99, 137], ["the severe respiratory syndrome", "PROBLEM", 247, 278], ["epidemic", "PROBLEM", 286, 294], ["viral", "OBSERVATION_MODIFIER", 112, 117], ["respiratory illness", "OBSERVATION", 118, 137], ["severe", "OBSERVATION_MODIFIER", 251, 257], ["respiratory syndrome", "OBSERVATION", 258, 278]]], ["1 On January 7, 2020, the virus was identified as a new strain of coronavirus and temporarily named 2019-nCoV, 1 making it the third notable coronavirus outbreak in recent times following SARS and Middle East Respiratory Syndrome (MERS).", [["coronavirus", "DISEASE", 66, 77], ["coronavirus", "DISEASE", 141, 152], ["SARS", "DISEASE", 188, 192], ["Middle East Respiratory Syndrome", "DISEASE", 197, 229], ["coronavirus", "ORGANISM", 66, 77], ["coronavirus", "ORGANISM", 141, 152], ["coronavirus", "SPECIES", 66, 77], ["the virus", "PROBLEM", 22, 31], ["a new strain of coronavirus", "PROBLEM", 50, 77], ["the third notable coronavirus outbreak", "PROBLEM", 123, 161], ["SARS", "PROBLEM", 188, 192], ["Middle East Respiratory Syndrome", "PROBLEM", 197, 229], ["notable", "OBSERVATION_MODIFIER", 133, 140], ["coronavirus", "OBSERVATION", 141, 152], ["Middle", "ANATOMY_MODIFIER", 197, 203], ["Respiratory Syndrome", "OBSERVATION", 209, 229]]], ["The first cases of 2019-nCoV were linked to Huanan Seafood Wholesale Market where there was sale of animal meat for human consumption.", [["meat", "ANATOMY", 107, 111], ["meat", "ORGANISM_SUBDIVISION", 107, 111], ["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121]]], ["As a result, it was presumed that the virus was spread through direct contact with animals.", [["the virus", "PROBLEM", 34, 43], ["virus", "OBSERVATION", 38, 43]]], ["However, on January 21 st , 2020 WHO reported a case of a 35-year-old female who tested positive for 2019-nCoV with no history of known contact with confirmed 2019-nCoV cases or wild animals in Wuhan City.", [["female", "ORGANISM", 70, 76]]], ["2 As of January 24, 2020 there are 895 laboratory-confirmed cases of 2019-nCoV infections with 26 deaths reported.", [["infections", "DISEASE", 79, 89], ["deaths", "DISEASE", 98, 104], ["nCoV infections", "PROBLEM", 74, 89]]], ["The first Real time Reverse Transcription-Polymerase Chain Reaction (rRT-PCR) test positive case of 2019-nCoV in the United States was confirmed by the Centers of Disease Control and Prevention (CDC) on January 21 st .", [["Chain Reaction", "TEST", 53, 67], ["rRT-PCR", "TEST", 69, 76], ["Disease Control", "TREATMENT", 163, 178], ["Disease", "OBSERVATION", 163, 170]]], ["Although all cases seen outside China had a travel history to Wuhan, 3 the increasing number of cases is concerning for possible person-to-person transmission, as was the prior two corona virus outbreaks of SARS and MERS.", [["SARS", "DISEASE", 207, 211], ["MERS", "DISEASE", 216, 220], ["person", "SPECIES", 129, 135], ["SARS", "PROBLEM", 207, 211], ["concerning for", "UNCERTAINTY", 105, 119]]], ["4 The 2019-nCoV was found to have 70% similarity in genetic sequence to SARS-CoV, which first emerged in China in 2002 and spread to 29 countries/regions through a travel-related global outbreak with 8,098 cases and a case fatality rate of 9.6%.", [["SARS", "DISEASE", 72, 76], ["SARS-CoV", "ORGANISM", 72, 80], ["2019-nCoV", "DNA", 6, 15], ["SARS-CoV", "SPECIES", 72, 80], ["SARS", "PROBLEM", 72, 76], ["CoV", "PROBLEM", 77, 80], ["a case fatality rate", "TEST", 216, 236]]], ["5 The Chinese health authorities initially notified WHO on 31 st December 2019 of this virus that prompted surrounding countries to institute screening and quarantine measures for travelers from Wuhan.", [["this virus", "PROBLEM", 82, 92], ["institute screening", "TEST", 132, 151], ["quarantine measures", "TREATMENT", 156, 175]]], ["6 Health care professionals should be suspicious for 2019-nCoV when a patient presents with fever, symptoms of lower respiratory illness and there is a history of travel to Wuhan, China in the last 14 days prior to symptom onset, close contact with a person who is under investigation for the virus or is a laboratory-confirmed 2019-nCoV patient.", [["respiratory", "ANATOMY", 117, 128], ["fever", "DISEASE", 92, 97], ["lower respiratory illness", "DISEASE", 111, 136], ["patient", "ORGANISM", 70, 77], ["patient", "ORGANISM", 338, 345], ["patient", "SPECIES", 70, 77], ["person", "SPECIES", 251, 257], ["patient", "SPECIES", 338, 345], ["fever", "PROBLEM", 92, 97], ["symptoms", "PROBLEM", 99, 107], ["lower respiratory illness", "PROBLEM", 111, 136], ["the virus", "PROBLEM", 289, 298], ["lower", "ANATOMY_MODIFIER", 111, 116], ["respiratory", "ANATOMY", 117, 128], ["illness", "OBSERVATION", 129, 136]]], ["6 It is important to implement droplet and contact precautions for suspected and confirmed cases.", [["contact precautions", "TREATMENT", 43, 62]]], ["The WHO has published detailed interim guidance for clinical management of severe acute respiratory illness when 2019-nCov is suspected.", [["respiratory", "ANATOMY", 88, 99], ["acute respiratory illness", "DISEASE", 82, 107], ["clinical management", "TREATMENT", 52, 71], ["severe acute respiratory illness", "PROBLEM", 75, 107], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["respiratory", "ANATOMY", 88, 99], ["illness", "OBSERVATION", 100, 107]]], ["At present, there is no specific anti-nCoV treatment for patients with suspected or confirmed nCoV.", [["anti-nCoV", "SIMPLE_CHEMICAL", 33, 42], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["specific anti-nCoV treatment", "TREATMENT", 24, 52], ["no", "UNCERTAINTY", 21, 23]]]], "e756e5d5dde183721fc40738953b6723eb58974e": [["As the largest payer for healthcare services, the Centers for Medicare & Medicaid Services (CMS) sets quality and safety standards for all participating healthcare facilities, and has been facilitating the healthcare system transformation to focus on value-based care.", [["largest", "OBSERVATION_MODIFIER", 7, 14]]]]}